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ABSTRACT 
Langerhans cell histiocytosis (LCH) is a rare disease of unknown origin. LCH may occur at any 
age but affects mainly children and the most severe forms of the disease are seen in the 
youngest children. In LCH, granulomatous lesions are formed in various organs. These lesions 
always contain CD1a
+ 
dendritic cells (LCH DCs), and multinucleated giant cells (MGCs) of 
unknown origin are also commonly seen in the lesions. The course of LCH is extremely 
variable ranging from self-healing, solitary lesions in the bone or the skin, to recurrent multiple 
lesions or progressive disseminated forms of the disease. Recently, a mutation in BRAF, a 
pivotal kinase in the RAS-RAF-MAPK signaling pathway, important for cell survival and 
proliferation, was identified in LCH DCs. Still it is, however, not known whether the disease 
has a neoplastic origin or whether it is triggered by inflammatory stimuli allowing for 
secondary pro-survival mutations to take place.  
 
In terms of survival, the prognosis is usually good except for children with severe disseminated 
forms of the disease, but long term permanent consequences of LCH are common. One severe 
complication is a slowly developing neurodegeneration, linked to CNS inflammation, which 
may develop in around 10-25% of the children. In spite of improved therapies for LCH in 
general, the cause of the neurodegenerative process and how it can be haltered is still unknown. 
Once MRI changes are evident, substantial neuronal loss has already occurred.  Therefore, it 
would be valuable to detect signs of ongoing neurodegeneration earlier than with MRI. This 
would also provide an opportunity to more promptly evaluate treatment interventions. 
 
In paper I in this thesis we evaluated the presence of three well-known biomarkers in the 
cerebrospinal fluid (CSF) of children with radiologically manifest neurodegeneration; NF-L, 
TAU and GFAp. The results indicate that patients with neurodegenerative LCH have elevated 
levels of at least one CSF biomarker and that NF-L, TAU and GFAp analyzed together may be 
useful to detect ongoing neurodegeneration in LCH. NF-L might be of special interest as a 
marker of progressive neurodegeneration. However, further studies are needed to evaluate this. 
 
Previous register studies have indicated an overrepresentation of LCH among Swedish children 
born after in vitro fertilization (IVF) 1982-2005. By confirming the diagnoses and 
characterizing the disease in these children, in paper II we verified a, possibly temporary, 
overrepresentation of LCH in children born after IVF, which was not due to over-diagnosis of 
mild forms of the disease. The reasons for this finding, that might provide a clue to the origin of 
LCH, are however, still unknown. The possible correlation between IVF and LCH should also 
be confirmed in independent studies from other countries.  
 
IL-17A is a pro-inflammatory cytokine involved in the pathogenesis of many chronic 
inflammatory disorders. In papers III, IV and V we investigated how IL-17A affects 
monocyte-derived immature dendritic cells (mo-DCs) and a possible role for IL-17A in LCH. 
We found that IL-17A modifies mo-DCs to cells with a mixed macrophage-DC phenotype, 
spontaneously resistant to apoptosis, associated with up-regulation of the pro-survival protein 
BCL2A1. IL-17A-treated DCs were prone to undergo cell fusion to form MGCs and expressed 
a variety of pro-inflammatory molecules, in many ways resembling LCH DCs. We also found 
that IL-17A was present in LCH lesions and that mo-DCs from LCH patients secreted IL-17A, 
in contrast to cells from healthy donors. Moreover, Mo-DCs from LCH patients also expressed 
BCL2A1 and underwent cell fusion spontaneously, a process that was dependent on IL-17A.  
  
The significance of IL-17A in the pathogenesis of LCH is under debate. Yet, our findings 
indicate a role for this cytokine in LCH where IL-17A might contribute to the pro-
inflammatory, tissue degrading environment, characteristic for LCH lesions, and an inefficient 
immune response resulting in the failure of the body to clear the LCH lesions. Moreover, IL-
17A may contribute to an increased viability of LCH DCs allowing for formation of MGCs and 
pro-survival mutations to take place.  
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FOREWORD 
 
 
This thesis embraces studies of different aspects of Langerhans cell histiocytosis 
(LCH). The last three papers focus on a potential role for an inflammatory cytokine, 
interleukin IL-17A (IL-17A), in LCH, while the first two papers of the thesis deal with 
neurodegeneration in LCH and a possible correlation between in vitro fertilization 
(IVF) and LCH, respectively. 
 
To readers outside the immunologic or histiocytosis research fields, the first part of the 
introduction aims to provide a general background of human immunology, of factors 
important for dendritic cell homeostasis and of IL-17A. This part is followed by an 
introduction to LCH and questions that are currently debated regarding the origin of the 
disease. Next, there is a presentation and a discussion of the results of the research 
underlying this thesis with concluding remarks and speculation on future perspectives. 
The final section includes the five papers comprising the thesis.  
 
 
Stockholm, October 2013 
 
 
Selma Olsson Åkefeldt 
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1 INTRODUCTION 
 
1.1 THE IMMUNE SYSTEM – A SHORT OVERVIEW 
 
1.1.1 Innate versus adaptive immunity 
 
The immune system is traditionally divided into two parts; innate immunity and 
adaptive immunity. Innate immunity is responsible for the initial immune response to 
foreign invaders. The first hinder to overcome is provided by physical barriers, such as 
the skin and the mucosa, in combination with antimicrobial peptides (defensins) and 
other antimicrobial agents secreted from the epithelium (Gallo and Hooper, 2012). 
Cells of the innate immune response include monocytes, macrophages, mast cells, 
granulocytes (neutrophils, eosinophils and basophils), natural killer (NK) cells and 
dendritic cells (DCs). The innate immune system recognizes and reacts to molecular 
motifs that have been conserved throughout evolution, known as pathogen-associated 
molecular patterns (PAMPs), in contrast to the disease specific antigens recognized by 
the adaptive immune response. Lipopolysaccharide (LPS), from gram-negative 
bacteria, unmethylated repeats of the CpG dinucleotides present in bacterial DNA, or 
double stranded RNA in viruses are examples of ubiquitous microbial molecules 
recognized through pattern-recognition receptors (PRRs) including toll like receptors 
(TLRs) (Heine and Lien, 2003, Janeway and Medzhitov, 2002). Macrophages, 
neutrophils and dendritic cells engulf (phagocyte) invading pathogens and in response 
to the stimuli mentioned above they secrete biologically active molecules known as 
chemokines and cytokines with a capacity to attract (chemokines) and stimulate 
(cytokines) other cells of the immune system, such as T or B lymphocytes (T or B 
cells).  
 
T and B cells are central for the adaptive immune response. These cells are 
characterized by an extreme variety of receptors, generated by a process called somatic 
recombination, recognizing specific antigens. While B cells mature in the bone marrow 
T cells mature in the thymus where they undergo a rigorous selection process in which 
self-reactive T cells are usually sorted out. DCs are in firm control over this process, 
which is important for “tolerance towards self”. Upon the encounter of a ”non-self” 
molecule DCs initiate cross-talk between the innate and the adaptive immune responses 
by migrating to a lymph node (or other secondary lymphoid organs) where T and B 
cells are activated,  leading to a  clonal expansion of lymphocytes and the establishment 
of specific immunological memory. Thus, the adaptive immune response is slower but 
highly specific and effective upon the re-encounter of a specific antigen (Delves and 
Roitt, 2000b, Delves and Roitt, 2000a) 
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1.1.2 Lymphocytes 
 
T cells mediate cell-mediated immunity whereas B cells support humoral immunity, 
characterized by the formation of antibodies that bind to pathogens mediating their 
destruction by macrophages or the complement system. Cell-mediated immunity is 
important in fighting intracellular infections caused by viruses or intracellular bacteria 
but also in the control of cancer cells. 
 
B and T lymphocytes are original in their highly variable expression of specific antigen 
receptors called BCR (for B cell receptor) and TCR (for T cell receptor), respectively. 
Circulating lymphocytes are naïve as long as their specific antigen receptors have not 
been engaged and they need an additional co-stimulatory signal to enter the cell cycle. 
Thus, two signals are required to activate naïve lymphocytes and to make them divide. 
Following antigen presentation by DCs to T cells, co-stimulation of TCR and CD28 
leads to a double progeny of effector and memory T lymphocytes. In the CD4
+
 (or 
“helper T cell”) sub-population, the activated T lymphocytes express CD154 (or CD40-
ligand), aiding B cell activation. Following the binding of (soluble native) antigen on 
the BCR and CD40 co-stimulation, B cells divide and give rise to a double progeny of 
effector (called plasmocytes) and memory B lymphocytes. In addition the quality and 
intensity of lymphocyte functions are fine-tuned by cytokines. 
 
The transduction chain of TCR, responsible for intracellular TCR signaling, is called 
CD3. Thus all T cells express CD3.
 
There are two major T cell subpopulations: the 
CD4
+
 or helper T cells, able to regulate the functions of other lymphocytes, and the 
CD8
+
 or cytotoxic T lymphocytes (CTLs), able to kill cells infected with intracellular 
pathogens. TCRs recognize antigens as short peptides bound to a major 
histocompatibility complex (MHC) molecule. There are two types of MHC molecules, 
MHC class I and MHC class II. In humans, MHC molecules are referred to as Human 
Leukocyte Antigens (HLA) and HLA-DR corresponds to MHC class II. MHC class II 
molecules are expressed by antigen presenting cells (APCs), including DCs but also 
macrophages and B cells, which capture and present extracellular antigens to helper T 
cells. The T cell co-receptor CD4 binds to a conserved site on the MHC class II 
molecule. In contrast, MHC class I molecules are expressed by almost all nucleated 
cells in the body and present antigens from intracellular pathogens. CTLs are activated 
as their TCRs bind antigens presented on MHC I molecules of infected cells. To initiate 
killing, the binding of their co-receptor CD8 to a specific site on the MHC class I 
molecule is necessary. (Murphy, 2011). 
 
Before 2005, two subclasses of helper T cells had been described: Th1 and Th2, 
characterized by their cytokine profiles. Th1 cells stimulate phagocytosis by 
macrophages and neutrophils either by direct contact with macrophages or by secreting 
activating cytokines, mainly IFN-γ. They are also important in stimulating CTL 
responses. Likewise, B cells depend on stimulation from Th2 cells for their 
differentiation and production of antibodies by cytokines such as IL-4, IL-5 and IL-6. 
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(Delves and Roitt, 2000b, Delves and Roitt, 2000a). In 2005 a third group of helper T 
cells, Th17, was discovered majorly secreting IL-17A but also IL-17F, IL-21, IL-22, 
tumor necrosis factor- α (TNF-α) and IL-26 (Harrington et al., 2005, Park et al., 2005). 
 
Regulatory T cells (Tregs) constitute another subset of T cells that have received much 
attention in the last decade. Tregs come in many forms but those best characterized are 
the naturally occurring CD4
+
CD25
+
 Foxp3
+
 natural regulatory T cells (nTreg cells). 
However there are also types of regulatory T cells (iTreg cells) that are Foxp3
+/-
 and 
that can be induced in the periphery (Toda and Piccirillo, 2006). Regulatory T cells are 
potent suppressors of T cell responses and can induce tolerance to antigens by several 
mechanisms, including secretion of IL-10 and transforming growth factor- β (TGF-β), 
modifying DC stimulation of T cells.  
 
NK cells belong to the innate immune system. They are capable of killing target cells 
through secretion of perforin and other cytotoxic substances. Once activated, they also 
secrete large amounts of cytokines, such as IFN-γ. NK cells are important in tumor 
surveillance and in killing virus-infected cells but also in terminating an immune 
response (Moretta et al., 2002, Janka, 2012). 
 
1.1.3 Monocytes 
 
Monocytes are mononuclear cells that circulate the blood, spleen and bone marrow. 
They do not proliferate under steady state conditions. Upon inflammation they migrate 
to sites of inflammation where they have the potential to differentiate into macrophages 
(under the influence of macrophage colony-stimulating factor (M-CSF)) or into DCs 
(under the influence of granulocyte macrophage colony-stimulating factor (GM-CSF) 
and IL-4) (Auffray et al., 2009, Geissmann et al., 2010). 
  
1.1.4 Macrophages  
 
Macrophages are resident phagocytic cells in lymphoid and non-lymphoid tissues that 
are believed to be important in tissue homeostasis by the clearance of apoptotic cells 
and production of growth factors. Macrophages express a number of pattern-
recognition receptors making them efficient in responding to foreign material and 
initiating an immune response by secreting inflammatory cytokines.  
 
1.1.5 Dendritic cells (DCs) 
 
DCs constitute a heterogeneous group of hematopoietic cells. Immature DCs are 
equipped with a strong phagocytic capacity. As they process antigens, DCs mature to 
potent antigen presenting cells, efficient in initiating adaptive immune responses. For 
naïve T cells to be activated by DCs two signals are required: TCR engagement by an 
antigen presented by MHC molecules on the surface of the DCs and CD28 binding by 
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co-stimulatory molecules expressed by DCs such as CD80 and CD86. Co-stimulatory 
molecules are up-regulated in DCs in response to danger signals downstream of PRR 
activation. Depending on the type of immune response needed, in addition to activating 
cell cycling in naïve T cells, DCs can direct T cell differentiation into different kinds of 
effector T cells through secretion of different cytokines. Furthermore, DCs are also 
critical in inducing tolerance, to protect us from unwanted immune responses. DCs 
initiate programmed cell death in self-reactive T cells that bind too hard to self-MHC 
molecules in the thymus but they can also render T cells in the periphery anergic, as 
occurs when a T cell recognizes an antigen bound to an MHC molecule in the absence 
of co-stimulatory molecules.  
 
DCs are distributed throughout the body but are enriched in lymphoid organs and 
where environmental contact is high. Normally, however, they are quite rare cells, 
accounting for around 1 % of all cells in lymphoid organs and even lower numbers in 
non-lymphoid organs and in the blood (Steinman, 1991). As DCs have taken up 
antigens they move from sites of infection to lymphoid organs to interact with T cells. 
 
DC subsets are characterized by their membrane markers, their localization in vivo, 
their migrating abilities, their cytokine production and their functions (Geissmann et al., 
2010, Merad and Manz, 2009). Individual DC populations may share tissue markers 
with macrophages and may sometimes be difficult to ascribe to one population or 
another (Geissmann et al., 2010). Classical myeloid DCs are normally separated from 
plasmacytoid DCs. Plasmacytoid DCs are specialized in secreting type I interferons in 
response to viral infections and to prime T cells against viral antigens. They have a 
relatively long half-life (Liu, 2005). In the text below, the focus is on classical myeloid 
DCs.  
 
In vivo, steady state DC half-life is not really known but studies on mice have indicated 
that it ranges from days to a few weeks depending on the localization (Kamath et al., 
2002, Ruedl et al., 2000). With the exception of Langerhans cells (LCs), microglia and 
thymic DCs (as demonstrated in mice), DCs generally do not divide, and are thought to 
be replaced by blood-borne progenitor cells. (Merad and Manz, 2009, Ajami et al., 
2007).  
 
Mouse studies have shown that DCs can be obtained from a very early bone-marrow 
derived progenitor shared with the other cells of the mononuclear phagocyte system, 
monocytes and macrophages, called the “monocyte-macrophage-DC progenitor” 
(MDP). Downstream of this progenitor there is a common DC progenitor (CDP) that 
can give rise to classical myeloid DCs and plasmacytoid DCs but not to monocytes or 
macrophages, which thus normally develop independently of DCs (Hettinger et al., 
2013, Liu et al., 2009). Under steady state conditions, fms related tyrosine kinase 3 
ligand (FLT3L) has been shown to be the major cytokine of importance for DC 
differentiation and survival in vivo (Merad and Manz, 2009).  
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Even if monocytes are thought to contribute little to DC development under steady state 
conditions, in inflammatory conditions monocytes do differentiate into DCs and 
provide an important source of these cells, as has been shown in mice by Cheong et al. 
and in humans by Segura et al. (Cheong et al., 2010, Segura et al., 2013). Accordingly, 
during inflammation GM-CSF increases in serum (Merad and Manz, 2009). 
 
In vitro, DCs can be generated either by differentiation of CD34
+
 progenitors, highly 
enriched in cord blood, with GM-CSF and TNF-α (Caux et al., 1992) or by 
differentiation of monocytes in the presence of GM-CSF and IL-4 (Sallusto and 
Lanzavecchia, 1994). Similarly to LCs, all DCs generated from monocytes with GM-
CSF and IL-4 express CD1a. 
 
1.1.6 Langerhans cells (LCs) 
 
LCs were actually the first dendritic cells to be described, named after Dr Paul 
Langerhans, who first characterized them as early as 1868 (Langherhans, 1868). LCs 
are mainly found in the epidermis of the skin where they constitute about 2-8% of the 
epidermal cells, providing a barrier against foreign invaders. In 1961, following the 
introduction of electron microscopy and the possibility to study LCs ultrastructurally, 
the discovery of the intracytoplasmic Birbeck granules was made (Birbeck et al., 1961). 
Demonstration of Birbeck granules has since then been a method to identify LCs in 
other tissues than the skin.  
 
However, it was not until the major advances of immunology following the discovery 
of the MHC molecules and the role of DCs in initiating immune responses (Steinman 
and Cohn, 1973) at the beginning of the 1970’s that the role of LCs began to be 
revealed. LCs have then successively been shown to be antigen presenting cells 
constitutively expressing MHC class II and high levels of Langerin/CD 207 and CD1a 
(Rowden et al., 1977, Silberberg, 1971, Valladeau et al., 2000, Romani et al., 2010). 
  
While Langerin/CD207 is a transmembrane protein that binds microbial glycolipids, 
which induces the formation of intracellular Birbeck granules, CD1a is an MHC class I 
homolog that is important for the presentation of foreign glycolipids and lipid antigens 
to T cells (Porcelli and Modlin, 1999, Valladeau et al., 2003). Langerin/CD207 is 
internalized by receptor-mediated endocytosis and accumulated in the Birbeck granules 
where antigens then are loaded onto CD1a and presented to T cells in the lymph nodes. 
Both CD1a and Langerin/CD207 are often used to identify human LCs. However, in 
humans, CD1a is also a marker of monocyte-derived DCs and lately it has been shown 
in mice that Langerin/CD207 is also expressed by CD8
+
 DCs in lymphoid organs and 
by a population of DCs present in the lung and dermis (Bursch et al., 2007, Ginhoux et 
al., 2007, Poulin et al., 2007, Idoyaga et al., 2009). Thus, neither CD1a nor 
Langerin/CD207 are exclusive markers for LCs. 
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In their resting state LCs express adhesion molecules, such as E-cadherin and EpCAM 
(CD326, TACSTD1), anchoring the cells to neighboring keratinocytes (Tang et al., 
1993, Merad et al., 2008). Upon stimulation by an antigen, E-cadherin and CCR6 are 
down-regulated, while CCR7, the receptor for the chemokines CCL19 and CCL21, is 
induced. This facilitates detachment from the epithelium and migration towards 
draining lymph nodes. As LCs leave the epidermis they undergo a maturation process 
demonstrated by up-regulation of MHC class II molecules and co-stimulatory factors 
such as CD80, CD86 and CD40 useful for T cell activation (Merad et al., 2008).  
 
In contrast to other DCs, LCs have a remarkably long lifespan with a half-life of 53-78 
days in the epidermis (Vishwanath et al., 2006). They also proliferate at a low rate, 
approximately 2-3% of the LCs are constantly cycling, but it has been shown that this 
number can increase upon inflammation in response to keratinocyte signaling (Chorro 
et al., 2009). LCs are also resistant to irradiation as has been shown by the presence of 
host LCs in transplanted patients up to 18 months post transplantation (Chorro et al., 
2009, Merad et al., 2002). Under steady state conditions, and perhaps also 
inflammatory conditions, self-renewal of differentiated LCs is thus thought to sustain 
LC homeostasis independently of circulating precursors. This has raised the question of 
the origin of these cells and quite recently it was suggested that LCs develop from an 
embryonic precursor that populates the epidermis before birth, proliferating during the 
first week after birth to establish the LC network (Chorro et al., 2009, Chorro and 
Geissmann, 2010). However, in settings where LCs are depleted, such as pronounced 
inflammation, there might still be a role for replacement by bone-marrow derived 
precursor cells including monocytes (Ginhoux et al., 2006, Merad et al., 2008). This 
discussion is of importance to LCH research as there is currently a debate concerning 
the origin of the pathological DCs in Langerhans cell histiocytosis (LCH DCs). Gene 
expression in LCH DCs has been compared to gene expression in LCs, myeloid and 
plasmacytoid DCs, implicating that Langerhans cells are not the cells of origin for LCH 
DCs after all (Allen et al., 2010b, Hutter et al., 2012). 
 
Studies on mice have shown that TGF-β is critical for LC development in vivo (Merad 
and Manz, 2009). Experimentally, LCs can be generated from monocytes by 
stimulation with IL-4, GM-CSF and TGF-β (Geissmann et al., 1998) and from CD34+ 
hematopoietic progenitors by stimulation with various cytokines including GM-CSF, 
TNF-α and TGF-β (Jaksits et al., 1999, Caux et al., 1992).  
 
1.1.7 Giant cells 
 
Multinucleated giant cells (MGCs) are seen in various infectious and non-infectious 
granulomatous disorders, including tuberculosis, schistosomiasis, Crohn’s disease, 
sarcoidosis and LCH. They are thought to arise by the fusion of cells from the myeloid 
lineage in response to microbial or inflammatory stimuli as has already been 
demonstrated for another type of MGCs, osteoclasts, which are bone resorbing cells. 
The latter can be obtained in vitro by the fusion of either monocyte or dendritic cells in 
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the presence of M-CSF and receptor activator of nuclear factor κВ ligand (RANKL) 
(Fujikawa et al., 1996, Rivollier et al., 2004).  
 
 
Figure 1. Schematic, simplified picture of the differentiation of DCs in relation to   
                other cells of the mononuclear phagocyte system.  
 
 
 
Under steady state DCs differentiate from DC progenitors under the influence of FLT3L. Under 
inflammatory conditions monocytes differentiate into DCs. GM-CSF is thought to be important 
for this way of DC differentiation. HSC Hematopoietic stem cell, CMP common myeloid 
progenitor, MDP monocyte/macrophage, CDP common DC progenitor, cMOP common 
monocyte progenitor. LC homeostasis is thought to be sustained independently of circulating 
precursors under steady state and perhaps also under inflammatory conditions. 
 
 
1.1.8 Tumor-associated macrophages (TAMs) 
 
In recent years there has been growing evidence for a role of so called tumor-associated 
macrophages (TAMs) in tumor development. As monocytes are attracted to tumor sites 
the microenvironment surrounding the tumor promotes differentiation of macrophages 
with different characteristics. Analogous to the classical Th1/Th2 distinction of T cells 
macrophages can be divided into M1 and M2 subtypes (Mantovani et al., 2002). 
“Classical”, or M1-type macrophage activation, occurs either in response to microbial 
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alarm signals or to IFN-γ and is of vital importance in the defense against microbes but 
also in eliminating tumor cells. M1 macrophages are potent APCs, promote Th1 
responses, and generate high amounts of toxic compounds such as nitric oxide (NO) 
and reactive oxygen species. They are characterized by a high expression of MHC class 
II, inducible nitric oxide synthase (iNOS), TNF-α, IL-12 and IL-23 as well as a low 
expression of IL-10 (Sica et al., 2008, Mantovani et al., 2002). This type of 
macrophages is rarely found at a tumor site except in the early phases of tumor 
development (Sica et al., 2008). When the tumor is growing, TAMs are usually 
converted from an M1 to an M2, or “alternative”, phenotype by factors in the 
microenvironment, such as IL-4 or IL-13 (Sica et al., 2008, Biswas et al., 2013). M2 
macrophages are thought to be of importance in the protection against parasites and in 
tissue remodeling but can also promote tumor growth in several ways. They are 
characterized by a low expression of IL-12, IL-23 and MHC class II but a high 
expression of IL-10, TGF-β, macrophage mannose receptor (MMR), arginase-1 (Arg-1) 
and scavenger receptors. Tumor growth and spread is facilitated by their secretion of 
matrix metalloproteinases (MMPs) and other tissue degrading enzymes, as well as 
secretion of proangiogenic and growth promoting substances (e.g. epidermal growth 
factor (EGF), vascular endothelial growth factor (VEGF) and TGF-β). Inhibition of 
adaptive anti-tumor responses is also achieved through induction and recruitment of 
Tregs, inhibition of DC maturation and inhibition of Th1 cell responses (Mantovani et 
al., 2013, Sica et al., 2008).  
 
1.1.9 Myeloid-derived suppressor cells (MDSCs) and tumoral DCs 
 
Myeloid-derived suppressor cells (MDSCs) constitute a heterogeneous population of 
immature myeloid progenitor cells including precursors of DCs, macrophages and 
granulocytes, recruited to tumoral sites that are also thought to be important in 
suppressing an anti-tumoral immune response (Gabrilovich and Nagaraj, 2009). 
Although mature DCs are potent initiators of immune responses against tumors, factors 
secreted by tumor cells or associated cells, such as IL-10 may retain DCs in an 
immature state (Gabrilovich, 2004). Since the expression of co-stimulatory molecules 
on immature DCs is low, interaction with T cells supports T cell anergy rather than 
activation, thus preventing an efficient anti-tumor response. DCs affected by a tumoral 
microenvironment have also been shown to be able to induce Tregs and to skew 
immune responses towards a Th2 type of immunity of little value in the fight against 
tumors (Ghiringhelli et al., 2005, Yang et al., 2010).  
 
1.1.10 Histiocytes 
 
“Histiocyte” is the traditional, historic name to describe a tissue resident cell of the 
mononuclear phagocytic system lineage, i.e. macrophages and dendritic cells, in 
contrast to circulating monocytes.  
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1.1.11 Granulomas 
 
Granulomas are small nodules of inflammatory mononuclear cells accompanied by 
other infiltrating leukocytes, fibroblasts and MGCs. The mononuclear cells can be more 
or less organized and are often surrounded by fibrosis. Granulomas associated with 
tuberculosis often have a necrotic chore which is usually not the case in non-infectious 
granulomas. Granulomas are thought to be a means to wall off foreign substances that 
are not possible to eliminate but are also associated with a high inflammatory activity 
and tissue destruction. As for Crohn’s disease or sarcoidosis, exactly what triggers 
granuloma formation in LCH is unknown.  
 
 
1.2 DENDRITIC CELL HOMEOSTASIS 
 
Since DCs are normally not able to proliferate (LCs and microglia excepted) their 
homeostasis is dependent on their production from precursor cells and their ability to 
survive. Tight control of DC homeostasis is important to avoid overstimulation of 
immune responses, resulting in tissue damage and autoimmunity as has been shown in 
autoimmune lymphoproliferative syndrome type II (ALPS type II) (Wang et al., 
1999b). DC half-life can be prolonged by inflammatory or infectious stimuli (Marsden 
and Strasser, 2003). Considering that the proliferation rate of LCH DCs is thought to be 
low (around 2%) (Senechal et al., 2007, Brabencova et al., 1998), an increased viability 
rather than proliferation of LCH DCs might contribute to the pathological accumulation 
of LCH DCs typically seen in this disease.  
 
As for other cells, DC life is controlled through apoptosis. Apoptosis, or programmed 
cell death, is initiated through extrinsic or intrinsic pathways. Extrinsic apoptosis is 
mediated through death ligands such as CD95/FASL, tumor necrosis factor (TNF) or 
TNF-related apoptosis-inducing ligand (TRAIL). When these molecules stimulate their 
receptors (including FAS, TNFR1 and TRAIL-R) a death-inducing signaling complex 
(DISC) is activated. This activation in turn initiates caspase activation and 
mitochondria independent apoptosis (Kischkel et al., 1995). Death receptors are 
specifically important to terminate an immune response. DCs express several of these 
receptors, CD95/FAS, TNFR and TRAIL-R, and are sensitive to apoptosis mediated 
through FASL, TNF and TRAIL depending on the dose (Chen et al., 2006, Diehl et al., 
2004, Funk et al., 2000). However, formation of the death-inducing signaling complex 
can be inhibited by a protein called CFLAR (CASP8 and FADD-like apoptosis 
regulator) formerly named FLIP (FLICE-inhibitory protein). The relative resistance to 
CD95/FAS-mediated apoptosis seen in myeloid DC is thought to depend on the 
expression of CFLAR by these cells (Willems et al., 2000).  
 
While immature DCs in general are quite resistant to extrinsic death factors they have 
been shown to be very sensitive to UVB irradiation, which leads to apoptosis through 
intrinsic apoptosis (Nicolo et al., 2001). Intrinsic apoptosis in general results from 
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intracellular stress such as UV irradiation, cytokine withdrawal or cytotoxic drugs and 
is controlled by the proteins of the B-cell lymphoma 2 (BCL2) family (Marsden and 
Strasser, 2003). Proteins belonging to the BCL2 family regulate survival and 
susceptibility to apoptosis by governing mitochondrial outer membrane 
permeabilization and release of cytochrome c from mitochondria in the intrinsic 
apoptotic pathway (Frenzel et al., 2009). This family consists of three different groups 
of proteins, sharing sequence homology in their BCL2 homology (BH) domains. Pro-
survival members constitute one group and include BCL2, MCL1, BCLXL, BCLW 
and BCL2A1. Pro-apoptotic members are divided into two groups, the multidomain 
proteins, BAX and BAK and the BH3-only proteins BIM, BID, BAD, PUMA and 
NOXA (Youle and Strasser, 2008). An intrinsic balance between these proteins 
controls the activation of BAK and BAX. Activated, BAK and BAX form pores in the 
outer membrane of the mitochondria, which leads to cytochrome c release, activation of 
caspases and triggering of the death cascade, resulting in apoptosis. Classically, in 
living cells, BAK and BAX are thought to be sequestered by pro-survival members of 
the BCL2 family. Activation of the BH3-only proteins by cellular stress leads to direct 
activation of BAK and BAX or binding and inhibition of the pro-survival members, 
resulting in apoptosis. However, the exact mechanisms that regulate these events under 
different conditions are not fully known. 
 
Aberrant expression of pro-survival BCL2 family proteins is common in human 
cancers as a consequence of carcinogenic mutations, and associated with resistance to 
therapy. However, up-regulation of pro-survival BCL2 proteins is also seen in response 
to inflammatory stimuli, as reported for example in inflammatory bowel disease (IBD), 
where up-regulation of BCL2 and BCXL downstream of IL-6 is associated with 
prolonged T cell survival and reinforced inflammation (Mudter and Neurath, 2007). 
 
Compared to lymphocytes, knowledge of DC survival regulation by the BCL2 family is 
rather scarce. MCL1 has been described to be expressed at steady state in granulocytes, 
monocytes and dendritic cells (Kelly and Strasser, 2011, Craig, 2002). However, 
inflammatory stimuli, drastically enhancing survival of DCs, seemingly act on various 
molecules of the BCL2 family. TLR signaling, for example, has been shown to up-
regulate BCL2 and BCLXL, as well as inhibitor of apoptosis (IAP) proteins, in DCs 
(Park et al., 2002). In addition, Björck et al. have demonstrated that DCs up-regulate 
BCL2 in response to CD40 ligation by T cells (Bjorck et al., 1997).  
 
Several cytokines prolong the viability of DCs. The role of FLT3L in differentiation 
and survival of DCs in vivo has already been touched upon. GM-CSF has been shown 
to synergize with FLT3L to stimulate DC survival in vivo (Kingston et al., 2009). 
Withdrawal of GM-CSF from bone-marrow derived DCs resulted in up-regulation of 
the pro-apoptotic factor BIM and an accelerated cell death. Further, as M-CSF and 
RANKL stimulate MGC osteoclast formation by fusion of DCs, BCL2 is up-regulated 
(Rivollier et al., 2004, Yamashita et al., 2008). On the contrary, in one study, IL-10 
promoted DC apoptosis in monocyte-derived DCs from humans by inhibiting 
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expression of the pro-survival molecules BCL2, BCL2A1 and BCLXL (Chang et al., 
2007). 
 
Several of these mechanisms may affect the survival of LCH DCs as is further 
discussed in section 1.9.3 and 1.9.4. 
 
 
 
 
  
 
 
Figure 2. Schematic picture of the intrinsic and extrinsic apoptosis pathways. 
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1.3 IL-17A 
 
1.3.1 Molecular characteristics 
 
IL-17A was first described in 1993 and was then referred to as cytotoxic T lymphocyte 
antigen 8 (CTLA8) (Rouvier et al., 1993). It was initially recognized to have a viral 
homolog encoded within the Herpesvirus Saimiri (HVS), a T lymphotrophic virus 
known to infect primates. Subsequently, several molecules with a homologous domain 
shared with IL-17A, have been described, constituting the IL-17 family: IL-17A 
(previously known as IL-17) IL-17B, IL-17C, IL-17D, IL-17E (IL-25) and IL-17F 
(Iwakura et al., 2011). IL-17A remains the best characterized member of the IL-17 
family. The gene for IL-17A is located on chromosome 6p12. IL-17A is to almost 60% 
homologous to IL-17F and the genes are located nearby in the same chromosomal 
region. These cytokines share many functions, however, IL-17F is a weaker inducer of 
inflammatory cytokines than IL-17A. Both IL-17A and IL-17F can be secreted as 
homodimers but they can also form functional heterodimers called IL-17A/F with an 
intermediate activity between IL-17A/A “high activity” and IL-17F/F “low activity”. 
(Chang and Dong, 2007, Wright et al., 2007). The human IL-17A is composed of 155 
amino acids and weighs about 17 kDa. Human IL-17F weighs about 18 kDa. 
 
1.3.2 Receptor signaling 
 
Members of the IL-17 family signal through IL-17 receptors (IL-17R). Today five 
different subunits have been characterized (IL-17RA to IL-17RE). IL-17A/A and IL-
17F/F homodimers as well as the IL-17A/F heterodimer signal through a multimeric 
receptor complex composed of one IL-17RA and two IL-17RC subunits (Kramer et al., 
2006, Toy et al., 2006). IL-17RA is ubiquitously expressed, with particularly high 
levels in immune cells while IL-17RC is preferentially expressed in non-immune cells 
(Haudenschild et al., 2002, Kuestner et al., 2007). Therefore, it is still not clear how 
myeloid cells which are IL-17RA
+
/IL-17RC
-
 bind IL-17A. Different expression of IL-
17RA and IL-17RC in different cell types may account for tissue specific functions of 
IL-17A (Zhu and Qian, 2012). 
 
Most genes encoding pro-inflammatory molecules that are up-regulated by IL-17A are 
induced by the transcription factor NF-κВ (Qian et al., 2007). As IL-17A binds to its 
receptor the adaptor molecule Act1 is recruited. This in turn leads to recruitment of 
TRAF6 (an adaptor molecule used also for TLR and TNF signaling), and the kinase 
TAK1 (transforming growth factor β-activated kinase 1). The Act1/TRAF6/TAK1 
complex then activates the transcription factors NF-κВ, C/EBP (CCAT/enhancer-
binding proteins) and AP-1. In 2011 it was demonstrated that IL-17RA could also 
signal through a TRAF6 independent pathway, involving the inducible kinase IKKi 
(inducible inhibitor of NF-κВ (IκВ) kinase), which is recruited to the IL-17R-Act1 
complex and mediates Act1 phosphorylation (Iwakura et al., 2011). This pathway is 
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still not very well characterized. The capacity of IL-17A to up-regulate pro-
inflammatory molecules is generally not as strong as that of some other potent pro-
inflammatory cytokines, such as TNFα or IL-1β. However, IL-17A often acts in 
synergy with other cytokines to up-regulate pro-inflammatory molecules. Several IL-
17A target genes are also controlled post transcriptionally by stabilization of mRNA, 
e.g. CXCL1, CXCL2 and IL-6 (Hartupee et al., 2007, Onishi and Gaffen, 2010). 
 
1.3.3 Sources of IL-17A 
 
Th17 cells, described in 2005, were initially thought to be the exclusive source of IL-
17A (Harrington et al., 2005, Park et al., 2005), but later studies have shown that also 
other cell types can secrete IL-17A, including many cells of the innate immune system 
in response to innate signals. Such cells include γδ-T cells NK cells, NKT cells, 
lymphoid tissue inducer-like cells, neutrophils, macrophages, mast cells and, as 
presented in paper III in this thesis, DCs (Cua and Tato, 2010, Coury et al., 2008). The 
crucial combination of cytokines to stimulate Th17 differentiation in humans is still 
debated. Several studies have shown that TGF-β, IL-1β and IL-6 are important (Manel 
et al., 2008). Some cytokines also have the capacity to amplify a Th17 response, such 
as IL-21, IL-23, TNF-α and IL-1β. Out of these, IL-23 is necessary for the expansion, 
stabilization and maintenance of the Th17-phenotype and may serve as a survival factor 
for these cells (McGeachy and Cua, 2008). Th17 cells characteristically express the 
chemokine receptor CCR6, allowing their migration to sites of inflammation (Hirota et 
al., 2007). Although other transcription factors may also induce IL-17A, the 
transcription factor RORγt (retinoic acid related orphan receptor gamma t) has been 
best characterized as a positive regulator of IL-17A (Zhu and Qian, 2012).  
 
1.3.4 IL-17A in host defense 
 
IL-17A is thought to be important in host defense against certain microbes but has also 
been implied as a driving factor in chronic inflammation. 
 
IL-17A exerts an effect on a wide variety of cells, including fibroblasts, endothelial 
cells, epithelial cells and immune cells (Kolls and Linden, 2004, Xu and Cao, 2010) . 
Molecules induced by IL-17A include many potent cytokines (e.g. IL-6, G-CSF, TNF-
α), chemokines (CXCL1, CXCL2, CXCL8 and CCL20), inflammatory effectors (acute 
phase proteins, complement factors, nitric oxide, PGE2) and antimicrobial proteins 
(defensins, mucins). G-CSF and CXCL-8 are important for granulopoesis and 
recruitment of neutrophils to sites of inflammation (Schwarzenberger et al., 1998, 
Forlow et al., 2001). IL-17A also mediates recruitment of Th1 cells through release of 
chemokines such as CXCL9, CXCL10 and CXCL11 (Khader et al., 2007). By inducing 
release of CCL20 from fibroblasts and Th17 cells, IL-17A attracts CCR6
+
 DCs and 
more Th17 cells, thus creating a positive feedback loop favoring their own recruitment 
and amplifying the inflammatory response (Pene et al., 2008). 
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IL-17A is rapidly up-regulated in response to microbial infection in mice, and mice 
lacking IL-17A or IL-17RA are susceptible to infection with various bacteria, fungi and 
parasites such as Citrobacter rodentium, Escherichia coli, Pseudomonas aeruginosa, 
Klebsiella pneumoniae, Candida albicans and Toxoplasma gondii (Shibata et al., 2007, 
Liu et al., 2011, Ye et al., 2001, Huang et al., 2004, Kelly et al., 2005, Mangan et al., 
2006).  For extracellular bacteria the susceptibility to infection following a defective 
IL-17A response is largely thought to depend on impaired production of chemokines 
and the lack of a granulocyte response. When it comes to clearance of intracellular 
bacteria the role of IL-17A is less clear. IL-17A is thought to contribute to the Th1 
response of main importance against these pathogens (Lin et al., 2009, Khader and 
Gopal, 2010). It is required for an efficient vaccine response to Mycobacterium 
tuberculosis and has been shown to be of importance in the formation of granulomas 
against mycobacteria (Khader et al., 2007, Umemura et al., 2007, Okamoto Yoshida et 
al., 2010).  
 
Lately, several genetic conditions where an impaired IL-17A response is thought to 
contribute to the clinical picture have been identified, including IL-17RA deficiency 
(Puel et al., 2011) but also hyper Ig-E syndrome (HIES) (Milner et al., 2008) resulting 
in recurrent cutaneous candidiasis or staphylococcal infections. 
 
There are however also examples of exaggerated IL-17A production following 
bacterial infection that may lead to increased tissue damage, e.g. gastritis in 
Helicobacter pylori infection (Luzza et al., 2000) or extensive granuloma formation in 
schistosomiasis (Rutitzky and Stadecker, 2011). In schistosomiasis as well as in 
mycobacterial infection the balance between an immune response sufficient to take care 
of the infection and an exaggerated immune response, resulting in granuloma-induced 
pathogenesis and tissue damage, is important for the clinical outcome. A pathological 
role of IL-17A in granuloma-induced pathogenesis has been demonstrated by Cruz et 
al. (Cruz et al., 2010). It has for long been known that repeated exposure to Bacille 
Calmette-Guerin (BCG) of animals previously infected with mycobacteria might result 
in increased tissue damage at the site of infection, a response called the Koch 
phenomenon. Cruz and co-workers showed that such tissue damage was associated 
with increased IL-17A producing cells in the lesions and that antibodies blocking IL-
17A prevented this pathological response in mice (Cruz et al., 2010).   
 
Further, IL-17A is thought to contribute to the cytokine storm seen in some viral 
infections. In an influenza infection model survival was better for IL-17RA-/- mice 
than for wild type mice, linked to a reduction in neutrophil stimulating cytokines and 
chemokines (Crowe et al., 2009). 
 
1.3.5 IL-17A in chronic inflammatory and autoimmune diseases 
 
The etiology of autoimmune diseases is still not clear even if it is generally believed to 
be based on an escape of autoreactive T and B cells from the normal selection leading 
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to tissue infiltration and inflammation. Through animal disease models or the study of 
patients IL-17A has been implied in the pathogenesis of several inflammatory and 
autoimmune conditions such as rheumatoid arthritis (RA), multiple sclerosis, IBD, 
sarcoidosis, psoriasis and systemic lupus erythematosus (SLE) (Onishi and Gaffen, 
2010, Vaknin-Dembinsky et al., 2006, Yen et al., 2006, Kotake et al., 1999, Miossec, 
2009, Qian et al., 2010, Facco et al., 2011). IL-17A is up-regulated in synovial fluid 
from patients with RA and in CSF from patients with multiple sclerosis as well as in the 
inflamed gut in patients with Crohn’s disease and ulcerative colitis (Chabaud et al., 
1999, Lock et al., 2002, Fujino et al., 2003). In humans, polymorphisms in the IL-23R 
gene important to maintaining an IL-17A response has been shown to be associated 
with IBD and psoriasis (Duerr et al., 2006, Nair et al., 2009). 
 
IL-17A has been shown to act in synergy with various other factors such as IL-1β, IL-
22, TNF-α, IFN-γ, oncostatin M, CD40, B cell-activating factor (BAFF) and vitamin 
D3 (1,25-dihydroxyvitamin D3) (Onishi and Gaffen, 2010, Zhu and Qian, 2012). 
Considering the broad repertoire of pro-inflammatory molecules induced by IL-17A it 
contributes to inflammation in several ways. In rheumatoid arthritis for instance it has 
been suggested to stimulate IL-1β, TNF-α, IL-6 and CXCL8 and other potent pro 
inflammatory cytokines and chemokines. It also induces RANKL and MMPs leading to 
degradation of cartilage matrix, osteoclastogenesis and bone erosion (van den Berg and 
Miossec, 2009, Shen et al., 2005, Chabaud et al., 2000). Although IL-17A seems 
clearly destructive in RA and multiple sclerosis, in IBD different animal models have 
rendered different results and it is still not clear whether IL-17A has a protective role or 
aggravates inflammation here. Nor is the contribution of IL-17A and IL-17F 
respectively, clear regarding the pathogenesis of IBD (Zhang et al., 2006, Yang et al., 
2008, Xu and Cao, 2010). Another granulomatous disease of unknown etiology where 
the role of IL-17A is not fully elucidated is sarcoidosis even if IL-17A producing cells 
have been shown around and inside sarcoid granulomas indicating a role for IL-17A in 
granuloma formation also in this disease (Facco et al., 2011).  
   
1.3.6 IL-17A in malignancies 
 
Virchow postulated that chronic inflammation might facilitate carcinogenesis and 
tumor growth already in the 19
th
 century. This can be exemplified by the development 
of colon carcinoma following IBD or gastric cancer following Helicobacter pylori 
induced gastritis. Vice versa, cancer might be accompanied by inflammation. In many 
settings neoplastic cells elicit an inflammatory environment, especially in their 
premalignant state, utilizing the effects of pro-inflammatory substances to survive and 
grow (Coussens and Werb, 2002, Mantovani et al., 2008). Thus the inflammatory 
response to cancer is a delicate balance between an immune response aiming at 
eliminating neoplastic cells versus promoting their growth. 
 
As IL-17A is associated with chronic inflammation there is a potential for IL-17A to be 
involved in carcinogenesis. Clinically, infiltration of IL-17A producing cells in tumors 
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has been associated with a poorer prognosis for several cancers including colon, 
hepatocellular and breast cancer (Tosolini et al., 2011, Wu et al., 2012, Chen et al., 
2013). IL-17A induction of MMP2 or MMP9 has also been associated with a higher 
frequency of hepatocellular carcinoma metastasis (Li et al., 2011). 
 
However, the role of IL-17A in cancer is controversial, probably reflecting the wide 
variety of effects that IL-17A exerts on different cell types and the intricate interactions 
between cytokines and different cell types in vivo. IL-17A is thought to indirectly 
enhance tumor growth by inducing growth stimulating factors in various tumors, e.g. 
induction of VEGF in mouse models of fibrosarcoma or colon adenocarcinoma 
(Numasaki et al., 2003) or IL-6 promoting growth and survival of human cervical 
cancer cells in nude mice (Tartour et al., 1999). In these studies no direct effect on 
tumor proliferation of IL-17A was seen in vitro. Nevertheless, a direct pro-survival 
effect of IL-17A in combination with TGF-β has been shown in breast cancer cells 
although the molecular mechanisms behind this were not further investigated (Nam et 
al., 2008). On the other hand for two hematopoietic tumors, mastocytoma and 
plasmocytoma, IL-17A prevented tumor development in nude mice through stimulating 
synthesis of specific anti-tumoral CTL (Benchetrit et al., 2002).  
 
Subsequent studies on mice have shown contradictory results regarding tumor 
development in IL-17A -/- knockout mice (Kryczek et al., 2009, Wang et al., 2009). 
Wang et al. noted a reduction of tumor growth in IL-17A-/- mice and thus a tumor 
promoting effect of IL-17A, related to induction of IL-6 in tumor and stromal cells 
(Wang et al., 2009). In contrast, Kryczek et al. reported that tumor growth and 
metastasis was enhanced in IL-17A deficient mice (Kryczek et al., 2009). The 
conflicting results can presumably be attributed to different models. However, in the 
study by Kryczek and colleagues the increase in tumor growth was associated with a 
reduced IFN-γ response, indicating that a potential protective role of IL-17A against 
tumors might be mediated through (or in concert with) IFN-γ. In line with this, He et al. 
has shown that IL-17RA deficient mice do not develop tumors in contrast to IFN-γ 
receptor deficient mice (He et al., 2010). In that study it was also shown that IL-17A 
administration positively correlated to MDSCs infiltrating the tumor and to a reduced 
CD8
+
 T cell infiltration. Further analysis showed that IL-17A was required for the 
development and tumor promoting activity of the MDSC in the mice with tumors. 
 
How IL-17A affects DCs is an important question to address bearing in mind the 
central role that DCs have in initiating and sustaining immune responses in cancers as 
well as in autoimmune or chronic inflammatory diseases and in response to pathogens. 
Following the results from paper III indicating that monocyte-derived DCs treated 
with IL-17A fused to form multinucleated giant cells and were rendered resistant to 
apoptosis, we proceeded to investigate this issue further in paper IV. 
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1.3.7 IL-17A mediated cell survival 
 
The effects of IL-17A on apoptosis and survival have been investigated in a few studies 
and depending on the cell type IL-17A affects cell viability differently. Thus, IL-17A 
has been demonstrated to indirectly enhance survival in fibroblast-like synoviocytes 
(FLS) from patients with RA by modifying expression of the pro-survival protein 
synoviolin (Toh et al., 2010). In a separate study, IL-17A has also been shown to 
prolong survival of FLS from RA patients (in contrast to FLS from patients with 
osteoarthritis) through up-regulation of BCL2 (Lee et al., 2013). STAT 3 was found to 
mediate the IL-17A mediated BCL2 regulation in this case. However, it cannot be 
excluded that this effect was secondary to IL-17A induced IL-6. The different effects of 
IL-17A on FLS from RA patients and patients with osteoarthritis respectively were 
attributed to the different amounts of IL-17A receptors expressed on the respective 
cells, the receptor being more frequent in cells from RA patients.  
 
Studies on mice have shown an increased survival of alveolar macrophages following 
IL-17A stimulation (Sergejeva et al., 2005). Further, Hou et al. have shown an 
increased survival in astrocytes and an increased survival and up-regulation of BCL2 
and BCLXL proteins in B cells and bone marrow cells, but not in bone marrow-derived 
DC (BMDC), following IL-17A stimulation (Hou et al., 2009). On the other hand, there 
are also reports of IL-17A having pro-apoptotic effects on various cells, such as 
vascular endothelial cells and cardiomyocytes (Zhu et al., 2011, Liao et al., 2012). 
Together with TNF-α, IL-17A has also been reported to promote apoptosis in 
oligodendrocytes from mice (Paintlia et al., 2011).  
 
Before we undertook our studies, to our knowledge, there were no studies on how IL-
17A affects human DC survival, let alone whether this could be a mechanism of 
importance to sustain granuloma formation in LCH. 
 
 
  
  
18 
 
1.4 HISTORICAL BACKGROUND OF LCH 
 
Langerhans cell histiocytosis (LCH) is a disease that comes in many guises. This is 
reflected in the long time it took to group the different aspects of the disease under one 
diagnosis and the difficulties, still as of today, to establish the etiology of LCH.  
 
Non-fatal but painful bone lesions, possibly LCH, were already described by 
Hippocrates around 400 BC (Donadieu and Pritchard, 1999). However, LCH begins to 
emerge in the medical literature in 1865 when Dr. Thomas Smith published a case 
report on a four and half-year-old boy with skin eruptions and three large erosions in 
the skull regarded as a congenital condition but later suggested to be the first reported 
case of LCH (Smith, 1865). Nevertheless, the earliest report of LCH most often 
referred to is a case report from 1893 by Dr. Alfred Hand at Philadelphia Children’s 
Hospital who described a three-year-old boy with skull lesions, exophthalmos, 
polydipsia and polyuria, hepatosplenomegaly and a macular rash. These findings were 
initially ascribed to tuberculosis (Hand, 1893). In 1915, Dr. Arthur Schüller in Vienna 
described two other patients with skull lesions and exophthalmos, one girl of four who 
also had diabetes insipidus (DI) and one adolescent with adiposogenital dystrophy. This 
caused Schüller to believe that the pituitary gland was involved in both cases (Schüller, 
1915). It was Dr. Henry A. Christian in Boston, however, who in 1919 suggested that 
the triad of exophthalmos, skull lesions and DI were interconnected and the eponym 
Hand-Schüller-Christian disease eventually came in to use. Christian ascribed the 
findings primarily to pituitary dysfunction (Christian, 1919) and treated the DI 
successfully with subcutaneous pituitary extract. Hand was however troubled by the 
lack of effect of pituitary extract on the lytic bone lesions and suggested that the disease 
was caused by pressure from either a neoplastic or a benign (infectious) process, hereby 
foreseeing a still ongoing debate (Hand, 1921). 
 
In 1924, Dr. Erich Letterer in Tübingen described an acute, fulminant disorder of the 
reticulo-endothelial system in a six-months-old child with hepatosplenomegaly, anemia 
and purpura not perceived as leukemia (Letterer, 1924). Nine years later Dr. Sture Siwe 
in Lund reported a similar case and grouped them under the name Letterer-Siwe 
disease, a condition including hepatosplenomegaly, lymphadenopathy, localized tumors 
of the bone, hemorrhagic tendency, anemia and hyperplasia of non-lipid-storing 
macrophages in various organs (Siwe, 1933). 
 
A third form of LCH was described in 1940. That year two reports from New York on 
what was later termed eosinophilic granuloma of the bone, were presented by Dr. 
Sadao Otani and Dr. Joseph C. Ehrlich (Otani and Ehrlich, 1940) and by Dr. Louis 
Lichtenstein and Dr Henry Jaffe (Lichtenstein and Jaffe, 1940) respectively. The 
condition was thought to be benign in spite of the radiological and the microscopic 
picture. Surprisingly, already the same year Dr. Arvid Wallgren in Gothenburg, and 
one year later Dr. Sidney Farber in Boston, presented evidence that bone lesions in the 
three conditions presented above (Hand-Schüller-Christian disease, Letterer-Siwe 
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disease and eosinophilic granuloma) were microscopically identical (Farber, 1941, 
Wallgren, 1940). Dr. Farber suggested that all three disorders represented “variations in 
degree, stage of involvement and localization of the same basic disease process”. In 
1953, Dr. Lichtenstein introduced the unifying concept of “Histiocytosis X” 
(Lichtenstein, 1953). Twenty years later, in 1973, Nezelof et al. suggested that the 
disease was the result of proliferation and dissemination of LCs (Nezelof et al., 1973). 
The name was eventually changed to Langerhans cell histiocytosis following the 
recommendations of the Writing Group of the, at that time, recently founded Histiocyte 
Society, in 1987 (Chu et al., 1987).  
 
The Histiocyte Society was founded in 1985 with Dr. Christian Nezelof as its first 
president. The Histiocyte Society is a nonprofit international organization gathering 
clinicians and researches to share and spread information about the histiocytic disorders 
as well as coordinating clinical and laboratory studies. The year after, the Histiocytosis 
Association was founded, a supportive international organization of parents, patients, 
physicians and friends.  
 
 
1.5 INCIDENCE AND EPIDEMIOLOGY OF LCH 
 
1.5.1 Incidence 
 
LCH can present at any age from birth to old ages but with a peak incidence in children 
between 0-4 years of age (Salotti et al., 2009, Guyot-Goubin et al., 2008, Stalemark et 
al., 2008) The incidence differs in recent studies from 2.2 per million children (0-18) 
(Muller et al., 2006) and year to 8.9 per million children (0-15 years) and year 
(Stalemark et al., 2008), probably reflecting differences in the identification of patients 
(suggesting under-reporting in some studies), and different age cut offs, as LCH is 
more common at a younger age (Alston et al., 2007, Muller et al., 2006, Salotti et al., 
2009, Stalemark et al., 2008, Guyot-Goubin et al., 2008). Nevertheless, genetic or 
environmental factors influencing the incidence of LCH in different areas cannot be 
ruled out. In reality, the incidence of LCH may be even higher than reported since mild 
cases may go underdiagnosed.  
 
The higher incidence in young children was illustrated in a recent study from the UK 
and Ireland including 94 pediatric LCH cases identified through various methods 
(Salotti et al., 2009). The incidence rate of LCH in children 0-14 years of age was 
reported to be 4.1 per million children and year in this study but in children < 1 year of 
age the incidence was 9.9 per million and year. The incidence dropped markedly in 
children 10 years and older.  
 
In adults, the incidence is even harder to evaluate since the wide spectrum of clinical 
manifestations leads the patients to a variety of clinicians and LCH symptoms may go 
misinterpreted due to lack of awareness of LCH.  
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Males are affected somewhat more often than females and a male:female ratio as high 
as 2:1 has been reported (Broadbent et al., 1994). 
 
1.5.2 Associated factors 
 
Several studies have shown an association between smoking and the development of 
pulmonary LCH in young adults (Colby and Lombard, 1983, Vassallo et al., 2000). 
Otherwise the knowledge of factors that could possibly contribute to LCH is quite 
scarce.  
 
In an extensive Danish epidemiological study, including one million children under the 
age of 15 years, 90 children with LCH were found (diagnosed between 1975 and 1989), 
giving an incidence of 5.4 per million children per year (Carstensen and Ornvold, 
1993). In that study possible effects of pre- and post-natal risk factors such as route of 
delivery, birth complications, low birth weight, AB0 and Rh blood type, were analyzed 
but none of these factors turned out to be significant. 
 
Two often cited reports from North America were published in 1997 (Bhatia et al., 
1997, Hamre et al., 1997). Hamre et al. found an association between LCH and 
maternal urinary tract infection during pregnancy as well as feeding problems, 
medication use and post natal blood transfusions during the first six months of life 
(Hamre et al., 1997). This study also showed an association with a family history of 
benign tumors. The second study, which was a larger case-control study, including 459 
children with LCH, showed an association between LCH and infections in the neonatal 
period, as well as between LCH and thyroid disease in the proband and in the family 
(Bhatia et al., 1997). The association with thyroid disease in the proband depended to 
some extent on pituitary involvement of LCH but remained also after exclusion of such 
cases. In addition, this study showed a protective role of childhood vaccinations. As 
with the problems in infancy it is however hard to know whether this could be related 
causally to LCH. Both studies found an association with solvent exposure and LCH, 
especially for single system disease.   
 
No association with a family history of thyroid disease was seen in a recently 
performed case-control study in Los Angeles focusing on the Hispanic population 
(Venkatramani et al., 2012). Moreover, in this study no statistically significant 
differences between cases and controls could be found with regard to smokers in the 
family, maternal problems during pregnancy or pesticide exposure. However, cases 
were more likely to report a family history of cancer, infection during infancy, and 
parental occupational exposure to metal, granites, or wood dust. Salotti et al. reported 
only sporadic cases of infections in the neonatal period and only one case of 
hypothyroidism in a mother in their study (Salotti et al., 2009). 
 
  
21 
 
Interestingly, 76% of the children in an incidence study by our team were diagnosed in 
the fall and the winter (Stalemark et al., 2008). Other studies have reported a higher 
incidence during summer months in wet regions or during periods of heavy rain-fall 
(Chen et al., 2003, Soto-Chavez et al., 2007). In the study from the UK and Ireland 
however, a higher number of cases than expected were seen in March to June (Salotti et 
al., 2009). As pointed out by Salotti et al., regional variations in infectious rates and 
time for school holidays may account for these differences. 
 
1.5.2.1 Association with malignancies 
There is a well-known association with LCH and malignancies, i.e. LCH and a 
malignant neoplasm occurring more often in the same individual than could be 
expected by chance alone. Several reports have shown predominantly hematological 
malignancies such as acute leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma 
and myeloma, but also solid tumors, including breast cancer, neuroblastoma and lung 
carcinoma to occur prior to, concurrently with or after a diagnosis of LCH (Egeler et 
al., 1993b, Fischer et al., 1999, Kager et al., 1999, Rodig et al., 2008). A first literature 
review on this issue was performed by Egeler et al. in 1993 and to study this further the 
Langerhans Cell Histiocytosis-Malignancy study group was established in 1991 (Egeler 
et al., 1993b). 
 
Their studies have shown that leukemias are the malignancies most commonly 
associated with childhood LCH, acute myeloid leukemia (AML) being somewhat more 
common than acute lymphoblastic leukemia (ALL) (Egeler et al., 1998). The temporal 
association between LCH and AML is distinct in that AML normally occurs after a 
diagnosis of LCH while ALL often precedes LCH (Egeler et al., 1998, Egeler et al., 
1993b). The reason for these associations is unclear. There may be an underlying 
genetic instability, LCH may occur as a reactive process in response to disease or 
treatment, or therapy (chemotherapy and radiotherapy) may induce a secondary 
malignancy (Egeler et al., 1998, Whitlock et al., 1991). In most cases of lymphoma and 
lung carcinoma in adults LCH usually occurs concurrently with the primary malignant 
neoplasm and it has been suggested that these cases represent a Langerhans cell 
reaction to the primary tumor (Egeler et al., 1993b). 
 
Based on the findings of a chromosomal translocation affecting a myelodysplastic 
disorder (MDS)-associated region on chromosome 7 in cells from an LCH lesion 
(further developed in section 1.9.4) and a report on MDS and LCH occurring 
simultaneously in four children, Egeler has suggested a possible connection between 
pediatric myelodysplastic disorders and LCH and raised the question of whether LCH 
could be a myeloid dendritic stem cell disorder (Egeler and Willman, 2000, Surico et 
al., 2000).  
 
LCH has also been reported to be associated with some major congenital 
malformations and syndromes such as Di George syndrome and thrombocytopenia-
absent radius (TAR) (Sheils and Dover, 1989, Giordano et al., 2011, Levendoglu-Tugal 
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et al., 1996). However, LCH patients lack the phenotype usually associated with 
conditions where genetic instability is known to confer an increased risk of neoplasia, 
such as Fanconi anemia or Li-Fraumeni syndrome (Cohen and Levy, 1989). 
 
1.5.2.2 Association with in vitro fertilization (IVF) 
In a recently published large Swedish study, a follow-up of a previous study, 26 692 
children born after in vitro fertilization (IVF) during the years 1982-2005 were 
compared to all children born in Sweden during the same years, and not conceived by 
IVF, regarding the incidence of cancer (Källén et al., 2010, Källén et al., 2005). The 
study compared data from all IVF clinics in Sweden and linked this information with 
other data from the Swedish Medical Birth Register and the National Swedish Cancer 
Register. A small, but statistically significant, increased risk for childhood cancer in 
general was found; 53 cases against 38 expected, giving a total cancer risk estimate of 
1.42 95% CI 1.09–1.87. The condition which was most overrepresented was LCH, 
with six cases found against one expected. In addition, two cases of Letterer Siwe 
disease in this cohort had been previously identified in the National Hospital Discharge 
Register (Källén et al., 2005). 
 
As around 3% of all children born in Sweden today are conceived by IVF (Sweden, 
2009), it is important to clarify any specific risks that these children may encounter and 
whether these risks are due to the IVF procedure per se or factors underlying IVF. In 
the case of LCH it is also possible to speculate that risks already known to be 
associated with IVF, such as children being born preterm or being small for gestational 
age might be associated with the development of LCH (Jackson et al., 2004). As a 
means to learn more about LCH we found it interesting to study these children more 
closely. The results of this study are presented in Paper II.  
 
1.5.2.3 Association with autoimmune disorders  
Apart from the association with thyroid disease reported by Bhatia et al. no certain 
associations prevail between LCH and autoimmune diseases (Bhatia et al., 1997). LCH 
has been reported to occur simultaneously with Crohn’s disease but no clear association 
has been proven (Lee-Elliott et al., 1996). Notably, at our clinic we have had a child 
who was initially misdiagnosed as having Crohn’s disease and it can be speculated 
whether the patient presented in the case report mentioned above also had LCH 
initially. However, whether there is an association between these granulomatous 
entities or to what extent LCH is misdiagnosed as Crohn’s disease remains to be 
studied. 
 
1.5.2.4 Familial disease 
LCH is usually considered a sporadically occurring disorder. However, a number of 
case reports have been presented of LCH in family members (Yoon et al., 2013, Shahla 
et al., 2004, Hanapiah et al., 1993) and around 1% of patients with LCH have been 
calculated to have another affected family member (monozygotic or dizygotic twin, 
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sibling, parent, first cousin) (Arico et al., 1999). Arico et al. have also shown that 
concordance for LCH is higher among presumed monozygotic twins than for dizygotic 
twins (86% versus 12%) indicating a possible genetic component in the pathogenesis of 
LCH (Arico and Danesino, 2001). Notably, some of the reported cases in these studies 
were reported before the standardized diagnostic criteria for LCH were introduced in 
1987 (Chu et al., 1987). Further, in the Danish study no clustering or familial disease 
was seen (Carstensen and Ornvold, 1993). 
 
A potential clustering of LCH described in some families may have several 
explanations. Considering the small number of cases with familial disease one would 
imagine that the cause of LCH is multifactorial. Arico has also suggested that 
expression of specific alleles of a group of genes might confer susceptibility to LCH, 
but to develop LCH another event, a “second hit” would be required. 
 
 
1.6 CLINICAL PRESENTATION 
 
Clinical manifestations of LCH vary extremely from a single lytic bone lesion resolving 
spontaneously (more frequent in older children) via recurrent multiple lesions and 
chronic disease to patients presenting with acute disseminated life-threatening disease. 
Virtually any organ may be affected but bone lesions are the most common 
manifestations of LCH (Group, 1996, Bernstrand et al., 2005). In adults liver and 
spleen involvement is unusual but there is a higher incidence of lung disease, associated 
with smoking as previously mentioned (Broadbent et al., 1994, Vassallo et al., 2000). 
  
LCH is categorized into single system disease (SS LCH), affecting only one organ, or 
multisystem disease (MS LCH), affecting two or more organs, with or without organ 
dysfunction. Bone lesions are further characterized as to whether they are unifocal or 
multifocal. Extensive multisystem disease is predominantly seen in very young children 
(Egeler et al., 2010, Huang and Arceci, 1999). The most severe disease is seen in 
children with involvement of risk organs. These have traditionally been lung, spleen, 
liver and the hematopoietic system (Lahey, 1975a). However, in the new international 
treatment study protocol, LCH-IV, that has recently been launched, lung is no longer 
considered a risk organ. The reasons for this is the frequent association of pulmonary 
involvement with involvement of other risk organs, a low relative hazard ratio in a 
multivariate analysis, and that it has proved difficult  to evaluate disease activity and 
therapy response in the lungs. 
 
In the incidence study from our group already mentioned (Stalemark et al., 2008), 69% 
of the patients had SS LCH at diagnosis and 31% had MS LCH which is in line with 
other reports (Carstensen and Ornvold, 1993, Salotti et al., 2009). As the burden of 
disease may vary over time, which may be valuable to identify in addition to disease 
extension at diagnosis, our group has introduced the concept of “maximal extent of 
disease” (Bernstrand et al., 2005). This concept includes all organs that have been 
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involved during the disease course in a particular patient. Of the patients who initially 
presented with SS LCH in the study mentioned above, one quarter later developed MS 
LCH, giving a peak incidence of MS LCH at the maximal extent of disease in this 
cohort of 48%. Of the patients with MS LCH around one third had involvement of risk 
organs (liver, spleen, lung or hematopoietic system). The majority of these children 
were under one year of age. This is also in line with other studies (Stalemark et al., 
2008).  
 
1.6.1 Prognosis and sequelae  
 
In terms of survival, the prognosis is excellent for children with SS LCH or MS LCH 
without risk organ involvement (Gadner et al., 2008, Gadner et al., 2001, Howarth et 
al., 1999). Patients with isolated bone disease have the best prognosis (Howarth et al., 
1999). However, although lower than in patients with MS LCH, disease reactivations 
are common also in patients with bone lesions only. As many as 18-40% of these 
patients experience reactivation of their disease. (Titgemeyer et al., 2001, Willis et al., 
1996). There is also a substantial risk for permanent consequences of the disease, to a 
large extent depending on the site of the lesion(s). Patients with isolated skin lesions 
sometimes progress into chronic disease or to MS LCH (Titgemeyer et al., 2001, 
Bernstrand et al., 2005).  
 
The prognosis for MS LCH correlates with the involvement of risk organs and response 
to initial therapy as evaluated after six weeks (Gadner et al., 2001). Children with risk 
organ involvement who fail to respond to initial therapy have substantial morbidity and 
still today 15% of all patients with risk organ involvement die within 5 years of 
diagnosis (Gadner et al., 2013). Young children (<2 years of age) are at special risk of 
developing the more severe forms of the disease, with a higher risk of risk-organ 
involvement. However, low age of by itself is not an independent risk factor for a poor 
prognosis (Gadner et al., 2008). When it comes to reactivation of the disease, as many 
as 37-54% (depending on the length of continuation therapy) of patients with MS LCH 
without risk organ involvement and 27% of survivors with risk organ involvement still 
have reactivations of their disease (Gadner et al., 2013). Recurrences may appear late 
after the initial diagnosis. Lahey et al. have reported that a plateau of event-free 
survival was not reached until 16 years after diagnosis (Lahey, 1975a). Even if most 
reactivations occur in non-risk organs, during the last ten years several papers have 
focused on the association between disease reactivations and the risk for permanent 
consequences (Morimoto et al., 2008, Pollono et al., 2007, Gadner et al., 2008). 
 
Several studies have suggested that the incidence of sequelae in LCH patients may be 
higher than previously believed (Bernstrand et al., 2005, Haupt et al., 2004, Willis et 
al., 1996). Haupt et al. reported that at least one permanent consequence of LCH 
occurred in 52% of the patients in their long-term follow-up study (Haupt et al., 2004). 
The highest number was observed in MS LCH patients where 71% of the survivors 
reported permanent consequences of their disease. Other studies have given similar 
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results (Bernstrand et al., 2005, Willis et al., 1996). DI is the most frequently reported 
sequel occurring in around 15-25% of all patients (Bernstrand et al., 2005, Haupt et al., 
2004, Willis et al., 1996, Gadner et al., 2001). Other permanent sequelae include 
orthopedic problems, endocrinopathies (including growth hormone deficiency), lung 
fibrosis, liver failure, and/or neurological and neuropsychological problems. 
  
Considering the high number of survivors with long time sequelae it is important to 
develop uniform criteria and standardize selection of patients who need long term 
follow-up, to be able to offer appropriate support, as has been suggested by Nanduri et 
al. (Nanduri et al., 2006). 
 
1.6.2 Characteristics of specific organ involvement in LCH 
 
1.6.2.1 Bone  
Around 80% of LCH patients have one or several bone lesions at some time during 
their disease course (Group, 1996, Bernstrand et al., 2005, Broadbent, 1986). Although 
any bone might be affected in LCH, lesions most frequently occur in the skull. Other 
common sites are the long bones of the extremities and the flat bones of the pelvis, ribs, 
mandible, and the spine. Lesions are often accompanied by adjacent soft tissue 
swelling. Symptoms and complications relate to the site of the lesions ranging from 
swelling and pain and pathological fractures in the long bones to floating teeth and 
gingival swelling in the case of mandible involvement, proptosis in periorbital 
engagement or, the collapse of a vertebrae with a risk of spinal cord compression 
(Broadbent et al., 1994, Egeler and D'Angio, 1995).  
 
Grois et al. have shown that osteolytic lesions of the craniofacial bones are associated 
with a higher frequency of DI and neurodegeneration (Grois et al., 1994, Grois et al., 
2010, Grois et al., 2006). Differential diagnoses include osteomyelitis and 
malignancies, such as Ewing sarcoma or lymphoma, chronic recurrent multifocal 
osteomyelitis (CRMO), vanishing bone disease and cat scratch disease.  
 
1.6.2.2 Skin  
Skin rashes in LCH are common, seen in around 40% of the patients (Group, 1996, 
Bernstrand et al., 2005). The clinical presentation varies widely from pinkish brown 
papules affecting the diaper region, the neck and the axillary folds to lesions on the 
scalp resembling cradle cap. Skin disease is often an initial presenting feature and is 
particularly common in infancy (Broadbent et al., 1994). Isolated cutaneous lesions 
might go undiagnosed and spontaneous regression is frequent (Egeler and D'Angio, 
1995). A self-limiting form of LCH (“Hashimoto-Pritzker disease”) is seen in neonates 
(Hashimoto and Pritzker, 1973). Still, general skin involvement in children <2 years 
has been associated with the development of MS LCH with risk organ disease and a 
poor prognosis (Broadbent, 1986).  
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1.6.2.3 Ears 
Aural discharge is another common feature in LCH that may arise from extension of a 
skin rash into the aural canal causing external otitis or from a polyp of LCH tissue from 
a bony lesion extending into the canal. Engagement of the mastoid and chronic middle 
ear disease may cause deafness from destruction of the ossicles (Broadbent et al., 1994, 
Irving et al., 1994). 
 
1.6.2.4 Lymph nodes 
Lymph node involvement may occur as part of a disseminated disease or may reflect 
engagement of neighboring skin or bone lesions (Egeler and D'Angio, 1995). LCH in a 
lymph node sometimes also occurs as a solitary finding. Most commonly cervical 
lymph nodes are involved but abdominal, mediastinal, inguinal or axillary glands may 
also be affected. 
 
1.6.2.5 Thymus 
Thymic lesions are more rarely reported in LCH but are frequently seen at autopsy in 
patients who died from the disease (Egeler and D'Angio, 1995, Hamoudi et al., 1982). 
Yet, with the use of computed tomography (CT) and positron emission tomography 
(PET) thymic lesions are increasingly recognized. 
 
1.6.2.6 Liver and spleen 
Hepatomegaly is present in one third to one half of the children with disseminated LCH 
although actual LCH involvement of the liver occurs less frequently (Schmitz and 
Favara, 1998). In combination with clinical signs of liver dysfunction, hepatomegaly is 
a poor sign (Broadbent et al., 1994, Lahey, 1975a). Some children with hepatic 
involvement develop a progressive sclerosing cholangitis requiring liver transplantation 
(Braier et al., 2002, Jaffe, 2004). Splenomegaly may be massive and contribute to 
anemia and cytopenia in refractory disease.  
 
1.6.2.7 Hematopoietic involvement – bone marrow 
Pancytopenia is a relatively frequent phenomena in patients with disseminated disease 
but massive infiltration by LCH DCs in the bone marrow is less often seen, and if so 
associated with a very poor prognosis (McClain et al., 1983). Dysfunction of the 
hematopoietic system has per se been shown to be associated with a poor prognosis 
regardless of bone marrow infiltration by LCH DCs (Gadner et al., 2001, Lahey, 
1975a). 
 
1.6.2.8 Lungs 
Isolated pulmonary LCH is most frequently seen in adults, especially in young adult 
smokers, but may also be seen in children. In the pediatric population, lung 
involvement is otherwise normally seen in the course of MS LCH (Bernstrand et al., 
2001, McDowell et al., 1988). Cough or tachypnea, as well as spontaneous 
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pneumothorax, can be the initial presentation signs of pulmonary LCH. On plain 
radiography, interstitial infiltration is typically seen. High resolution computed 
tomography (HRCT), however, is a more sensitive method to detect nodules and cysts 
(Bernstrand et al., 2007). For regular monitoring of pulmonary LCH, pulmonary 
function tests, including diffusing capacity, can also be of value and are not associated 
with radiation. Lung fibrosis has been reported in up to 33% of patients with pulmonary 
involvement (Haupt et al., 2004). 
 
1.6.2.9 Gastrointestinal tract 
Oral involvement with ulceration of the palatal and gingival mucosa is a rather 
common feature of LCH and the premature eruption of milk teeth is characteristic. 
LCH of the gut is rare but probably underestimated in its mild forms. The most 
common sign is “failure to thrive” (Broadbent et al., 1994). Some cases of LCH may 
also be misdiagnosed as IBD as mentioned earlier. 
 
1.6.2.10 Endocrine system 
The most common endocrinopathy in LCH is diabetes insipidus (DI) that occurs in as 
many as 15-25% of all LCH patients or 40-50% of those with MS LCH (Bernstrand et 
al., 2005, Grois et al., 2006, Haupt et al., 2004, Willis et al., 1996, Donadieu et al., 
2004b). DI may occur prior to, concurrently with or years after the development of 
other lesions (Arico and Egeler, 1998). Isolated DI presents a diagnostic challenge and 
a careful diagnostic work-up is mandatory to exclude other differential diagnoses, such 
as germ-cell tumors. DI is treated with replacement therapy of anti-diuretic hormone 
(desmopressin) but no curative treatment for DI has been reported, nor has any patient 
with established and complete DI reverted to normal (Broadbent and Pritchard, 1997, 
Dunger et al., 1989). Growth hormone deficiency is the second most observed 
endocrinopathy in LCH and affects around 10% of the patients (Group, 1996, 
Bernstrand et al., 2005, Grois et al., 1995, Grois et al., 2010). In patients with DI, 
overall anterior pituitary deficiency develops in as many as 60%. (Donadieu et al., 
2004a, Haupt et al., 2004). 
 
1.6.3 Central nervous system (CNS) involvement 
 
The background to CNS involvement in LCH has been expanded for two reasons. 
Firstly, CNS involvement causes some of the most severe complications of the disease. 
Secondly, paper I of this thesis deals with neurodegeneration in LCH. 
 
An LCH CNS study was initiated by the Histiocyte Society in the year 2000 to better 
characterize CNS disease and its natural course in LCH. Through this study a uniform 
diagnostic and follow-up program was introduced, including serial magnetic resonance 
imaging (MRI) evaluations, repeated neurological testing with the Expanded Disability 
Status Scale (EDSS) and the International Cooperative Ataxia Rating Scale (ICARS), 
psychological studies and electrophysiological examinations. Grois and her colleagues 
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in Vienna have performed much of the work regarding CNS involvement in LCH. 
Considering the rarity of LCH and the even rarer event of neurodegeneration, close 
international collaboration is important for research to proceed in this area.  
 
The concept of CNS-LCH includes tumorous lesions in the soft tissue of the brain, 
including the pituitary-hypthalamic regions, as well as neurodegenerative lesions (Grois 
et al., 2010). Clinical symptoms depend on the site and the type of CNS involvement. 
Tumorous lesions of the choroid plexus, the meninges or in the brain parenchyma are 
unusual but can lead to headache, seizures and obstruction of the ventricles with 
increased CNS pressure and even hydrocephalus (Grois et al., 2004, Prayer et al., 
2004). DI is considered to reflect LCH infiltration of the hypothalamic pituitary region.  
The clinical picture accompanying LCH-associated neurodegenerative lesions is highly 
variable. While some patients do not present any symptoms for years, others develop 
progressive neurological disturbances. Neurological symptoms sometimes precede an 
LCH diagnosis but most often develop several years after the initial diagnosis (Grois et 
al., 1998). Symptoms may follow a cerebellar pontine pattern, starting with mild 
tremor, reflex disturbances, or discrete gait disturbances sometimes progressing to 
severe ataxia rendering the patients wheel-chair bound (Grois et al., 2010). Dysphagia, 
dysarthria and other cranial nerve deficits may occur and in extreme cases 
neurodegeneration might be fatal (Grois et al., 1998). Abnormal behavior, learning 
difficulties, or sometimes psychiatric disease are consequences also seen (Grois et al., 
2010, Van't Hooft et al., 2008, Nanduri et al., 2003). Disturbances in social behavior, 
appetite, temperature regulation or sleep might accompany changes in the hypothalamic 
region (Grois et al., 1998). 
 
Clinical CNS neurodegeneration is thought to affect at least 10% of LCH patients (19% 
of all patients with multisystem disease) (Bernstrand et al., 2005, Nanduri et al., 2006, 
Willis et al., 1996). The exact incidence of radiological LCH lesions or LCH-associated 
neurodegeneration is hard to evaluate since still only patients with clinically suspected 
or potential CNS involvement usually undergo MRI of the brain. However, a study 
from our group has indicated that radiological neurodegenerative changes are present in 
at least 24% of all patients (Laurencikas et al., 2011). Another study has found similar 
results (20%) (Mittheisz et al., 2007). As mentioned above, the relationship between 
radiological findings and clinical symptoms is not fully understood where the degree of 
clinical symptoms often does not correlate to the extension of MRI findings. 
Presumably this reflects the reserve capacity of the human brain. However, a long-term 
follow-up of a small group of patients has indicated that radiologic neurodegeneration 
seems to be a slowly progressive process accompanied by clinical deterioration (Prosch 
et al., 2007, Wnorowski et al., 2008). Yet, in some patients it seems to halter and 
further longitudinal studies are needed to better clarify the natural history of 
radiological and clinical neurodegeneration. Such a study is included in the LCH-IV 
protocol. 
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Risk sites to develop DI or other CNS-LCH manifestations are lesions involving the 
orbital, temporal, sphenoid, ethmoid or mastoid bone and the paranasal sinuses and 
anterior or middle cranial fossa (Grois et al., 2006). DI is in itself a risk factor for 
neurodegenerative LCH (Donadieu et al., 2004b, Grois et al., 1995, Haupt et al., 2004). 
Multisystem disease, chronic and reactivating disease has also been associated with an 
increased risk of endocrine deficiencies and other CNS complications (Donadieu et al., 
2004b, Grois et al., 2010, Grois et al., 2006). In order to better control the disease and 
avoid reactivations maintenance therapy has been prolonged in the latest international 
treatment studies (LCH-III and LCH-IV).   
 
1.6.3.1 MRI findings 
MRI is today the standard method to detect neurodegenerative lesions in LCH (Martin-
Duverneuil et al., 2006, Prayer et al., 2004). The hypothalamic-pituitary region is by far 
the most commonly involved intracranial region in LCH. The typical finding for DI is 
enlargement of the pituitary stalk, sometimes progressing into space-occupying tumors 
extending to the pituitary or hypothalamus (Grois et al., 2010). The characteristic “loss 
of bright spot” in MRI with gadolinium contrast represents a loss of antidiuretic 
hormone containing vesicles (Tien et al., 1991). LCH-associated MRI changes in the 
pineal gland often accompany pituitary findings and comprise solid masses or cystic 
lesions (Grois et al., 2004). The co-appearance of pituitary and pineal gland 
involvement perhaps reflects the fact that these organs belong to the same 
circumventricular organ system located outside the blood-brain-barrier. Tumorous 
lesions can further occur in the meninges, the choroid plexus and the brain parenchyma 
as single or multiple lesions. Tumors of the brain parenchyma might follow a random 
or a vascular pattern (Barthez et al., 2000, Prayer et al., 2004). The differential 
diagnoses include craniopharyngioma, sarcoidosis, germ cell tumors or other histocytic 
disorders such as Erdheim-Chester disease or Rosai-Dorfman disease (Prayer et al., 
2004). 
 
There are no specific pathological changes detected with MRI in neurodegenerative 
LCH but the pattern, the signal intensity and the contrast enhancement together with the 
clinical picture is suggestive for this diagnosis. Importantly, similar findings are not 
seen in healthy children. Typically, a combination of changes is seen in the cerebellum, 
the basal ganglia and/or the pons. Less frequently the brain stem or the forebrain are 
involved (Barthez et al., 2000, Martin-Duverneuil et al., 2006, Prayer et al., 2004). A 
usual finding is symmetric, hyperintense signal changes on T2-weighted images and 
hypo- or hyper-intense signals on T1-weighted images involving the gray matter of the 
cerebellum but sometimes extended to the surrounding white matter. In the basal 
ganglia the findings usually consist of hyperintense signals on T1-weighted images and 
variable signal intensity on T2-weighthed images, most often involving the globus 
pallidus. Additionally, two types of white matter changes are also seen, dilated 
Virchow-Robin spaces and, more seldom, a leukoencephalopathy-like pattern. The role 
of the dilated Virchow-Robin spaces in CNS-LCH is not clear. They might be related to 
an active inflammatory process or be the consequence of such a process. Neither is the 
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significance of the leukoencephalopathy-like pattern clear and such findings should 
warrant investigation for differential diagnoses such as metabolic or degenerative 
disorders (Prayer et al., 2004, Grois et al., 2010). Atrophy can be localized to the 
cerebellar hemispheres or it may be global. It is not a common finding but it is 
sometimes seen in patients with progressive symptoms (Martin-Duverneuil et al., 2006, 
Prayer et al., 2004). MRI findings indicative of neurodegenerative LCH are normally 
irreversible (Wnorowski et al., 2008, Prosch et al., 2007). 
 
1.6.3.2 Experimental radiology  
PET studies with the tracer fluorodeoxycglucose (FDG-PET) have shown an increased 
uptake by tumorous CNS lesions and a reduced uptake in neurodegenerative lesions 
(Buchler et al., 2005, Calming et al., 2002, Phillips et al., 2009, Steiner et al., 2005). It 
has been reported that proton magnetic resonance spectrometry that measures the 
concentration of neuronal metabolites shows a decrease peak of N-acetyl-aspartate 
infratentorially, corresponding to neurodegenerative findings in the cerebellum of one 
patient (Steiner et al., 2005). However, these methods need to be evaluated further and 
have no regular place in the diagnosis of CNS-LCH today.   
 
1.6.3.3 Histopathological findings 
Histopathological revision of samples from twelve patients with CNS-LCH, applying 
modern immunocytochemical techniques and correlating the findings to MRI findings 
and clinics, was quite recently carried out by the LCH CNS study group (Grois et al., 
2005). According to the findings of this group, three types of lesional patterns can be 
distinguished in CNS-LCH: (1) Circumscribed granulomas in the connective tissue of 
the brain, corresponding to LCH lesions elsewhere in the body with infiltrating CD1a+ 
cells but accompanied by a higher amount of CD8
+
 T cells than is usually seen. (2) 
Neurodegenerative lesions, mainly affecting the cerebellum and the brainstem. In these 
lesions no CD1a
+ 
cells are seen but they are characterized by marked inflammation and 
infiltration of CD8
+
 T cells associated with neuronal and axonal degeneration and 
myelin loss. This results in atrophy of the cerebellar cortex and white matter. (3) 
Granulomas of infundibular tumors that invade the hypothalamic region. Here, a 
diffuse infiltration of the surrounding CNS tissue by CD1a+ cells surrounded by 
neurodegenerative findings (loss of neurons and axons accompanied by heavy 
inflammation dominated by CD8
+
 T cells) is seen.  
 
1.6.3.4 Etiology of LCH-associated neurodegeneration 
The cause of neurodegeneration in LCH is unknown. As Grois et al. suggest it is 
tempting to speculate that it is triggered in response to the heavy cytokine load seen in 
LCH lesions in neighboring tissues, or even in other parts of the CNS. This 
inflammation might be sustained even after any initial lesion has disappeared, maybe 
through a secondary autoimmune process (Grois et al., 2010). It is also possible that 
neurodegeneration associated with multisystem disease is a form of paraneoplastic 
syndrome, where antigens characteristic of CNS components are produced by 
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peripheral tumors (Darnell and Posner, 2003, Imashuku et al., 2004). Autoantibodies in 
patients suffering from cerebellar degeneration have been described in several cancers 
(Graus and Dalmau, 2007, Shams'ili et al., 2003). A case with antibodies against a 
subtype of NMDA receptors (anti-GluRe2, seen in, among other conditions, 
Rasmussen encephalitis and acute disseminated encephalitis) in a boy with 
neurodegenerative LCH was recently published (Nakamura et al., 2012). As NMDA 
receptors are expressed by the Purkinje cells in the cerebellum this could perhaps 
explain the propensity for neurodegenerative LCH to affect this area. However, this 
possible etiology needs further exploration. Interestingly, neurodegenerative LCH 
shares similarities with human immunodeficiency virus (HIV)-related dementia, where 
an excessive stimulation of NMDA glutamate receptors by neurotoxins or cytokines 
secreted from virus-infected macrophages and microglia leads to neuronal damage and 
cell death (Grois et al., 1998, Lipton and Gendelman, 1995). This mechanism has also 
been proposed as the etiology behind neurodegenerative LCH (Grois et al., 1998). The 
role of treatment as a cause of neurodegeneration has been lively discussed over the 
years. However, the fact that neurodegeneration also occurs in patients who have not 
received any treatment contradicts this theory.  
 
1.6.3.5 Treatment of CNS-LCH 
No specific treatment against neurodegenerative LCH has so far been shown to be 
clearly effective to stop, or slow down, the neurodegenerative process. In LCH-IV, the 
chemotherapeutic drug cytosine arabinoside/cytarabine (ARA-C) and intravenous 
immunoglobulin (IVIG) will be evaluated as we and others have reported positive 
effects of these treatments in patients with clinical signs of neurodegeneration (Allen et 
al., 2010a, Gavhed et al., 2011, Imashuku et al., 2008). Imashuku et al. treated four 
patients with clinical neurodegeneration with IVIG for >12 months and reported a 
positive response compared to eight patients who did not receive this treatment 
(Imashuku et al., 2008). McClain and co-workers treated eight patients with ARA-C 
alone or in combination with vincristine. Out of these patients five improved clinically 
and to some extent, also radiologically, with follow-up time varying between two 
months to seven years (Allen et al., 2010a).  
 
To prevent neurodegeneration from the start, in the future, patients will hopefully 
benefit from prolonged continuation therapy and more aggressive treatment of “special 
site” bone lesions. Tumorous CNS lesions usually respond well to treatment but in an 
attempt to reduce neurodegeneration, 2-chlorodeoxyadenosine/cladribine (2-CdA) will 
be evaluated as the first-line treatment of isolated CNS lesions in LCH-IV, based on 
some encouraging experience by Dhall et al. (Dhall et al., 2008). 
 
1.6.3.6 Cerebrospinal fluid (CSF) findings 
An important problem in diagnosing neurodegeneration is that when MRI findings or 
clinical findings are evident, substantial CNS damage has already taken place and may 
be irreversible. Hence, there is a need to detect CNS inflammation and 
neurodegeneration early, prior to the development of radiological lesions or clinical 
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deterioration, in order to intensify and evaluate treatment or to initiate experimental 
treatment in the advent of more specific regimens. Trying to find biomarkers of 
ongoing neurodegenerative CNS activity was the aim of paper I in this thesis.  
 
There are some sporadic case reports of cerebrospinal fluid (CSF) investigations 
performed in LCH (rather reporting the presence of LCH DCs in the CSF in the case of 
LCH with CNS involvement) (Ghosal et al., 2001, Hamilton et al., 1982), but to our 
knowledge no systematic studies of CSF markers or cytokine characteristics of CSF in 
LCH have so far been published apart from the report presented here (paper I). CSF 
sampling is not routinely performed in LCH.  
 
Biomarkers are (ideally) objective measures of biological or pathogenic processes used 
to evaluate disease risk or prognosis, to guide clinical diagnosis and to monitor 
treatment interventions. Since the CSF is in direct contact with the brain, biochemical 
changes in the brain are often reflected in the CSF. The CSF biomarkers used for the 
study presented in paper I were chosen because they are well established markers of 
other neurodegenerative and neuroinflammatory diseases, including Alzheimer disease, 
Parkinson disease, multiple sclerosis and vascular dementia and in the evaluation of 
acute brain damage such as stroke (Blennow et al., 1995, Blennow et al., 2001, 
Rosengren et al., 1996, Wallin et al., 1996, Aurell et al., 1991, Teunissen et al., 2005). 
 
The neurofilament protein is a major component of the axonal skeleton proteins and 
regulates the diameter and shape of the axon. It consists of three chains of different 
weight, the light (NF-L), medium (NF-M) and heavy (NF-H) chains. Following axonal 
damage neurofilament is released into the extracellular fluid and can thus be measured 
in the CSF. Increased NF-L levels are found upon acute damage in multiple sclerosis 
(Teunissen and Khalil, 2012) but also in neurodegenerative diseases, such as 
amyotrophic lateral sclerosis (ALS) and vascular dementia (Rosengren et al., 1996). 
 
Tau proteins are microtubule-associated proteins that are thought to be important for 
the maintenance of axonal microtubules. Hyperphosphorylated tau (p-TAU) is a key 
component of the neuritic tangles in Alzheimer disease where tau protein levels are 
typically elevated in the CSF (Blennow et al., 2012). However, tau proteins are also 
elevated in other neurodegenerative disorders, such as multiple sclerosis and 
Creutzfeldt-Jakob disease (Otto et al., 1997, Teunissen et al., 2005). There are several 
isoforms of tau proteins in the CSF and tau can be phosphorylated at several sites 
(Portelius et al., 2008). The most common assay to measure total tau detects all 
isoforms of tau independently of phosporylation status (Blennow et al., 1995). In the 
following text TAU refers to total tau. 
 
Glial fibrillary acidic protein (GFAp) is an important component of the cytoskeleton in 
astrocytes and elevated levels are considered to reflect acute astroglial cell damage in 
CSF but it is also as a marker of astrogliosis following damage to the CNS and elevated 
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in many chronic brain disorders (Wallin et al., 1996, Aurell et al., 1991, Blennow et al., 
2001). 
 
1.6.4 LCH in adults 
 
Adult LCH has been reported to most commonly involve the skin, the lungs, bone and 
the anterior pituitary gland giving rise to DI (Baumgartner et al., 1997). Isolated 
pulmonary LCH primarily affects young adult smokers but lung involvement may also 
be part of a multi-system disease. The prognosis for adults with isolated bone lesions is 
very good but worse for patients with multi-system disease. An association with MDS 
has also been reported for adults (Billings et al., 2006). 
 
 
Figure 3. T1-weighted image demonstrating high signal intensity in nucleus     
                dentatus and globus pallidus due to neurodegenerative changes.  
                Courtesy of Dr. Evaldas Laurencikas. 
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1.7 DIAGNOSIS 
 
The Histiocyte Society classifies the histiocytic diseases into disorders with varied 
biological behavior and those that are truly malignant (Favara et al., 1997). The former 
group is classified based on the affiliated cell type, with macrophages and dendritic 
cells being the most common cell types involved. Hemophagocytic lymphohistiocytosis 
(HLH), a severe condition with abnormal macrophage activation, is the most common 
of the macrophage associated disorders while LCH is the most common of the dendritic 
cell related diseases. Other forms of dendritic cell related histiocytoses include juvenile 
xanthogranuloma and related disorders. Erdheim-Chester disease is a rare form of 
systemic non-Langerhans cell histiocytosis belonging to the juvenile xanthogranuloma 
family and normally seen in adults only. Truly malignant dendritic cell tumors are 
extremely rare. 
 
Based on the expression of the key distinguishing markers for LCs, CD1a and 
Langerin/CD207, LCH is currently classified by the World Health Organization 
(WHO) as a hematological disease derived from LCs (Jaffe et al., 2008). 
 
1.7.1 Histopathology 
 
The main feature for a diagnosis of LCH is the presence of cells with the morphology 
of LCH DCs in lesions with typical features. (The characteristics and features of LCH 
DCs and LCH lesions are further presented in sections 1.9.1 to 1.9.3.) For a definitive 
diagnosis, some lesional cells should stain positive for CD1a and/or Langerin/CD207 
(Chikwava and Jaffe, 2004, Lau et al., 2008, Jaffe et al., 2008). The demonstration of 
Birbeck granules by electron microscopy was previously the diagnostic “gold standard” 
for the diagnosis of LCH but since it has been shown that the expression of 
Langerin/CD207 confirms the presence of Birbeck granules, electron microscopy is no 
longer necessary (Valladeau et al., 2000). Additional markers helpful in characterizing 
LCH DCs are CD14, CD68 and S100 (seen in 50-60% of LCH DCs) and ATP-ase and 
alpha-D-mannosidase on specially prepared sections (Henter et al., 2004, Egeler et al., 
2010, Geissmann et al., 2001). Depending on the site of the lesion, histopathological 
differential diagnoses may include osteomyelitis, (non-) Hodgkin’s lymphoma, 
malignancies, skin disorders, IBD or sarcoidosis (Egeler et al., 2010, Schmitz and 
Favara, 1998). 
 
An LCH diagnosis can be made on the basis of a biopsy or through fine needle 
aspiration, although a shortcoming with fine needle aspiration is that it does not reveal 
the granulomatous-like appearance seen in histological sections (Schmitz and Favara, 
1998). The histiopathological picture of LCH lesions is rather uniform independent of 
the clinical severity (Nezelof and Basset, 1998, Schmitz and Favara, 1998). However, it 
is influenced to some degree by the site of the lesion and especially by the age of the 
lesion. Initially the lesions are cell rich, with a predominance of myeloid cells, while 
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older lesions tend to have a more fibrotic appearance, with few or no CD1a+ cells, 
sometime making diagnosis difficult (Schmitz and Favara, 1998). 
 
1.7.2 Diagnostic evaluation  
 
A modified presentation of pre-treatment diagnostic evaluations as recommended in the 
LCH-IV study protocol is presented in Table I. 
 
Table I. Baseline diagnostic evaluations in LCH 
 
History 
 
Physical Examination  
 
Laboratory Evaluation  
 
Radiographic 
Evaluation 
 
Fever  
Pain 
Irritability 
Swelling  
Skin rashes  
Otorrhea  
Loss of appetite 
Weight loss or   
  poor weight gain  
Growth failure 
Polydipsia 
Polyuria  
Diarrhea  
Changes in 
  activity level  
Dyspnea  
Cigarette smoke 
  exposure  
Behavioral and 
  neurological 
  changes 
 
Temperature  
Height and weight 
Pubertal status  
Skin and scalp rashes 
Jaundice  
Pallor  
Bleeding 
Lymphadenopathy  
Ear discharge  
Orbital abnormalities 
Gum and palatal lesions 
Dentition  
Soft tissue swelling 
Lesions on the genital 
  and anal mucosa 
Tachypnea, intercostal 
  retractions  
Ascites or edema  
Liver and spleen size  
Neurological signs or 
  symptoms  
Full blood count: 
Hemoglobin  
White blood cell  
  and differential count  
Platelet count  
ESR  
 
Blood chemistry: 
Albumin, bilirubin, 
ALT, AST, alkaline 
phosphatase,  
γ-glutamyl transferase 
(γ-GT), blood urea 
nitrogen (BUN), 
creatinine, electrolytes, 
ferritin 
 
Coagulation studies:  
PT, APTT/PTT,  
fibrinogen 
 
Early morning urine 
sample: 
Specific gravity and 
osmolality 
 
Chest x-ray 
 
Skeletal x-ray 
survey*  
 
Abdominal 
ultrasound  
(liver and 
spleen) 
 
 
 
 
 
*Functional imaging like bone scan or PET is optional and can be performed in addition to 
skeletal survey. 
 
Further laboratory investigations, imaging and clinical assessments are recommended upon 
specific indications at diagnosis or at follow-up, including MRI of the head or spine, CT 
scans, neurological assessment, endocrine assessments, bronchoalveolar lavage (BAL), 
endoscopy, bone marrow aspirate/biopsy and liver, lung or gut biopsies.  
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Table II. Definition of risk organ involvement according to LCH-IV 
 
Hematopoietic involvement  
(with or without bone marrow involvement):  
At least 2 of the following: 
Anemia: Hemoglobin <100 g/L,  
infants <90 g/L, not due to other causes, e.g. 
iron deficiency.  
Leukocytopenia: Leukocytes < 4 x 10
9/
L. 
Thrombocytopenia:  
Platelets < 100 x 10
9/
L 
 
Spleen involvement: Enlargement > 2 cm below the costal margin 
in the midclavicular line* 
 
Liver involvement:   Enlargement > 3 cm below the costal margin 
in the midclavicular line* and/or  
dysfunction (hypoproteinemia < 55 g/L or 
hypoalbumenia < 25 g/L not due to other 
causes) and/or histopathological findings of 
active disease 
 
*as assessed by palpation 
 
 
Many teams have looked for a serum marker of LCH activity that could be helpful in 
diagnosis and disease monitoring. However, no specific marker has yet been validated.  
Elevated serum levels of soluble IL-2 receptor (sIL-2R) have been reported to correlate 
with multi-system multi-site LCH and poor response to treatment in two studies (Rosso 
et al., 2002, Ishii et al., 2006) and sIL-2R  has, together with soluble CD40L (sCD40L), 
been suggested as indicators of inflammation in LCH. They have however not been 
evaluated in larger studies. Additionally, soluble RANKL (sRANKL) has been reported 
to be high in serum from LCH patients and the ratio of sRANKL/osteoprotegrin a 
measure of osteolytic activity in LCH (Ishii et al., 2006).  
 
Angiotensin converting enzyme (ACE) is a marker popularly used to measure disease 
activity in sarcoidosis, although it is not specific for sarcoidosis and serum levels do not 
always correlate with the severity of disease (Culver, 2012). While there is one case 
report of elevated levels of ACE in LCH, ACE levels have been reported to be normal 
in another three patients (Rosenstein et al., 1995, Lieberman et al., 1979). ACE has not 
been further evaluated in LCH.  
 
ESR and platelets may be helpful in monitoring disease activity (Calming and Henter, 
1998) but the evaluation of treatment and at follow-up relies on the extent of the disease 
and the organs involved.  
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1.8 TREATMENT 
 
Treatment of LCH has shifted depending on how the etiology has been perceived. In 
the 1950’s antibiotics were used, but with the shift of view to LCH as being a 
neoplasm, in the next twenty years the role of chemotherapy in LCH was established 
(Komp et al., 1977, Lahey, 1975b, Starling et al., 1972, Aronson, 1951). In the 1980’s 
thymic hormones and their derivates were tried out following reports of LCH as an 
immunological condition but with limited success and therefore abandoned (Davies et 
al., 1983, Osband, 1986).  
 
While therapy options for isolated skin lesions and single bone lesions have largely 
been up to the clinician, three large-scale, international, prospective therapeutic studies 
(LCH-I to III) for MS LCH have been conducted by the Histiocyte Society since 1991, 
focusing on the pediatric population. The information and lessons drawn from these 
studies provide the basis for the next study, LCH-IV, which has recently been opened.  
 
1.8.1 Previous international treatment studies 
 
The first larger co-operative studies, the Italian AIEOP-CNR-HX 83 and the 
Austrian/German DAL-HX 83/90, demonstrated complete response rates of 60-90% 
using vinblastine (VBL), etoposide and other chemotherapeutic drugs in combination 
with prednisolone (PDN) (Ceci et al., 1993, Gadner et al., 1994, Minkov et al., 2000). 
In LCH-I (1991-1995), 6 months therapy with either VBL or etoposide together with an 
initial 3-day pulse of methylprednisolone was compared for all patients with MS LCH 
(Gadner et al., 2001). VBL and etoposide regimens proved similar in terms of response, 
survival, disease reactivation, permanent consequences and toxicity but were inferior to 
the results of a more aggressive regimen including five drugs and longer treatment (12 
months) that had been administered in the DALHX-83/90 study (Gadner et al., 1994, 
Minkov et al., 2000). The LCH-I trial demonstrated that involvement of one or several 
risk organs is associated with a poor prognosis and that the response after 6 weeks 
treatment is a powerful and independent predictor of outcome. 
 
In LCH-II (1996-2001), MS LCH patients were thus stratified according to risk. 
Treatment was intensified for the high risk patients (< 2 years old and/or with risk organ 
involvement (RO+)). These patients were randomized to treatment with either a 
combination of VBL and PDN alone or with additional etoposide. 6-mercaptopurine was 
added to the continuation therapy in both arms. However, treatment duration was not 
prolonged compared to LCH-I (Gadner et al., 2008). Both treatments rendered a faster 
disease resolution and a higher survival rate than LCH-I but reactivation numbers still 
remained high (44%). A thorough analysis showed a significantly higher survival rate in 
the arm that received etoposide, further underlining the benefits of an intensified 
treatment for RO+ patients. Because of its leukemogenic potential (Haupt et al., 1997) 
etoposide has however not been further studied in LCH.  
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Instead, in LCH-III (2001-2008), the addition of methotrexate (MTX) and prolonged 
treatment duration to 12 months for all RO+ patients was evaluated as well as prolonged 
intense initial therapy in patients only partially responding after 6 weeks. For patients 
without risk organ involvement (RO- patients) the impact of 6 versus 12 months 
treatment was tested. Results recently published have shown that the addition of MTX 
did not accelerate disease resolution or increase survival for RO+ patients, but was 
associated with higher levels of cytotoxicity (Gadner et al., 2013). Nevertheless, survival 
rates for RO+ patients of both arms were better in the LCH-III trial than in previous 
studies. This has been attributed to the more intense and prolonged initial treatment. An 
aggressive salvage treatment with 2-CdA-based regimens or bone marrow 
transplantation also proved to be rather effective, albeit toxic, in patients not responding 
to the protocol therapy. Twenty one of the twenty seven patients receiving 2-CdA and 
seven of the ten transplanted patients survived.  
 
An exploratory historical comparison of the response and outcome of RO+ patients in 
the three LCH trials (with matched patients with regard to diagnostic and stratification 
criteria) has shown a survival rate of 84% in LCH-III compared to 62% in LCH-I and 
69% in LCH-II. LCH-III RO+ patients also had a markedly lower 5-year risk of 
reactivations compared to the earlier studies; 27% versus 55% (LCH-I) and 44% (LCH-
II), stressing the importance of prolonged treatment duration as a way to reduce 
reactivations. The benefit of prolonged continuation therapy was also shown for the RO- 
patients.  
 
On the basis of the previous experience indicating that prolonged systemic combination 
treatment reduced the occurrence of reactivations, an arm for treatment of patients with 
only bone involvement but with multifocal lesions was also included in LCH-III. 
(Minkov et al., 2008). These patients were treated with VBL and PDN for 6 months. The 
same therapy was recommended to patients with single bone lesions at special sites 
conferring a risk of CNS-complications or damage to the spine. 
 
1.8.2 LCH-IV 
 
The main goals of the recently opened LCH-IV study are to further increase survival of 
RO+ patients, while not “over-treating” responders, to reduce reactivations and 
sequelae by prolonging maintenance therapy even more and treating multi-focal bone 
lesions and “risk-site” single bone lesions more aggressively. As already mentioned, 
there will also be special protocols to treat isolated CNS-lesions and neurodegeneration.  
 
In the LCH-IV protocol there is a focus on stratification and “risk-tailored” treatment.  
The basis will still be VBL and PDN but with an early switch to salvage treatments in 
patients with risk organ involvement and lack of therapy response at 6 or 12 weeks. 
Salvage treatments include 2-CdA/ARA-C and bone marrow transplantation, based on 
the positive results from earlier studies (Weitzman et al., 2009, Akkari et al., 2003, 
Bernard et al., 2005). A second line treatment for patients without risk organ 
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involvement who fail to respond to initial treatment or reactivate will also be evaluated. 
This regimen will contain ARA-C, vincristine (VCR) and PDN, relating to a positive 
previous report regarding this combination of drugs (Egeler et al., 1993a). Experience 
from a British group indicates that a non-steroidal anti-inflammatory drug (NSAID), 
indomethacin, might constitute a less toxic alternative to 6-mercaptopurine (6-MP) in 
continuation therapy and this will also be tested in this cohort (Munn et al., 1999, 
McLean and Pritchard, 1996). For isolated CNS-tumors 2-CdA will be evaluated and 
for clinically neurodegenerative LCH, ARA-C or IVIG is recommended as mentioned 
earlier. 
 
Furthermore, an attempt to collect information on the natural course of conservatively 
or locally treated isolated lesions will be made in LCH-IV. Such treatment alternatives 
include curettage, steroid injections or expectancy for single bone lesions (Bernstrand 
et al., 1996, Cohen et al., 1980) or topical treatment of corticosteroids or nitric mustard 
on skin lesions (Munn and Chu, 1998). 
 
1.8.3 Alternative treatments 
 
Over the years an abundance of reports on the effect of alternative treatments in LCH 
have been published. IFN-α has been used successfully in a few cases but has not been 
properly evaluated (Bellmunt et al., 1992, Jakobson et al., 1987). A few studies have 
been made on cyclosporine A (CSA). On the whole the results have not proven 
beneficial as treatment in LCH (Arico, 1991, Mahmoud et al., 1991, Minkov et al., 
1999, Minkov et al., 2003). Our group has reported a positive effect of the TNF-α-
inhibitor etanercept in a patient with multi-system LCH and risk organ involvment 
(Henter et al., 2001) Bisphosphonates have been reported to be beneficial in bone 
lesions but have not become widely used (Morimoto et al., 2011, Sivendran et al., 
2011). Lately, following the findings of oncogenic BRAF mutations in LCH and 
Erdheim-Chester disease (developed further in section 1.9.4), treatment with an 
inhibitor of mutated BRAF (vemurafenib) has been reported. In a case report three 
grown-up patients with refractory Erdheim-Chester disease, and LCH occurring 
simultaneously in two of the cases, were successfully treated with vemurafenib. 
Vemurafenib is a drug that is otherwise normally used in melanoma (Haroche et al., 
2013). 
 
1.8.4 Treatment for adults 
 
For adults the treatment recommendations are not as thoroughly grounded as for the 
pediatric population. Treatments that are used for children may sometimes be less 
effective or even toxic to adults.  Thus, many clinicians prefer monotherapy with either 
2-CdA or Ara-C to VBL and PDN for adults.  Efforts have been made to systematically 
study adult LCH patients but it has been difficult to recruit patients (Arico, 2004, 
Girschikofsky et al., 2013, Tatevossian et al., 2006). A recent review summarizes 
treatment options for LCH in adults (Girschikofsky et al., 2013).  
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In summary, the treatment of LCH has improved during the last twenty years. Still, 
with a mortality rate of about 15% in patients with risk organ involvement and a 
recurrence rate of around 30% for patients with MS-LCH (Gadner et al., 2013), leading 
to significant suffering and sequelae, there is a need to further improve treatment.  To 
investigate a potential role of IL-17A inhibitors in combination with other 
chemotherapeutic drugs in the therapy for LCH was one of the goals of papers IV and 
V. 
 
 
1.9 PATHOGENESIS OF LCH 
 
Based on the many common features, Nezelof et al. proposed that pathological LCH 
DCs arise from Langerhans cells (Nezelof et al., 1973). Regardless of theories 
considering the underlying triggering event, the cells at the heart of LCH lesions were 
then for many years largely regarded as LCs. However, this has recently been 
challenged in a series of papers (Allen et al., 2010b, Hutter et al., 2012, Merad et al., 
2008). 
 
1.9.1 Characteristics of LCH DCs 
 
Although LCH DCs share many similarities with normal LCs, they are different to 
normal LCs in terms of shape and phenotype. In contrast to normal LC, LCH DCs are 
rounded and lack typical dendritic extensions. LCH DCs stained with haematoxylin and 
eosin have moderate amounts of pink cytoplasm and lobulated nuclei (Schmitz and 
Favara, 1998). As normal LCs they co-express CD1a and Langerin/CD207 to a high 
degree (75-100%) as observed in several studies and reported to be independent of 
disease localization or clinical severity (Dziegiel et al., 2007, Chikwava and Jaffe, 
2004, Geissmann et al., 2001). Still, lower numbers of CD1a
+
 cells co-expressing 
Langerin/CD207 have been reported in LCH lymph nodes (Favara and Steele, 1997) 
and observations made by our group indicate that LCH DCs in bone lesions may be 
CD1a
+
 CD207
- 
(unpublished data) which has also been supported by a Dutch study 
(Rust et al., 2006). LCH DCs are readily also positive for the macrophage marker 
CD68 and the monocyte marker CD14, preferentially in bone lesions (Geissmann et al., 
2001, Emile et al., 1994a). Normal LCs express no CD14 and CD68 (Davis et al., 
1988).  
 
On one hand, LCH DCs express some markers normally found on activated/mature 
LCs, such as CD54 and CD58, and the pattern of adhesion molecules is also consistent 
with an activated phenotype, e.g. down-regulation of E-cadherin (Geissmann et al., 
1997, Emile et al., 1994a). Still, they keep several markers of resting/immature cells, 
including the Birbeck granules which normally tend to disappear in activated LCs 
(Teunissen, 1992).  Further, LCH DCs rarely express the maturation markers CD83, 
CD86 or DC-LAMP and continue to express MHC class II molecules intracellularly 
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(Geissmann et al., 2001). They are also poor stimulators of naïve T cells (Yu et al., 
1995). However, following in vitro activation of CD40, LCH DCs mature and become 
functioning antigen presenting DC. It is of interest to note that isolated or self-healing 
skin lesions have been associated with a more mature phenotype of LCH DCs and a 
lower number of IL-10 expressing cells than lesions from other disease localizations 
(Geissmann et al., 2001). Chemokine receptor expression further emphasizes the mixed 
resting/activated phenotype. Following activation of normal LCs, CCR6 (the receptor 
for CCL20) is down-regulated and CCR7 up-regulated. CCR7 responds to CCL19 and 
CCL21, directing the cells toward the lymph nodes. Two groups have reported that 
LCH DCs express CCR6, one of the groups also found that they expressed CCR7 in 
addition (Annels et al., 2003, Fleming et al., 2003). β-catenin is an E-cadherin 
associated molecule connecting to the cytoskeleton that also serves as a transcriptional 
co-activator. Defective β-catenin has been suggested by Egeler’s team to be implied in 
the maturation arrest of LCH DCs (Egeler et al., 2010).   
 
In conclusion, LCH DCs differ from normal LCs both morphologically, phenotypically 
and functionally. LCH DCs typically express a mixed macrophage-monocyte-DC 
phenotype, are semi-mature and are poor at antigen presentation (Geissmann et al., 
2001, Nezelof and Basset, 1998).  
 
1.9.2 Origin of LCH DCs 
 
Despite the proposition from Nezelof that LCH DCs originate from LCs it is hard to 
understand how LCs, that constitute a small population (1-8%) of epidermal cells,   
might leave the skin and give rise to LCH lesions, accumulating a large number of LC 
like cells with a low rate of proliferation, in organs where LCs are otherwise not found. 
The discoveries that LCs are replaced by local proliferation and that they develop as a 
separate entity of dendritic cells make this even more puzzling (Chorro and Geissmann, 
2010). Alternatively than from LCs, LCH DCs may originate from myeloid DC 
progenitors or precursors.  
 
In 2005, it was indeed demonstrated that myeloid circulating dendritic cells were 
increased in the blood of LCH patients (Rolland et al., 2005). In the same work it was 
demonstrated that FLT3L and M-CSF, two cytokines known to increase the number of 
DC progenitors and monocytes respectively were elevated. Further, GM-CSF has been 
reported to be elevated in the serum of children with disseminated disease (Emile et al., 
1994b). Although it cannot be excluded that these findings were related to treatment, 
they may support that LCH DCs originate from other cells than LCs, such as blood 
circulating DCs, DC progenitors expressing the FLT3 receptor, or monocytes.  
 
Additional support for a myeloid origin of LCH DCs is provided by a study from 
McClain’s group from 2010 (Allen et al., 2010b). In this work, global gene expression 
in Langerin/CD207+ cells from thirteen LCH samples (skin and bone) was compared 
with Langerin/CD207+ LCs from normal skin. Because several markers typical for 
myeloid DC (such as CD1d, CD33 and CD44) were over-expressed in the 
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Langerin/CD207+ cells from LCH subjects compared to normal LC, the authors 
suggested that a myeloid DC progenitor might actually be the precursor of pathological 
LCH DCs. Considering that other cells than LCs may express Langerin/CD207, LCH 
DCs might arise from such a progenitor.  
 
Another study by Hutter et al. (Hutter et al., 2012) has further supported the theory that 
LCH DCs may not derive from LCs. In this study LCH DCs were found to exhibit a 
distinct transcription profile that separates them from all previously known DCs based 
on their expression of both the Notch ligand Jagged 2 (JAG2) and its receptor 
NOTCH1. The role of NOTCH signaling in DCs is not clear but it is implied in DC 
differentiation (Cheng et al., 2010). Hutter and co-workers showed that the NOTCH1-
JAG2 signaling pathway was active in LCH lesions and that JAG2 signaling induced 
markers typical for LCH DCs in mo-DCs, indicating a role for this differentiation 
pathway in LCH: Incubation of monocytes with JAG2 and GM-CSF resulted in their 
differentiation into CD1a
+
 DCs, independently of IL-4, and addition of TGF-β gave rise 
to CD1a
+
Langerin/CD207
+
E-cadherin
-
 DCs much alike the phenotype observed for 
LCH DCs. Considering the recently described mutation of BRAF in LCH (described 
further in section 1.9.4), it is of note that NOTCH was activated independently of 
BRAF mutation status. NOTCH signaling has been suggested in the pathogenesis of 
many diseases including several hematological malignancies (Radtke et al., 2010). 
Interestingly, NOTCH signaling in LCH has been discussed before, following the 
detection of actively mutated NOTCH1 in a patient with LCH after T-ALL (Rodig et 
al., 2008).  
 
Discussing the origin of LCH DCs, it is also interesting to note that a mouse model 
suggestive of multisystem LCH has been created by generating transgenic mice 
expressing simian virus (SV40)  derived oncogenes specifically in classic CD8α+, 
Langerin/CD207
+ 
DCs derived from mouse spleen (Steiner et al., 2008). These mice 
develop LCH like lesions in the spleen, liver, bone marrow, thymus and mesenteric 
lymph nodes, again underlining the possibility of other cells than conventional LCs to 
be the precursors of LCH DCs. However, this model does not give rise to lesions in 
bone and skin which are the most common sites of LCH and its relevance to LCH is 
still not clarified. 
 
An alternative explanation for the differences between LCH DCs and LCs, presented 
by Badalian-Very et al., is that LCs undergo a transformation reprogramming process, 
or dedifferentiation, rendering them more alike myeloid DC, similarly to what is seen 
as epithelial cells undergo the transcriptional reprogramming necessary for neoplastic 
cells to spread and invade other tissues (Badalian-Very et al., 2013). Loss of E-cadherin 
and up-regulation of osteopontin was suggested to point in this direction (Allen et al., 
2010b, Geissmann et al., 1997).  
 
Whether LCH DCs develop an LCH phenotype in response to intrinsic events (e.g. 
mutations) or in response to environmental stimuli, possibly in combination with an 
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underlying immune dysregulatory defect, is not clear. However, LCH lesions are 
known to be abundant in cytokines with capacity to generate LCs from CD34
+
 myeloid 
progenitors or monocytes, including GM-CSF, TNF-α, IL-4, and TGF-β (Caux et al., 
1992, Geissmann et al., 1998, Jaksits et al., 1999, Garabedian et al., 2011). In both the 
papers by Allen et al. and Hutter et al., LCH samples clustered as being rather 
homogenous although collected from different sites in the body and at different disease 
stages, supporting that LCH is indeed one disease (Allen et al., 2010b, Hutter et al., 
2012).  
 
In summary, several sources for LCH DCs other than LCs can be proposed, including 
monocytes, circulating blood DCs or DC progenitors. The idea that LCH DCs may not 
be of LC origin has now started to become recognized by the LCH research 
community. Early considering a possible myeloid origin of LCH DCs motivated us to 
work on mo-DCs from LCH patients in paper III. This was by then an original 
approach.  
 
1.9.3 Characteristics of the LCH lesion 
 
LCH lesions are granulomatous lesions consisting of a mixture of cells, including 
macrophages, lymphocytes (predominantly CD4
+
 T cells), eosinophils and MGCs. 
Granulocytes, B cells and plasma cells are occasionally found but are not thought to be 
an integral part of the LCH lesions (Favara and Jaffe, 1994). In contrast to other 
granulomatous diseases, CD1a and/or Langerin/CD207+ cells are always present and 
are mandatory for the diagnosis.  
 
Macrophages are usually found in close contact with LCH DCs and T cells in bone and 
lymph node lesions but not in skin lesions. They have been pointed out as the source of 
IL-10 in LCH lesions (Geissmann et al., 2001). Eosinophiles are thought to be attracted 
to LCH lesions by CCL5/Rantes and sustained by IL-5 production from infiltrating T 
cells (Egeler et al., 1999). Eosinophile infiltration is most prominent in bone lesions. 
The role of eosinophiles in LCH is still not clarified. 
 
Both CD8
+
 and CD4
+
 T cells are present in LCH lesions. The majority of T cells are 
CD4
+
 T cells and express markers of recent activation such as CD40, CD45RO and 
RANKL (Egeler et al., 2000, Annels et al., 2003, da Costa et al., 2005). Importantly, T 
cells in LCH lesions have been shown to be polyclonal (Senechal et al., 2007). 
Although the antigen specificity remains unknown the T cells have been suggested to 
be attracted to the lesions by CCL20 and CXCL11 production from LCH DCs (Annels 
et al., 2003). In 2007, the presence of CD25
+ 
FoxP3
+
 T cells, regulatory T cells, were 
shown in LCH lesions (Senechal et al., 2007). Up to 20% of the T cells in the bone 
lesions examined in this study were found to be Tregs. Whether they are a result of an 
immunological attempt to attenuate a boiling inflammatory pot or the result of tumor 
(like) induced suppressive activities remains to be elucidated. That regulatory T cells 
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are not able to stop the inflammatory process is consistent with a non T cell origin of 
the inflammation in LCH.  
                                                                                                                                            
LCH lesions are characterized by an abundance of potent pro-inflammatory cytokines 
and chemokines, a picture sometimes referred to as a “cytokine storm”. The typically 
inflammatory appearance of the lesions has been held as an argument of an 
inflammatory etiology but the picture is also similar to what is seen in some 
malignancies, e.g. Hodgkin’s lymphoma (Badalian-Very et al., 2013). CD4+ T cells and 
LCH DCs are considered to be the major source of cytokines but macrophages, stromal 
cells and, to a less degree, eosinophils are also prominent cytokine producers (Laman et 
al., 2003). 
 
Cytokines and chemokines that have been documented in LCH lesions include IL‐1α, 
IL‐1β, IL-2, IL-3, IL‐4, IL-5, IL-7, IL-8, IL-10, IL-11, TGF-α, TGF-β, TNF-α, IFN-γ, 
GM-CSF, M-CSF, RANKL, leukemia inhibitor factor (LIF), CCL20, CCL5 and 
CXCL11 (Egeler et al., 1999, de Graaf et al., 1996, Garabedian et al., 2011, Andersson 
By et al., 2004, Bechan et al., 2006, Annels et al., 2003, da Costa et al., 2005). IL-6 
mRNA has been shown by in situ hybridization (Foss et al., 1996). While GM-CSF, 
TNF-α and IL-1 might promote the maturation of LCH DCs, IL-4 and IL-10 may 
contribute to keeping them in an immature state (Hart, 1997, Geissmann et al., 2001, 
Garabedian et al., 2011).   
 
Da Costa et al. showed that the receptor activator of NF-κВ (RANK) is expressed on 
LCH DCs and that RANKL and M-CSF is present in LCH lesions (Senechal et al., 
2007, da Costa et al., 2005). Based on the findings of Rivollier et al., that stimulation 
with RANKL and M-CSF can induce differentiation of immature DCs into osteoclasts, 
and their own findings, this group have thus suggested this pathway as a possible origin 
of MGCs in LCH (Rivollier et al., 2004, da Costa et al., 2005). As mentioned 
previously FLT3L and M-CSF has been reported to be increased in the serum of LCH 
patients in one study (Rolland et al., 2005) as has RANKL (Ishii et al., 2006), IL-1α, 
IL-6 (Murakami et al., 2012) and GM-CSF in children with disseminated disease 
(Emile et al., 1994b). Yet another cytokine that was detected in the serum of LCH 
patients by our group at the beginning of this thesis is IL-17A and we continued to 
explore the potential role of IL-17A on DC and in LCH (papers III-V). 
 
1.9.4 Theories on the etiology of LCH 
 
1.9.4.1 Is there an underlying immune regulatory defect in LCH? 
In 2004 Nezelof and Basset suggested that a limited underlying defect in a yet 
unidentified molecule, such as a receptor, might hinder the switch from an innate to an 
adaptive immune response in LCH patients (Nezelof and Basset, 2004). They proposed 
that proliferation and activation of LCs and macrophages, resulting in aberrant 
granuloma formation and the cytokine storm, could be viewed as reactive mechanisms 
trying to compensate for the absence of an adaptive immune response.  
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As stated, there is a well-known association between LCH and other malignancies but 
no specific susceptibility to infectious agents or clear association with autoimmune 
disorders (except for maybe thyroid disorders) has been shown as of today (Bhatia et 
al., 1997, Nezelof and Basset, 2004) Nor has any specific mutation or allelic variant 
been reported in LCH patients in this regard.  
 
Reports on immunological abnormalities in LCH children have been recurrent but the 
findings have been inconsistent and the reasons and implications often not evaluated 
further. Thus, in the early 1980’s Osband et al. reported that circulating T cells from 
LCH patients were spontaneously cytotoxic to cultivated fibroblasts and correlated this 
to low numbers of suppressor T cells (regulatory T cells) (Osband et al., 1981). This 
team successfully treated these patients with crude thymic extract. However, this 
treatment was not successful in a follow-up study (Ceci et al., 1988). In the 1980´s, 
hypergammaglobulinemia in LCH patients was also reported (Lahey et al., 1985). Low 
T cell counts in LCH children have been reported in some studies (McClain et al., 
2003, Ceci et al., 1988). In more recent years, Senechal et al. have reported normal 
absolute lymphocyte counts in peripheral blood from naïve LCH patients but an 
increased prevalence of circulating Tregs (Senechal et al., 2007). HLA-DRB1*03 has 
been suggested to protect against multisystem disease (Bernstrand et al., 2003). 
  
There is a link between LCH and hemophagocytic lymphohistiocytosis (HLH) in that 
severe forms of LCH sometimes are complicated by HLH (Henter et al., 2004). 
Recently, a male patient carrying the gene for the X-linked lymphoproliferative 
syndrome (XLP), SH2D1A, was also described to develop LCH prior to XLP (Zhang et 
al., 2011). Mutations in the SH2D1A gene cause a T cell dysfunction and result in a 
defective development of natural killer (NK) T lymphocytes. The authors speculated 
that this might let LCH DCs survive and thereby contribute to the development of 
LCH. 
 
In summary, the possibility of a (genetic) immunological dysfunction, perhaps 
predisposing for an aberrant immune response to a triggering factor or cancer 
development, is still not fully evaluated as having a potential role in the etiology of 
LCH. 
 
1.9.4.2 Is LCH an infectious disease? 
From the granulomatous appearance and the abundance of cytokines in LCH lesions it 
is tempting to assume that LCH is triggered by an infectious agent, either directly 
infecting DCs or by recruiting monocytes or circulating DCs to sites of infection. Hand 
first suggested that the symptoms described in his first classical report of LCH were 
due to tuberculosis (Hand, 1893). Still in the late 1940’s LCH was thought to be of 
infectious origin and treated with antibiotics (Aronson, 1951). However, no infectious 
agent has, so far, been shown to be causative of LCH.  
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Several studies have been performed trying to identify a viral cause of LCH. Human 
herpesvirus type 6 (HHV6) has been of special interest since this virus has been 
reported to be frequently involved in early childhood infections. Likewise, several case 
reports and one study, have also suggested a role for Epstein-Barr virus (EBV) in LCH 
(Chen et al., 2004, Sakata et al., 2008, Shimakage et al., 2004). 
 
In a study by Leahy et al., HHV6 DNA was detected by PCR in 14 out of 30 (47%) 
LCH lesions suggesting a role in the pathogenesis of LCH for this virus (Leahy et al., 
1993). However, McClain and co-workers did not find any evidence for a viral etiology 
of LCH in their studies including lesions from 56 LCH patients examined for nine 
different viruses (HHV6, herpes simplex virus (HSV), human cytomegalovirus 
(HCMV), Epstein-Barr virus (EBV), adenovirus, human T cell viruses type I and II 
(HTLV type I and II), human immunodeficiency virus (HIV) and human parvovirus) 
by PCR and in situ hybridization (McClain and Weiss, 1994, McClain et al., 1994). 
Furthermore, in an extensive study from 2008 Jeziorski et al. thoroughly examined the 
role of EBV, HCMV and HHV6 in LCH. In this study, the prevalence of EBV, HCMV 
and HHV6 in plasma and the antibody response against these viruses in 83 patients and 
236 age-matched controls were investigated, as well as the presence and cellular 
localization of these viruses in LCH tissue samples from 19 patients. The results 
indicated that, even if low copy numbers of EBV and HHV6 could be detected in LCH 
lesions, they originated from by-stander lymphocytes and were due to reactivation of 
these viruses due to the immunosuppressive microenvironment in LCH granuloma. The 
study did thus not support a role of any of the examined viruses in the pathogenesis of 
LCH (Jeziorski et al., 2008). 
Human herpesvirus type 8 (HHV8) has been studied separately in two studies without 
evidence for a role of HHV8 in the etiology of LCH (Jenson et al., 2000, Slacmeulder 
et al., 2002). In 1999, Ristevski et al. reported that a new type of endogenous type D 
retroviral particles were found in a SCID mouse thymic lymphoma that developed 
secondary to transplantation of LCH biopsy material into mice. Apart from this report 
there have been no other reports on retroviruses having a role in LCH (Ristevski et al., 
1999). 
Some members of the herpesvirus family had been investigated in LCH before we 
undertook our study but previous to the work reported by us in paper III there was no 
complete study of the herpesvirus family in LCH, let alone of the Herpesvirus Saimiri 
(HVS). 
1.9.4.3 Is LCH a neoplastic disease? 
A finding that is considered by many as one of the most important pieces of evidence 
for LCH being a neoplasm, is the results from X-chromosome inactivation studies in 
1994 showing that LCH DCs from non-pulmonary LCH were monoclonal, both in 
localized and disseminated forms of LCH (Willman et al., 1994, Yu et al., 1994). 
However, the presence of monoclonal cells is per se not sufficient proof of a neoplastic 
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origin since aggressive immune disorders may also sometimes go with oligoclonal 
expansion of immune cells (Weiss et al., 1985). Additionally, the pathological LCH 
DCs involved in pulmonary LCH were shown to be non-clonal (Yousem et al., 2001).  
 
A number of cytogenetic alterations have been reported in LCH DCs but, as many other 
findings in LCH, these findings have been hard to repeat in follow-up studies and are 
thus of unclear significance. The first cytogenetic alterations in LCH were reported by 
Betts in 1998  (Betts et al., 1998). In this study, a t(7;12)(q11.2;p13) translocation was 
found in a small part of unsorted cells from an eosinophilic granuloma. Other 
abnormalities were found in another four patients. A subsequent study, using 
comparative genomic hybridization (CGH) and loss of heterozygosity (LOH) analyzis, 
also showed different chromosomal aberrations in LCH DCs. However this study 
included only seven samples (bone) and the reported abnormalities were nonrecurrent 
within the set of samples, indicating that they were rather sporadic findings than 
relevant to LCH pathogenesis (Murakami et al., 2002). Chikwava et al. found a higher 
degree of fractional allelic loss of tumor suppressor genes in samples from patients with 
multisystem disease and high-risk patients than in patients with SS LCH (Chikwava et 
al., 2007). In contrast, in a large study from 2009, no genomic aberrations could be 
found in CD1a+ or CD1a
- 
cells from LCH lesions with various techniques, including 
array CGH and SNP array (da Costa et al., 2009). As stated by the authors of the latter 
study, cryptic point mutations in unidentified genes (or a small viral insertion) could 
however not be excluded. Telomere lengths have been evaluated in two separate studies 
but with contradictory results, perhaps depending on different sensitivity in the methods 
used (Bechan et al., 2008, da Costa et al., 2007). 
 
Several genes regulating cell survival, proliferation and cell death have been shown to 
be overexpressed in LCH DCs, mainly by immunohistochemistry and in situ 
hybridization but in some cases with PCR. Both pro survival and pro apoptotic 
pathways have been shown to be active. Apart from the recent finding of the BRAF 
V600E mutation, no mutations in these molecules have repeatedly been demonstrated 
and stimulation might thus depend on cytokine or growth factor stimulation.  
 
Schouten et al. showed by immunohistochemistry that LCH DCs expressed TGF-β 
receptor I and II, p53, MDM2, BCL2, P21, P16 and Rb in more than 90% (≥27/30) of 
the tissue samples examined, (Schouten et al., 2002). While TGF-β receptors may play 
a role in tumor suppression, the other molecules belong to the p53- p21 and p16-Rb 
pathways, which can induce cell cycle arrest or apoptosis in response to DNA damage 
(Schouten et al., 2002). Notably, BCL2 was also detected in many other lesional cells. 
Consistent with this, Savell et al. demonstrated BCL2 mRNA and protein expression in 
LCH DCs in contrast to normal LCs, without finding evidence for any gene 
rearrangements (Savell et al., 1998). As it has been shown that DCs up-regulate BCL2 
in response to CD40 ligation by T cells, up-regulation of BCL2 was suggested to be a 
secondary event to such a mechanism (Bjorck et al., 1997). 
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Quite a high number of LCH DCs have been shown to express FAS and/or FASL. The 
frequency was higher in single-system disease (69%) compared to multisystem lesions 
(46%). This was interpreted as reflecting the higher spontaneous resolution frequency 
of solitary lesions and that more prominent lesions have found ways to circumpass 
apoptosis (Petersen et al., 2003).  
 
The proliferation stimulating oncogenes MYC and HRAS have also been demonstrated 
to be expressed in LCH by in situ hybridization, interestingly only in late stages of the 
disease (Abdelatif et al., 1990). Despite different results regarding the expression of the 
proliferation marker Ki-67 in between 2-25% of LCH DCs, the number of mitoses 
observed in LCH lesions is usually low (Schmitz and Favara, 1998, Bank et al., 2003, 
Laman et al., 2003, Senechal et al., 2007, Brabencova et al., 1998, Hage et al., 1993). 
Thus, the rate of cell division is low even if cell cycle pathways are active. This could 
perhaps be related to a high expression of P53 as suggested by Egeler et al. (Egeler et 
al., 2010). P53 is the only molecule that has repeatedly been found to be up-regulated in 
LCH. Normally expressed at low levels, expression of P53 is increased following 
cellular stress. It blocks progression of the normal cell cycle and may instead induce 
apoptosis. Being a tumor suppressor gene, it is often absent or mutated in cancer cells.  
 
In the recently published study documenting the BRAF V600E mutation, in a single 
sample (1/61) a known cancer-related mutation was detected in P53 (TP53 R175H). No 
mutations in P53, or the regulating protein MDM2, have otherwise been reported, or 
shown in the two studies that have specifically investigated this (Weintraub et al., 1998, 
Badalian-Very et al., 2010, da Costa et al., 2009). The normal (non-mutated) expression 
of P53 in LCH speaks against a neoplastic origin of LCH.  
 
BRAF is a pivotal protein kinase of the RAS-RAF-MAPK signaling pathway which 
regulates cell survival and proliferation used by several growth factors, e.g. GM-CSF 
(Nichols and Arceci, 2010). In 2010 the first repeatedly demonstrated mutation, a 
known oncogenic mutation in BRAF, BRAF V600E, was documented in 35/61 (57%) 
of archived LCH samples from bone and various other organs (Badalian-Very et al., 
2010). The authors used a genome assay, OncoMap, which tests 983 alleles from 115 
cancer-related genes. The findings were also validated through pyrosequencing. Apart 
from the recurrent findings of the BRAF V600E mutation, two other validated 
mutations were noted in one sample each; the mutation in P53 mentioned above, and 
MET E168D, a variant allele of c-Met, encoding the hepatocyte growth factor receptor 
(HGFR), although this allele could be a non-pathogenic polymorphism.  
 
Others have subsequently repeated the results of Badalian-Very et al. regarding BRAF 
V600E (Sahm et al., 2012, Satoh et al., 2012). Satoh et al. additionally identified two 
novel mutations of BRAF, a stimulating somatic mutation (BRAF 600DLAT) and a 
germ line, non-stimulating, mutation (BRAF T599A). (Satoh et al., 2012). This group 
studied the presence of BRAF mutations in peripheral blood mononuclear cells 
(PBMCs) and monocytes without finding evidence for somatic mutations in BRAF 
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arising at this level. Considering the debate on the origin of LCH DCs it is interesting to 
note that the mutations reported thus seem to arise in the tissue rather in circulating 
precursors. That a few progenitor cells harbored the mutation could however not be 
completely ruled out due to sensitivity limitations of the methods, allowing for a very 
small BRAF mutation-carrying myeloid-restricted clone in the bone marrow to avoid 
detection. 
 
Meanwhile, using a mutation-specific antibody against BRAF V600E, Sahm et al. have 
shown that the majority of cells co-express CD1a and BRAF V600E while only a 
fraction of these express Langerin/CD207 (Sahm et al., 2012). Sahm and colleagues 
also noted that the BRAF V600E mutation was harboured by cells of different 
maturation status. However, as the authors state, no conclusion can be drawn from this 
whether mutated cells acquire an LC phenotype or whether LCs dedifferentiate in 
response to mutations. 
 
In the original study the BRAF V600E mutation was not found in samples of 
dermatopathic lymphadenopathy, a disease characterized by proliferation of normal 
LCs, implying that this mutation is specific to pathological LCs (Badalian-Very et al., 
2010). The BRAF V600E mutation has later been shown to be present in Erdheim-
Chester disease as well, but not in other non-Langerhans cell histiocytoses (Haroche et 
al., 2012).  
 
Even if the BRAF V600E mutation has been firmly anchored in LCH history the role 
of this mutation in the pathogenesis of LCH is still not clear. The presence of mutated 
BRAF does not appear to correlate with disease stage even if it was shown to correlate 
negatively with age by Badalian-Very et al. (Badalian-Very et al., 2010). The RAS-
RAF-MAPK signaling pathway has also been shown to be active in LCH samples 
without a BRAF V600E mutation, possibly due to cytokine stimulation. Hence, the 
significance of BRAF V600E stimulation on this pathway is not clear.  
 
The BRAF V600E mutation has been found in several benign and malignant tumors 
(Davies et al., 2002, Michaloglou et al., 2008). Alone it is not sufficient to drive tumor 
development but in the presence of other pro oncogenic mutations it may contribute to 
tumorigenesis. In benign nevi a BRAF V600E mutation alone is thought to induce a 
resting state (oncogene-induce senescence) of the cell but in the context of other 
acquired mutations it may facilitate the development of malignant melanoma.  
(Michaloglou et al., 2008). A parallel has subsequently been suggested by Badalian-
Very et al. between self-limiting and aggressive LCH: Oncogene induced senescence 
may allow the clearance of self-limiting forms of LCH while additional mutations (not 
yet characterized) might lead to more aggressive forms of LCH.  
 
In a recent review Badalian-Very et al. argues that the recurrent findings of BRAF 
V600E mutation in addition to the formerly described clonality of LCH DCs are 
sufficient to assign LCH a neoplastic origin, carefully emphasizing neoplastic and not 
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malignant (Badalian-Very et al., 2013). As the technical advances in genetic research 
are impressive, new mutations will perhaps soon be described that definitively assign 
LCH a neoplastic origin. Still, mutations may occur as the result of the heavy 
inflammation pressure and may not be at the bottom line of LCH etiology. This might 
be supported by the finding that 40% of samples from isolated pulmonary LCH lesions, 
that are usually polyclonal, investigated by Badelian-Very et al., turned out to be 
positive for the BRAF V600E mutation (Badalian-Very et al., 2010). Intriguing are also 
still the facts that LCH DCs, in spite of disease stage, can be made to mature in vitro, 
that no cell line has successfully been established as well as the documented cases of 
spontaneous remission of LCH even in multi-systemic disease (Nezelof and Basset, 
2004). 
 
As is often the case, LCH etiology may turn out to be a synthesis of all theories. An 
immune dysregulation, or a pro-survival mutation in a DC progenitor cell, may result in 
an aberrant inflammatory response following an infection. This in turn may favor 
increased viability and possibly the accumulation of further mutations as in many cases 
of inflammation-driven cancer development. In the absence of massive cell division (in 
restricted cell lines such as DCs) this may give rise to a “pre-malignant like” condition 
and the generation of LCH lesions.  
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis was to contribute to the understanding of the 
pathogenesis, the search for new treatment options and improved monitoring of disease 
activity in children with LCH, and thus to improved survival and reduction of sequelae 
of affected individuals. 
 
The specific aims were: 
 
1. To identify laboratory parameters to evaluate ongoing neurodegeneration in children  
    with LCH (paper I) 
 
2. To clarify whether there is a correlation between IVF and LCH, and, if so, to    
    evaluate possible explanations for such a connection (paper II) 
 
3. To study cytokine profiles in LCH and viruses possibly involved in LCH (paper III) 
 
4. To understand why IL-17A treated healthy DC, which are LCH-DC-like cells, are     
    resistant to death and if this mechanism can be of importance in explaining LCH  
    (paper IV-V)  
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3 PATIENTS, MATERIAL AND METHODS 
 
This section will briefly describe the patients and methods included in papers I-V. For 
a more extensive description readers are kindly referred to the method section of each 
paper. Papers III-V are based on laboratory work with the focus to clarify effects of 
IL-17A on DCs and a potential role for IL-17A in the pathogenesis of LCH. They are 
the result of an international collaboration between France, Italy, Sweden and the 
Netherlands (paper III). The laboratory work was carried out by several team 
members, mainly under the supervision of Prof. Delprat. 
 
Ethical permission to perform the studies was provided by the Regional Ethical Review 
Boards in Stockholm and Gothenburg, and the local ethic committees in Italy, France 
and the Netherlands according to national regulations. Informed consent was obtained 
from each subject where so requested by the ethical permission.  
 
 
3.1 PATIENTS 
 
An overview of patients included in papers I, III and V is presented in Table III.  
 
The aim of paper I was to identify biomarkers in the CSF indicative of ongoing 
neurodegeneration associated with LCH. In this paper nine patients diagnosed with 
LCH, eight at Astrid Lindgren’s Children’s Hospital, Karolinska University Hospital in 
Stockholm, and one at Lund University Hospital (median age at LCH diagnosis 2.1 
years, range 0.4–6.3 years), and signs of LCH-related radiological neurodegeneration 
(as detected by MRI) were included. All patients showed either endocrine deﬁciencies 
and or clinical symptoms of neurodegeneration such as neurological symptoms or 
psychosocial problems diagnosed 0–6 years after the LCH diagnosis. The levels of 
biomarkers in the CSF of these patients were compared with  levels in the CSF of 110 
patients with newly diagnosed ALL aged 1–16 years (median 4.7 years, mean 6.4 
years), who had no signs of CNS-leukemia.  
 
In papers III and V patients with different disease categories (SS-LCH or MS-LCH) 
and with different disease activity, controlled at the clinics participating in the studies 
were included.  
 
All patients in papers I, III and V were assessed with regard to factors that might be 
relevant to the laboratory findings or affect the findings, such as age at diagnosis and at 
the time of study, organ involvement during the course of the disease, chemotherapy 
received prior to and at the time of sampling, and disease activity at sampling. Disease 
activity was graded according to the LCH-III study protocol in paper I and III, and in 
paper V according to LCH-IV. Disease state categories in LCH-IV include non-active 
disease (NAD), no active disease, resolution of all clinical signs and symptoms; active 
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disease (AD) better, regression of signs/symptoms, no new lesions; AD stable, 
persistence of signs or symptoms, no new lesions and AD worse, progression of signs 
or symptoms and/or appearance of new lesions. In an attempt to describe the severity of 
the disease at the time of sampling, disease activity was also rated as 0 – 4 where 0 
corresponded to NAD resolution, 1 to mild disease (regression of active disease or mild 
chronic disease, no hypoalbuminemia or ESR elevation, 2 to moderately active disease, 
mild thrombocytosis, hypoalbuminemia or ESR elevation, 3 to progressive disease or 
constantly marked active disease, marked hypoalbuminemia or ESR elevation and 4 to 
life-threatening disease. In papers I and V no patients fulfilled the criteria for level 4.  
 
Some of the patients were included in more than one study. See Table III for details. 
 
The patients in paper II were identified through crosslinking birth data from all IVF 
clinics in Sweden for children born following IVF with the Swedish Cancer Register 
and the Patient Register (previously the Hospital Discharge Register). Individuals born 
1982–2005 were included in the study: a ﬁrst cohort of children born 1982–2001, 
reported by Källén et al. 2005 (Källén et al., 2005), and a second cohort of children 
born 2002–2005 that were additionally included in a follow-up study (Källén et al., 
2010). The diagnoses that were searched for in the Swedish Cancer Register were: 
D76.0, C96.0, C96.1 (ICD-10); 202.9 (ICD-9); 202.1 and 289.5(ICD-7), and in the 
Patient Register⁄Hospital Discharge Register: D76.0, C96.0, C96.1 (ICD-10); 202F, 
202D, 277W, 272H (ICD-9); 279.03, 279.06 and 279.07 (ICD-8). The National Board 
of Health and Welfare granted permission for the study and performed the crosslinking.  
 
Eight children conceived by IVF and with an LCH diagnosis were identified this way. 
The medical records for each child were acquired from the hospitals where the 
diagnoses were made and the children treated. The records were reviewed to verify the 
LCH diagnosis and to characterize the disease for each child. Originally we had 
planned to contact the families to collect more information, such as the reasons for IVF 
or familial diseases, but after thorough discussions it was concluded that it could not be 
excluded that this would cause harm to the families and permission from the National 
Board of Health and Welfare for this was not obtained.  
 
Twenty seven children with LCH, previously identified in a population-based study 
performed by our group, including all children diagnosed with LCH in the Stockholm 
County between 1992 and 2001 were chosen as a reference group (Stalemark et al., 
2008). The information on neurodegenerative ﬁndings in this population comes from a 
separate study by our group on CNS involvement in LCH (Laurencikas et al., 2011).
  
   
Table III. Overview of LCH patients included in the different studies (papers I, III and V).  
                Patients of paper II (IVF-LCH) are not included for integrity reasons. 
 
Patient 
 
Sex Age at 
diagnosis 
Organs involved in the 
disease course 
(until latest study) 
Chemotherapy received 
(until latest study) 
 
Paper I 
Age at study 
start/Disease activity 
(class
#
)/Sequelae 
Paper III 
Age at study /Disease 
activity (class
#
)/Sequelae 
Paper V 
Age at study /Disease 
activity (class
#
)/Sequelae 
1 F 2 y ears*, skin*,  pituitary*,  
thyroid*, bone, gingiva, 
neurodegeneration
§
 
VBL, CST, MTX, VP-16,  
6-MP, radiotherapy, 
retinoid, IFNα, IVIG 
19 yr/AD, chronic 
(22) / PH, CNS 
symptoms 
20 yr/AD, chronic 
(21)/PH, CNS 
symptoms 
 
 
2 F 5 mo bone*, skin, spleen, liver, 
hematopoietic system, 
thymus, pituitary, 
neurodegeneration
§
 
VBL, CST, MTX, 6-MP, 
anti-TNFα,  2-CdA, IVIG  
5 yr/AD,  progression 
(33)/ DI, GHD,  
CNS symptoms 
6 yr/ AD, progression 
(333)/ DI, GHD,  
CNS symptoms 
10 -11-11yr/AD, chronic 
(222)/ DI, GHD,  
CNS symptoms 
3 M 5 mo bone*, skin*, ears*, 
spleen*, 
neurodegeneration
§
 
VBL, CST, MTX, 6-MP, 
VP-16 
12 yr/AD, chronic 
(1)/proptosis,  
CNS symptoms   
13 yr/ AD, chronic 
(11)/proptosis,   
CNS symptoms 
 
4 F 3 y bone*,  pituitary, 
neurodegeneration
§
 
CST, 6-MP, MTX, IFNα 15 yr/NAD (0)/DI 17 yr/NAD (0)/DI  
5  M 16 mo bone*, skin*, ears*, 
gingiva*, lungs, 
neurodegeneration
§
 
CST, VBL, 6-MP, MTX, 
anti-TNF, VP-16 
6 yr/AD, chronic 
(21)/ 
CNS symptoms 
  
6 M 6 y ears*, bone*, pituitary*, 
skin, neurodegeneration
§
 
CST, VBL, 6-MP, MTX,  
2-CdA 
13 yr/AD, progression 
(33)/ PH,  
CNS symptoms 
 18-20 yr/AD, chronic 
(21)/ PH,  
 CNS symptoms 
7 M 2 y ears*, skin* pituitary, 
neurodegeneration
§
 
CST, MTX,  
6-MP 
7 yr/ AD, chronic 
(2)/DI 
  
8 M 2 y bone*, skin*, ears*,  
pituitary, 
neurodegeneration
§
 
VBL, CST, MTX, 6-MP 9 yr/NAD (0) /DI, 
GHD, CNS symptoms 
  
9 M 4 y bone*, pituitary*, skin, 
neurodegeneration
§
 
 10 yr/NAD (0) /DI, 
GHD 
 13-15 yr/NAD resolution 
(00)/DI, GHD 
10  M 16 mo skin*, lung*, liver*, lymph 
node*, spleen* 
VBL, CST, MTX, 6-MP, 
2CdA, ARA-C 
 3 yr/AD, stable (2)/liver 
failure 
 
5
4
 
  
   
11  M 2 yr lymph node*, lung* VBL, CST,  
6-MP, MTX 
 3 yr/NAD (0)/liver 
failure 
 
12  F 15 mo bone*,skin* VBL, CST  18 mo/Active disease, 
diagnosis (311) 
 
13  M 10 yr lung*, bone* VBL, CST, 6-MP  13 yr/NAD (0)  
14  F 55 yr lung*, bone* VBL, CST, 6-MP  55 yr/AD, better (1)  
15  M 9 yr bone* VBL, CST  11 yr/NAD (0)  
16  M 7 mo skin*, lymph node*, liver*, 
ears*, spleen, bone, 
hematopoietic system, 
intestines 
VBL, CST, MTX, VP-16, 
2CdA, ARA-C, 6-MP 
 14 mo/AD, progression 
(4) 
5 yr/AD, better (2) 
17  F 4 mo bone*, skin*, lung*, lymph 
node* 
VBL, CST, MTX, 6-MP  6 yr/AD, better (1)  
18 M 5 mo skin*, lung*, lymph node*, 
ears* 
VBL, CST, 6-MP  7 yr/NAD (0)  
19  M 14 mo bone*, skin*, spleen* VBL, CST, 2CdA,   
ARA-C, 6-MP 
  2 yr/NAD (0) 
20 M 10 mo skin*, bone, pituitary VBL, CST, 6-MP   3 yr/Reactivation (3)/DI 
21 M 7 mo bone*, skin*    7 mo/Active, diagnosis (3) 
22 F 2 mo skin*, spleen VBL, CST, 6-MP, MTX   4-6 yr/AD, chronic (11)  
23 F 14 yr bone*, mucosal 
membranes, lung, pituitary 
VBL, CST   15 yr/AD, better (1)/DI 
24 M 2 yr  bone*, skin* VBL, CST   2 yr/AD, better (1) 
25 F 2 yr bone*, central nervous 
system* 
VBL, CST   3 yr/AD, better (1) 
26  M  2 yr skin*    2 yr/Active, diagnosis (2) 
27 F 9 yr skin*    9 yr/Active, diagnosis (2) 
28 M 3 yr bone* VBL, CST   3 yr/AD, better (1) 
29 M 18 mo bone* VBL, CST   3 yr/AD, better (1) 
5
5
 
  
   
 
 
 
 
 
 
Patient 
 
Sex Age at 
diagnosis 
Organs involved in the 
disease course 
(until latest study) 
Chemotherapy received 
(until latest study) 
 
Paper I 
Age at study 
start/Disease activity 
(class
#
) /Sequelae 
Paper III 
Age at study /Disease 
activity (class
#
)/Sequelae 
Paper V 
Age at study /Disease 
activity (class
#
)/Sequelae 
30 
 
F 17 mo skin*, lymph node*, bone* CST   19 yr/AD, chronic (1)/ 
coxarthrosis 
31 F 7 yr bone*    7 yr/Active, diagnosis (2) 
32 M 2 yr bone* VBL, CST   3 yr/AD, better (2) 
33 F 4 yr bone*    5 yr/ NAD (0) 
In paper III an additional 10 paraffin imbedded tissue samples from the Netherlands were investigated with immunofluorescence for the presence of IL-17A (7 
bone, 3 skin) and 10 tissue samples from Sweden (6 bone, 3 skin and 1 lymph node), taken at diagnosis, were investigated for the presence of herpes viruses. Three 
of the patients whose lesions were examined were later sampled for blood in paper III (pat 2, 16 and 19) and three (2, 6 and 16) were sampled for blood in paper 
V while two (6 and 7) were sampled for CSF in paper I. In paper V paraffin imbedded tissue samples from 2 patients were analyzed for the presence of BCL2A1. 
One of these patients (34) was also sampled for blood in this paper.  
  
 
 
 
 
 
Abbreviations: (Disease state categories in this table have been adjusted for all patients according to LCH-IV.)  2CdA, Cladribine; 6-MP, 6-mercaptopurine; AD, 
active disease (better, regression of signs/symptoms, no new lesions; chronic, chronic disease; stable, persistence of signs or symptoms, no new lesions; worse, 
progression of signs or symptoms and/or appearance of new lesions); ARA-C cytarabine; CNS symptoms, clinical CNS symptoms of variable character and degrees; 
CST, corticosteroids; DI, Diabetes insipidus; GHD, Growth hormone deficiency; IVIG, intravenous immunoglobulin; MTX, methotrexate; NAD, no active disease, 
resolution of all clinical signs and symptoms; PH, panhypopituitarism; VBL, vinblastine; VP-16, etoposide.  
 
#
Disease activity classes: (, sampled two or three times) 0, resolution (no signs of active disease); 1, mild (regression of active disease or mild chronic disease; no 
hypoalbuminemia or ESR elevation); 2, moderate (moderately active disease; mild thrombocytosis, hypoalbuminemia, or ESR elevation); 3, marked (progressive 
disease or constant markedly active disease; marked hypoalbuminemia or ESR elevation); 4, life-threatening disease; *indicates organ involved at diagnosis; 
§
CNS 
neurodegeneration evidenced by MRI. 
Chemotherapy at study: Paper I: Patients 1, 2, 5, 6 and 7 had ongoing chemotherapy during the study. Paper III: Patients 1, 2, 10, 11, 12, 14 and 16 had 
ongoing chemotherapy during the study. Paper V: Patients 2, 6, 16, 20, 22, 23, 24, 25, 28, 29 and 32 had ongoing chemotherapy during the study. 56
 
5
3
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3.2 MATERIAL AND METHODS 
 
3.2.1 CSF sampling and MRI evaluation  
 
In paper I, CSF was collected at the time of lumbar puncture, centrifuged for 
elimination of cells, and the supernatant separated into smaller portions immediately 
frozen to -20° C. The samples were transported in a frozen state to the laboratory where 
the analyses were carried out. Samples were collected from the LCH patients 4.6-12.8 
years after the LCH diagnosis.  
 
The patients in paper I were investigated by MRI prior to and following CSF 
sampling. The most recent MRI prior to the first CSF sampling was performed at a 
median age of 9.5 years (range 5.4-18.7 years). The CSF sampling was performed 0-6 
months after the MRI (median 2 months). The next MRI was performed 2-22 months 
(median 9 months) after the CSF sampling. The MRI pictures were examined by a 
neuroradiologist who was blinded to the results. The severity of neurodegeneration was 
graded by the neuroradiologist where MR-level “+” (mild) indicates increased signal in 
the basal ganglia and nucleus dentatus (T1 weighted) and locally increased signal (T2-
weighted) in the cerebellar white matter, predominantly in connection with the nucleus 
dentatus. MR-level “++” (moderate) includes the findings of MR-level “+” and, 
additionally, abnormally increased signal in the brainstem, thalami and corpus calosum. 
MR-level “+++” (severe) includes the findings in MR-level “++” and, in addition, 
subcortical and periventricular white matter and gray matter changes. Consecutive MRI 
examinations were compared and the development of MRI changes over time was 
classified as “Regression or status quo” or “Progression”. Correlations between CSF 
biomarker values and the extension of MRI abnormalities, changes of MRI over time 
and relation to disease activity outside CNS were made.  
 
In four of the nine patients CSF sampling was repeated at least once, two of these 
patients were sampled repeatedly over a period of 19 and 15 months, respectively.  
 
3.2.2 Blood samples and synovial fluid 
 
All experiments in paper IV were carried out on blood samples from healthy adult 
blood donors. Controls in paper III and V also consisted of blood samples from 
healthy adult blood donors. Synovial fluid from six patients with rheumatoid arthritis 
served as a positive control for IL-17A in paper III. In paper III, blood samples from 
13 patients with LCH, from Sweden (n = 7) and Italy (n = 6), were obtained. In paper 
V blood samples from 19 patients with LCH (11 males and 8 females), from Sweden (n 
= 8) and Italy (n = 11) were included.  
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3.2.3 Tissue samples 
 
In paper III immunohistological studies were carried out on 10 paraffin embedded 
tissue samples (3 from skin and 7 from bone) from Dutch patients with LCH. Another 
10 tissue samples (6 from bone, 3 from skin and 1 from a lymph node) from as many 
Swedish patients with LCH were examined with regard to the presence of 
herpesviruses. In paper V immunohistological studies were carried out on two paraffin 
embedded LCH tissue samples (bone) from Sweden.  
 
3.2.4 Cell cultures 
 
Considering the fact that LCH is such a rare disease and the scarcity of freshly available 
lesional cells, as well as the low circulating numbers of DCs in peripheral blood, DCs 
derived from monocytes constitute an alternative approach to study the effects of 
cytokines and other substances on DCs that might be of relevance in LCH. The role of 
monocytes as precursors of DCs in vivo has been established as previously outlined 
(Cheong et al., 2010, Segura et al., 2013) and the relevance in LCH is further supported 
by the recent findings pointing at a potential myeloid precursor of LCH DCs (Allen et 
al., 2010a, Hutter et al., 2012, Merad et al., 2008).  
 
In papers III, IV and V, CD14 
+
 monocytes were purified from the peripheral blood of 
LCH patients or healthy controls by ficoll and percoll gradients, followed by negative 
magnetic depletion of cells expressing CD3, CD56 or CD19. CD1a
+
 CD83
–
 immature 
monocyte-derived DCs were generated in vitro after 6 days of culture with GM-CSF 
(50 ng/ml) and IL-4 (500 U/ml) as presented by Rivollier et al. 2004 (Rivollier et al., 
2004). 
 
DCs were seeded in concentrations of 1,600–4,800 cells/mm2 in α-MEM (Life 
Technologies) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 
U/ml penicillin and 100 µg/ml streptomycin (Life Technologies) in the presence of 
medium only, M-CSF, GM-CSF, RANKL, TNF-α, IL-17A and IFN-γ solely or in 
combinations. Cytokines were replenished every week. IL-17A-dependent fusion 
activity in serum samples from LCH patients was studied by investigating fusion 
efﬁciency in healthy DCs after 12 days’ culture with IFN-γ and 5% serum from either 
healthy donors or patients with LCH, followed by addition of blocking antibodies 
against IL-17A or IFN-γ, respectively. In the experiments evaluating the effect of 
chemotherapeutic compounds on IL-17A and IFN-γ treated healthy mo-DCs, drugs 
were added either concomitantly with cytokines, or 24 hours later.  
 
To evaluate the source of IL-17A in serum from LCH patients, lymphocytes were also 
purified from the blood and T cells activated by a combination of antibodies to CD3 
and to the co-stimulator CD28. 
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3.2.5 DC survival and fusion efficiency studied after TRAP and Hoechst 
staining 
 
In long term cultures, surviving DCs became adherent and fused to form MGCs. 
Fixation of these adherent cells and staining with Tartrate resistant acidic phosphatase 
(TRAP) and Hoechst double staining was used in paper III and paper V to visualize 
the cytoplasm and the nuclei respectively. The total number of nuclei in viable mono or 
multi-nucleated (strictly > 2 nuclei) cells, per well and over time, was counted. This 
permitted us to calculate percentages of surviving cells at different time points as well 
as the fusion efficiency, defined as the percentage of nuclei inside giant cells. 
 
3.2.6 Flow cytometry analyses (FACS) 
 
Flow cytometers use laser light to characterize particles in as stream of homogenous 
fluid. The particles can be characterized and sorted according to size and density as 
well as to fluorescence that can be manipulated by fluorescent antibodies bound to 
intra- or extracellular molecules whose presence and amounts can then be investigated.  
 
In papers III-V flow cytometry was used for a number of purposes ranging from cell 
phenotype characterization and evaluation of production of IL-17A and other proteins 
to assessment of viability and proliferation. A drawback of this method (as with all 
methods using antibodies to detect molecules) is that the binding of antibodies may not 
be specific. Complimentary experiments to detect cytokine mRNA (RT-PCR) in the 
cells can be of value in this context. On the other hand, the mere detection of mRNA 
does not prove that there really are elevated levels of the protein since there might be 
discrepancies between transcription and translation of the protein (Raqib et al., 1996, 
Schindler et al., 1990). MRNA is also easily destroyed if samples are not treated 
correctly. Western blot provides an alternative method to detect cytokines and other 
molecules in tissues or cells. To confirm that a molecule detected by intracellular flow 
cytometry staining is really secreted, analyses to show the molecule in the cell 
supernatant should ideally be performed.  
 
3.2.6.1 Extra- and intracellular stainings  
Immunostaining was performed in 1% bovine serum albumin (BSA) and 3% human 
serum- phosphate buffered saline (PBS). For intracytoplasmic staining we blocked the 
Golgi apparatus with BD GolgiStop TM, fixed and permeabilized the cells with 0,33% 
saponin for 30 minutes. Fluorescence was quantified on an LSRII (Becton Dickinson) 
and analyzed using FlowJo software. 
 
3.2.6.2 CFSE and CD14-PE labeling for proliferation study 
Through the carboxyfluorescein diacetate succinimidyl ester (CFSE) assay it is possible 
to evaluate cell proliferation by flow cytometry by following the serial halving of the 
fluorescence intensity of the vital dye CFSE. With this technique 8-10 of discrete cell 
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divisions can be visualized. An advantage of this technique is that one can mark the 
cells with other surface markers to track modifications as the cells divide and it is also 
possible to sort out vital cells to perform functional analyses, in contrast to other 
proliferation assays that usually measures proliferation at a population level (Lyons, 
2000). 
 
To evaluate if DCs treated with IL-17A proliferated, in paper IV, DCs were suspended 
at 10
7
 cells/mL in α Minimum Essential Medium (α-MEM) containing 2% FCS. After 
15 minutes of incubation in the presence of 10µM CFSE, the CFSE incorporation was 
blocked by the addition of a large excess of α-MEM, containing 2% FCS. DCs were 
then washed twice by centrifugation at 1500 rpm for 10 minutes at 4° C in α-MEM 
containing 2% FCS and seeded in α-MEM containing 10% FCS with indicated 
cytokines. Cells were then harvested on day 7 by trypsin treatment (Sigma-Aldrich) and 
scraping, and finally immunostained with a CD14-PE antibody. The expression of 
CD14-PE and CFSE was quantified on an LSRII (Becton Dickinson) and analyzed 
using FlowJo software. 
 
3.2.6.3 DiOC6 and PI labeling for cell survival quantification by flow cytometry 
3,3′-dihexyloxacarbocyanine iodide (DiOC6) is a fluorochrome that stains intact 
mitochondria and is thus specific for viable cells (Zamzami et al., 1995). Propidium 
iodide (PI) is incorporated in the DNA of dead cells whose cell membranes have been 
permeabilized. Living cells are thus DiOC6
+
, PI
-
. 
 
Between day 0 and 7, > 95% of the IL-17A-treated DC were mononucleated and 
generally not adherent, available for flow cytometry analysis. In paper IV and V, 
DiOC 6 and PI double staining followed by flow cytometry analysis was used to 
evaluate the effects of IL-17A, with or without IFN-γ, on the survival of DCs from 
healthy donors and the survival of DCs from LCH patients compared to DCs from 
healthy controls. DiOC 6 and PI double staining was also used to evaluate the effect of 
17 different chemotherapeutic compounds on IL-17A and IFN-γ-treated healthy DCs.  
 
Cells were incubated 15 min at 37° C with 40 nM DiOC 6 (Molecular Probes) in 
culture medium. The total number of viable cells per well was quantified by a time-
monitored flow cytometry analysis. As the cells were found not to proliferate, the 
number of viable cells at day 7 were compared to the initial number of cells introduced 
at day 0, and the percentage of remaining viable cells calculated. Likewise, the 
percentage of cell death was compared for IL-17A and IFN-γ treated DCs exposed to 
different chemotherapeutic compounds compared to DCs treated with cytokines only at 
different time points (0, 4, 24, 48, 72 h). 
 
3.2.6.4 Functional analysis of mannose receptor (MR)-mediated endocytosis 
To evaluate functional properties of IL-17A-treated monocyte-derived DCs (mo-DCs), 
in paper V, the endocytotic capacity of DCs was analyzed with dextran FITC, a probe 
for MR-mediated endocytosis. As, in addition to receptor-mediated endocytosis, there 
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is some uptake of dextran FITC by pinocytosis, preincubation with mannan was 
performed to block the MR-mediated endocytosis and separate MR-mediated 
endocytosis from the background fluorescence of dextran FITC uptake by pinocytosis.  
Cells were cooled down in an ice water bath. Studies were performed at 0, 10 and 30 
min by re-warming the cells in a water bath to 37° C in the presence of dextran FITC (1 
mg/ml), or a 10 min pre-incubation with mannan (1 mg/ml) followed by dextran FITC 
(1 mg/ml). For quantitative evaluation of the receptor density, two-dimensional dot plot 
analysis was performed for the respective monocytes, mo-DCs, and these DCs treated 
with IL-17A for 7 days. Populations were gated out manually. The mean fluorescence 
intensity (MFI) of the FITC signal was determined and fluorescent dye uptake was 
quantified by calculating the fluorescent index (FI) for the different time points: 
FI=[MFI (10,30 min) - MFI (0 min)]/MFI (0 min). This normalization procedure was 
used to compensate for donor variability. 
 
3.2.7 Methods to detect soluble molecules in serum and supernatants 
 
Enzyme-linked immunosorbent assays (ELISAs) are commonly used antibody based 
assays to detect molecules in liquid samples. ELISAs were used in papers I and III. In 
paper I, CSF from all LCH patients was analyzed with regard to GFAp, NF-L and total 
TAU (normal and phosphorylated) using sandwich ELISAs as described previously by 
Prof. Rosengren and his team (Blennow et al., 1995, Rosengren et al., 1992, Rosengren 
et al., 1996). The analyses were carried out at the Clinical Neurochemistry Laboratory 
in Mölndal, Sweden, as part of their routine clinical test panel. Controls samples were 
analyzed for NF-L (110) and GFAp (108). For all CSF analyses of all the LCH patients 
except two, an assay with an NF-L detection level of 125 ng/L was used. In the 
remaining two cases some of the samples were analyzed with a higher dilution of the 
secondary antibody leading to a higher detection level of NF-L (250 ng/L). 
 
3.2.7.1 Reference values for biomarkers in the CSF 
As lumbar puncture is rarely performed in healthy children there is a lack of reference 
values for CSF biomarkers in children. Thanks to collaboration with Prof. Lars 
Rosengren and his colleagues in Gothenburg we were able to use a large set of CSF 
samples taken from children with ALL, with no signs of neurological involvement and 
prior to therapy, as controls with regard to GFAp and NF-L (Osterlundh et al., 2008).  
 
The detection level of GFAp was 32 ng/L. The mean GFAp concentration in this group 
was 177 ng/L (SD 98 ng/L, median 159 ng/L, range 16–488 ng/L, n=108), 
corresponding to a mean value +1 SD of 275 ng/L and a mean value +2 SD of 373 
ng/L. Based on the mean value of our ALL controls and their +2 SD levels and the 
established laboratory reference level (175 ng/L), the GFAp reference level in the 
current study was set at 275 ng/L (precisely 274 ng/L). Importantly, the GFAp content 
was not correlated to age (r=0.04) in our controls.  
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For NF-L, the detection level of the assay used for the controls was 125 ng/L. The NF-
L content was below the detection limit of 125ng/L in all the 110 ALL control CSF 
samples and the laboratory deﬁned all values above this level as pathological. 
 
TAU was previously studied at our laboratory in 15 healthy young individuals aged 17–
37 years and the CSF levels were all ≤250 ng/L (mean 143 ng/L, SD 74 ng/L). 
Accordingly, TAU levels >250ng/L were considered abnormal in our pediatric patient 
cohort. This is in line with a Dutch study reporting an upper 95% conﬁdence interval 
for TAU in healthy children to 178 ng/L (Van Gool et al., 2000). Since TAU levels 
have been reported to be age dependent in adults there have been concerns regarding 
whether there are also differences within the pediatric population (Sjogren et al., 2001). 
However, it has been reported that TAU levels in the CSF are not age-dependent in 
children aged 0–18 years (Van Gool et al., 2004). TAU was not analyzed in the ALL 
controls. 
 
In paper III we measured the amounts of IL-17A, RANKL and IL-22 in serum and 
cell culture supernatants with commercial ELISA kits (PeproTech). The amounts of IL-
1β, TNF-α and MMP-9 and MMP-12 were measured with the multiplex assays (R&D 
Systems and Becton Dickinson). An advantage of multiplex analysis to ELISA is that, 
although still much more expensive, several molecules can be analyzed simultaneously 
from a sample of similar size. This also allows for multiple correlation studies to be 
done more easily. 
 
3.2.8 IL-17A/anti-IL-17A IgG autoimmune complex titration of serum 
 
In paper III, an experiment to capture potential antibodies against IL-17A in serum 
from LCH patients was set up. The anti-human-IL-17A of the commercial ELISA kit 
described earlier was used to coat ELISA Nunc Maxisorp microplates overnight. Serum 
samples from LCH patients were then added to the wells and incubated for 2 h before 
three washes, whereupon addition of a goat anti-human IgG-Fcγ-antibody coupled to 
peroxidase was added for 30 minutes. After three washes the ABTS Liquid substrate 
solution (Sigma) was introduced. Color development was then monitored by reading 
the plate every 5 minutes for 20 minutes. The experiment was repeated with the 
addition of recombinant human IL-17A in the saturating concentration of 5 ng/mL to 
specifically separate the immune complexes.   
  
3.2.9 Immunohistochemical techniques 
 
Compared to conventional microscopes, confocal microscopy allows for better optical 
resolution and reconstruction of three dimensional structures. It is often used in 
combination with immunofluorescence, where primary antibodies directed towards 
molecules in the sample are revealed by fluorochromes either directly coupled (primary 
immunofluorescence) or indirectly coupled to anti-isotype secondary antibodies 
(secondary, or indirect, immunofluorescence). These fluorochromes emit light of 
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specific wavelengths that can be read and quantified. An advantage of this technique 
compared to traditional histochemistry is that double or triple marking of cells is 
possible.  
  
In papers III and V immunofluorescence and confocal microscopy analyses were 
carried out on paraffin embedded biopsies to investigate whether IL-17A and BCL2A1 
could be detected in LCH lesions and linked to LCH DCs.  
 
Two different protocols were used. For the IL-17A detection, 4-μm biopsy sections 
were deparaffinized and exposed to heat-mediated antigen-retrieval in a microwave 
using citrate buffer (10 mM, pH 6.0) and then incubated with primary antibodies 
overnight at 37°C in PBS-1% BSA. For the BCL2A1 detection 4-μm paraffin-
embedded bone and skin biopsies were deparaffinized and rehydrated. Following 
epitope retrieval, tissue sections were incubated 30 minutes in PBS-1% BSA with 3% 
human serum to block Fc receptors. They were then incubated with primary antibodies, 
overnight at 37°C. Replacement of the primary antibodies by non-relevant antibodies of 
the same immunoglobulin isotype was used as a negative control. Slides were then 
washed three times in PBS-1% BSA. In the IL-17A protocol, slides were incubated for 
15 minutes in PBS-1% BSA with 10% normal goat serum to block unspecific binding. 
Detection of the primary antibodies was performed with suitable isotype-specific 
secondary Alexa Fluor 488, 546 and 647-conjugated antibodies (Invitrogen, 10μg/mL) 
for 30 min. Following three washes in PBS-1% BSA, sections were mounted using 
Mowiol and then analyzed by confocal microscopy using a Carl Zeiss MicroImaging 
Inc. LSM 510 confocal microscope. Image acquisition was performed using 
MetaMorph 7.0 Software (Molecular Devices). 
 
In paper IV immunofluorescence techniques were also used to study the modifications 
induced by IL-17A on the cytoskeleton of mo-DCs transforming into MGCs and the 
effect of vinblastine (VBL), known to affect the microtubule network, on these cells.  
 
3.2.9.1 Immunocytofluorescence labeling of p65/RelA 
In paper IV the intracellular signaling pathway for IL-17A-mediated induction of 
BCL2A1 was investigated through studying nuclear translocation of the nuclear factor 
p65/RelA, a member of the NF-κB transcription factor family expressed in immature 
DC and a known regulator of BCL2A1 expression (D'Souza et al., 2004). 
 
Mo-DCs were cultured in the 8-well Lab-Tek TM Chamber Slide TM System (Nunc, 
Thermo Scientific) and the cellular location of p65/RelA before and after stimulation 
with IL-17A was investigated. At the indicated times, the chamber slides were gently 
centrifuged and cells were fixed in PBS with 4% paraformaldehyde for 30 min at 4° C. 
Cells were permeabilized with PBS, 0.2% Triton X-100 for 20 minutes at room 
temperature. After saturation (30 minutes at room temperature in PBS-1% BSA, 3% 
human serum), cells were incubated 2 h with 4 µg/mL anti-p65/RelA in PBS-1% BSA 
(C20, Santa Cruz Biotechnology, CA). After three washes in PBS-1% BSA, cells were 
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incubated 30 minutes at room temperature in the dark with Alexa Fluor 647 Goat anti-
rabbit IgG (10mg/mL, Molecular Probes, Invitrogen, CA). Finally, after three washes, 
cells were mounted in Dako Fluorescent Mounting medium (Dako, Denmark), and 
immunostaining images were analyzed using a Leica TCS-SP5 laser scanning confocal 
microscope (Leica, Wetzlar, Germany). 
 
The effect on p65/RelA translocation by the NF-κB inhibitor Bay-11-7085 was also 
investigated. 
 
3.2.10 Affymetrix genechip study, microarray analysis 
 
Microarray analyses have become widely used in the last decade to characterize mRNA 
expression patterns in subsets of cells. We puriﬁed RNA from mo-DCs derived from 
LCH patients or healthy controls, either untreated (LCH patients and healthy donors) or 
cultured for 12 days with IL-17A alone, or in combination with IFN-γ (healthy donors), 
after cell lysis, extraction in Trizol (Invitrogen) and puriﬁcation on a MEGAclear 
column (Ambion) to reach an RNA integrity number > 9 with Agilent bioanalyser. 
ProﬁleXpert (http://www.proﬁlexpert.fr) carried out the chip study. 
 
3.2.11 Real-time quantitative PCR  
 
In paper IV, RT-PCR was used to verify IL-17A induction of BCL2A1 mRNA 
indicated in the transcriptome analysis. Total RNA from 2 million cells was extracted 
using Trizol
®
 (Invitrogen) and RNeasy Mini Kit
®
 (Qiagen, Düsseldorf, Germany) to 
reach an RNA integrity number > 9 with the Agilent bioanalyzer. RT-PCR reactions 
were performed with Super Script
®
 II Reverse Transcriptase (Invitrogen). One µg total 
RNA was reverse-transcribed using oligo(dT)12-18 Primers (Invitrogen). For 
expression studies, 25 ng of cDNA were amplified in Stratagene Mx3000P apparatus 
(Agilent Technologies), using the QuantiTect
®
 SYBR
®
Green PCR Kit (QIAGEN). 
Primer sequences were as follows: BCL2A1, ACA GGC TGG CTC AGG ACT ATCT 
(forward), CTC TGG ACG TTT TGC TTG GAC (reverse); GAPDH, CAC CCA CTC 
CTC CAC CTT TGAC (forward), GTC CAC CAC CCT GTT GCT GTAG (reverse); 
TBP, QuantiTect primers specific Hs_TBP_1_SG QuantiTect Primer Assay (Qiagen). 
All samples were normalized to expression of GAPDH or TBP. 
 
In paper III, RT-PCR experiments were run to examine paraffin embedded tissue 
samples from 10 LCH lesions, 2 peripheral blood lymphocyte samples and 11 serum 
samples from LCH patients for the eight known human herpesviruses (HSV-1, HSV-2, 
VZV, EBV, CMV, HHV-6, HHV-7 and HHV-8) (Lundberg et al., 2006). We also 
constructed a PCR to detect Herpesvirus Saimiri (HVS) polymerase DNA. The PCR 
was constructed as a nested PCR involving two steps. A first step was performed with 
an outer forward primer: ACA CTA GAG GGT GCG AGC G and outer reverse 
primer: TAT GTT GTA AGG TGG CCA TTC for 20 cycles. Then a second set was 
performed with an inner forward primer: AAA TTT AGC CCA TCT TGT GC and an 
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inner reverse primer: GAG GAC ATG CAG ACT TAC AT for 40 cycles. The PCR 
product responded to a 250 base pair long fragment. A positive control was kindly 
provided by Armin Essner (Institut für Klinische und Molekulare Virologie, Erlangen, 
Germany) in the form of a cosmid, Cosmid 261, containing the full sequence of HVS 
polymerase and HVS viral IL-17A. It was positive down to 21 viral copies for HVS 
polymerase detection. Since HVS encodes a viral homolog of human IL-17A, 1 lesion 
and 6 peripheral blood lymphocyte samples from LCH patients were also analyzed for 
the HVS IL-17A DNA. The Cosmid 261 was positive down to 10 viral copies for HVS 
IL-17A detection. 
 
3.2.12 Western blot analysis  
 
Western blot analysis was used in paper III to validate the mRNA findings of 
BCL2A1 and MCL1 on the protein level. Three million cells were harvested, sonicated 
and lysed for 1 h at 4° C with RIPA buffer containing a protease inhibitor cocktail 
(Roche, Indianapolis, USA). Cellular debris were pelleted by centrifugation (10,000 g 
15 min at 4° C) and protein extracts (100 µg per lane) were loaded on to a 12% SDS-
polyacrylamide gel and blotted onto PVDF sheet (Bio-Rad Laboratories, Hercules, 
CA). Filters were blocked with 5% BSA in PBS/0.1% Tween 20 (PBS-T) for 2 h and 
then incubated over-night at 4° C with anti-BCL2A1/BFL1, 0.9 µg/mL in PBS-T 
(rabbit polyclonal ab75887, Abcam, Cambridge, UK). After three washes with PBST, 
filters were incubated 1 h with Biotin-conjugated goat antirabbit IgG, 2 µg/mL in PBS-
T, 5% BSA (Molecular Probes/Invitrogen, Eugene, OR). After three washes with 
PBST, filters were incubated 1 h with HRP-conjugated Streptavidin (StrepTactin-HRP, 
Bio-Rad Laboratories, Hercules, CA,) dilution 1:50,000 in PBS-T, 5% BSA. Detection 
was performed using Immun-StarTM WesternCTM Kit chemiluminescence system 
(Bio-Rad Laboratories, Hercules, CA,). Actin staining was realized using a rabbit 
polyclonal anti-βActin from SantaCruz (sc-130656, Santa Cruz, CA,) to calibrate the 
samples. 
 
3.2.13 Statistical analyses 
 
Paper I: The CSF levels of biomarkers for the control group (GFAp and NF-L) were  
compared to those of the patients with neurodegenerative LCH. TAU was not analyzed 
in the controls. Comparison of GFAp was performed with the nonparametric Mann–
Whitney U test. With regard to NF-L, for which many values were below the minimal 
detection level, Fisher’s exact test was used to compare values that were above the 
detection levels in controls and patients, respectively. Fisher’s exact test was also used 
to analyze if there was any association between neuromarker concentrations and 
disease activity outside the CNS (‘‘No active disease’’ and ‘‘Active disease,’’ including 
chronic disease and progressive disease). For this test the neuromarker concentrations 
in the CSF were categorized as below or above the reference values presented above.  
Further, the course of radiological ND over time was categorized into two categories 
(‘‘status quo or regression’’ and ‘‘progression’’), and the differences in neuromarker 
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levels between the two categories were analyzed by Mann–Whitney U tests. The 
association between neuromarker levels and extension of radiological ND (mild, 
moderate, severe) was studied by Spearman’s rho. Correlations between the 
neuromarkers were analyzed by Pearson’s correlation test. 
 
Paper II:  The odds ratio (OR) for the children born following IVF to develop LCH 
were calculated by comparing the risk of LCH in the group of children born following 
IVF to the risk of LCH in the general population as found in the Stockholm County 
study. Differences in disease characteristics between children with LCH born after IVF 
and children with LCH in the general population were calculated by Fisher’s exact test 
except for age at diagnosis, which was calculated by the Mann–Whitney U test. 
 
Paper III-V: Linear or polynomial statistical analyses and Mann-Whitney U test from 
GraphPad Prism 5 software were applied to detect correlations and differences between 
subgroups; p < 0.05 was regarded significant. 
 
3.2.14  Chemotherapeutic compounds  
 
Drugs used in paper IV and V were kindly provided by the Karolinska University 
Hospital pharmacy except for dexamethasone, 6-mercaptopurine and fludarabine, 
which were purchased from Sigma Aldrich (St Louis, MO, USA). The drugs used in 
the study are presented in Table IV. A ruff estimate of the magnitude of the 
microenvironment concentration around cells, in vivo, following administration of 
clinical doses, was calculated by approximating that the drug could be distributed in 
half of the body aqueous volume (30L) with the formula: [(injected concentration) x 
injected volume] / 30. The results were also compared to those indicated by 
pharmacokinetic studies. 
 
Table IV. Cytotoxic drugs tested on IL-17A and IFN-γ treated mo-DCs  
                 (papers IV and V)  
 
Glucocorticoids  
 
hydrocortisone methylprednisolone 
prednisolone 
betamethasone  
dexamethasone 
Calcineurin inhibitors 
 
cyclosporine A 
tacrolimus 
Purine analogues 
 
cladribine 
6-mercaptopurine  
fludarabine 
Pyrimidine analogue cytarabine 
Folate acid antagonist methotrexate 
Organometallic complex, purine linker cisplatin 
Vinca alkaloids vinblastine, vincristine 
Anthracycline antibiotic doxorubicine  
Topoisomerase II inhibitor etoposide 
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4 RESULTS AND DISCUSSION 
 
Studying rare diseases has its limitations in terms of available patient material and the 
possibility to strictly follow optimal study designs. The Histiocyte Society is crucial to 
the coordination of international collaboration efforts and to drive LCH research 
forward. Nevertheless, small studies from individual centers, in spite of their 
shortcomings, are also important to improve knowledge of LCH and generate ideas for 
further studies. 
 
 
4.1 BIOMARKERS TO DETECT ONGOING NEURODEGENERATION IN 
LCH 
 
As outlined in the introduction the exact incidence of neurodegenerative disease in 
patients with LCH is unknown. However, many studies have indicated that the 
incidence is higher than previously expected (Grois et al., 2010, Haupt et al., 2004, 
Laurencikas et al., 2011, Willis et al., 1996, Bernstrand et al., 2005, Mittheisz et al., 
2007). 
 
MRI is currently the standard diagnostic tool used to detect or confirm 
neurodegeneration in LCH. The relationship between radiological neurodegeneration 
and overt clinical symptoms is still not fully clarified. Neurodegenerative MRI findings 
may sometimes precede clinical symptoms, probably reflecting the reserve capacity of 
the human brain. Still, neurodegeneration in LCH seems to be a slowly progressive 
process and when MRI findings are present substantial neuronal loss is likely to already 
have occurred. It is unknown what initiates the neurodegenerative process in LCH or 
what drives it to progress to fatal disease in some cases while it seemingly halters in 
others. Nor do we know how this process can be efficiently stopped. The 
histopathological pattern, however, suggests that chronic inflammation contributes to 
the neuronal injury (Grois et al., 2010, Grois et al., 2005). Risk factors to develop 
neurodegeneration include lesions in the craniofacial bones, intracranial lesions, DI, 
multisystem LCH and long standing disease activity (outside the CNS) (Donadieu et 
al., 2004b, Grois et al., 2010, Grois et al., 2006, Haupt et al., 2004). 
 
In line with the evidence from multiple sclerosis that early treatment is important to 
minimize the consequences of the disease (Khademi et al., 2013), methods to detect 
signs of ongoing neurodegenerative disease early on could also be of high value in 
LCH. Even if there is currently no specific treatment for neurodegenerative LCH, this 
could help to evaluate effects of systemic or experimental therapy more rapidly than is 
possible with MRI. Investigating biomarkers in the CSF of patients with 
neurodegenerative LCH might also help us to better understand the underlying process.  
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In paper I we evaluated the findings of three biomarkers (TAU, GFAp and NF-L) in 
the CSF from nine LCH patients with radiological signs of neurodegeneration in 
addition to endocrine, neuromotor, cognitive and/or behavioral abnormalities. The 
patients were investigated by MRI prior to and following CSF sampling. One of these 
patients had not received any systemic treatment in line with previous reports, 
indicating that neurodegeneration in LCH is not induced by therapy. 
 
Table V. Neuromarkers in children with LCH and radiological signs of  
                 neurodegeneration 
 
Patient GFAp
*
 NF-L
*
 TAU
*
 
 
Extension of 
radiological 
neurodegeneration 
at LP
#
 
Course of 
radiological 
neurodegeneration
**
 
Clinical CNS 
symptoms/ 
endocrine 
dysfunction 
1 400 <125 340 ++ 0  Hypothalamic 
symptoms, 
cognitive 
impairment/PH 
2 500 310 430 +++ + Neurological 
symptoms (ataxia, 
tremor)/DI, GHD 
3 310 <125 310 + 0  Neuropsychological 
abnormalities 
4 480 <125 130 ++ + DI 
5 280 270 570 ++ + Neuropsychological 
abnormalities 
6 420 <125 320 ++ 0  Neuropsychological 
abnormalities/PH  
7 510 <125 830 ++ + DI 
8 170 150 260 + + Neuropsychological 
abnormalities, DI, 
GHD 
9 420 150 180 + 0  DI, GHD 
 
 
*
Pathological values in bold text. Reference values: GFAp > 275 ng/L, NF-L > 125 ng/L, TAU 
> 250 ng/L; 
**
Course of radiological neurodegeneration from previous MRI: “0”: status quo, 
“+”: progression # Extension of radiological neurodegeneration at lumbar puncture: ‘‘+’’: 
Increased signal in basal ganglia and nucleus dentatus (T1-weighted) and locally increased 
signal (T2-weighted) in the cerebellar white matter, predominantly in connection with nucleus 
dentatus,  ‘‘++’’: As ‘‘+’’ and in addition abnormally increased signal in brainstem, thalami and 
corpus callosum, ‘‘+++’’: As ‘‘++” and in addition subcortical and periventricular white matter 
and gray matter changes; DI: Diabetes insipidus, GHD: Growth hormone deficiency: PH: 
Panhypopituitarism. 
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As described in the background we chose the three neuromarkers mentioned above 
because they are well established markers proven to be helpful in the diagnosis and 
monitoring of other neurodegenerative and neuroinflammatory diseases, including 
multiple sclerosis, ALS, Alzheimer disease, Parkinson disease and vascular dementia 
and to evaluate acute brain damage such as stroke (Blennow et al., 1995, Blennow et 
al., 2001, Rosengren et al., 1996, Wallin et al., 1996, Teunissen et al., 2005, Aurell et 
al., 1991). They also reflect damage to different components of the CNS; while GFAp 
is a marker of astroglial cell damage, NF-L and TAU reflect neuronal damage. 
 
All patients in our study had increased levels of at least one biomarker compared to the 
reference values presented in section 3.2.7.1. Biomarkers were elevated in eight 
(GFAp), seven (TAU) and four (NF-L) out of nine patients, respectively. Since our 
patient group was small it was not possible to carry out extensive statistical analyses 
with reliable results. However, when comparing mean values between patients and 
controls, the LCH patients had significantly higher values of GFAp and NF-L than the 
controls. TAU was not analyzed in the control group. GFAp levels correlated with the 
extension of MRI changes in our patient group, which may reflect the active role of 
astrocytes in inflammation and repair of brain tissue (Osterlundh et al., 2008). No such 
correlation could be seen with NF-L or TAU. NF-L on the other hand tended to 
correlate to progression of MRI changes, although this could not be proven to be 
statistically significant.  
 
The most severely ill patient, who deteriorated during the study period both clinically 
and radiologically, had the highest values of NF-L and GFAp. She underwent repeated 
CSF sampling and MRI investigations during the study period. All her CSF markers 
were elevated compared to reference values and controls throughout the whole study 
period, suggesting that elevation of these markers is a reproducible finding. However, 
repeated, markedly high NF-L levels, was the most explicit finding and, preliminarily, 
it appears to us as if elevated NF-L levels in patients with ongoing  neurodegeneration 
is the most alarming sign. 
 
As pointed out in the material and method section, reference values regarding 
neuromarkers in CSF are scarce. One may argue that the patients in the control group 
were not completely healthy (newly diagnosed ALL patients without signs of CNS 
disease), but NF-L values were below detection level for all patients in the control 
group. The results for GFAp were somewhat higher than previously reported in a small 
cohort of 10 healthy children (Rosengren et al., 1992). At the time of our study no other 
references regarding healthy children were available for comparison and the children 
with LCH as a group had higher values than the control group. Importantly, the GFAp 
or NF-L content in our controls was not correlated to age. Neither TAU has been 
previously reported to be age dependent in the pediatric population (Van Gool et al., 
2000). 
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A recently published multi-center, retrospective study compared CSF biomarkers in 
patients with different neurological disorders to patients investigated for various 
symptoms that concluded in diagnoses seemingly not involving the CNS (transient 
headache, diffuse pain, suspected infections or habitual walking changes) (Shahim et 
al., 2013). In that study a weak correlation to age was seen for all the neuromarkers 
used by us (NF-L, TAU, and GFAp). If this finding is confirmed it will be important to 
take into consideration in future studies. However, to us, the most important finding of 
the study was that a clear difference in neuromarker levels, especially for NF-L, was 
observed between progressive and stable encephalopathy. This strengthens the potential 
of these neuromarkers to be used as indicators of ongoing neurodegeneration in LCH.  
  
Notably, in spite of lumbar puncture being carried out according to routine procedures 
by experienced physicians using fine needles, in our study, more patients than expected 
suffered complications after CSF sampling. These included severe headache and in one 
case a prominent spinal fluid leakage. The reasons for the increased risk of 
complications are unclear. The intracranial pressure (ICP) was not measured in the 
study and thus we do not know whether this might have contributed to spinal fluid 
leakage. However, one can also speculate as to whether inflammation-induced changes 
in the dura might predispose for complications.  
 
Our study included a very small number of patients and should be regarded as a pilot 
study. The results indicate that patients with neurodegenerative LCH have elevated 
levels of at least one CSF biomarker and that NF-L, TAU and GFAp analyzed together 
may be useful to detect ongoing neurodegeneration in LCH. However, further studies 
are needed to evaluate the relationship between these biomarkers and the progression of 
neurodegeneration versus the accumulated CNS damage, as well as their relationship to 
clinical symptoms. Consistent with previous reports, we did not see any case of 
regression of the neurodegenerative MRI findings although the progression seemed to 
halter in some patients. (Prosch et al., 2007, Wnorowski et al., 2008). It would, 
however, be interesting to do a long-term clinical and radiological follow-up study of 
the children in our study group to further evaluate the natural course of 
neurodegeneration. 
 
Within the LCH-IV study protocol, we and McClain’s group, plan to carry out studies 
on CSF as optional studies. Considering the inflammatory nature of neurodegenerative 
lesions in LCH it would be interesting to study not only neurodegenerative markers in 
CNS but perhaps also inflammatory markers as indicators of ongoing inflammation. 
Although pathological in sporadic cases, the CSF of the children in our study did not 
typically show pathological values of markers often used clinically to diagnose CNS 
inflammation, such as albumin, leukocytes or oligoclonal bands. This might reflect that 
the process is usually a rather low grade, but constant, inflammatory process. Dramatic 
flares are uncommon. It also underlines the need for other CSF markers. CSF markers 
that have been used in some neuroinflammatory diseases and that could be of interest to 
investigate in LCH are for example CCL2 (MCP-1), CXCL13, MMP-9, Osteopontin, 
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and IL-17A, of which the three last molecules have also been described in LCH lesions. 
To evaluate a broad panel of markers that could be of interest, multiplex studies, or 
even proteomics, on CSF might be considered. 
 
As neurodegeneration in LCH has been suggested to be a paraneoplastic phenomenon it 
might also be interesting to study anti-neuronal antibodies in the CSF of a larger set of 
patients with neurodegeneration. Such antibodies could include the anti-glutamate 
receptor antibody, GluRe2, or perhaps anti-purkinje cell antibodies (anti-Yo) as seen in 
cerebellar degeneration in for example breast cancer or other gynecological 
malignancies. The presence of specific auto-antibodies could provide an explanation as 
to why the neurodegeneration in LCH follows specific radiological patterns. However, 
this could perhaps also partly be explained by the vulnerability of these areas in terms 
of collateral blood supply. Speculatively, the unspecific symptoms experienced by 
some patients with neurodegenerative LCH, like headache, tiredness and dizziness 
might be attributed to cytokine production. 
  
IL-17A is thought to be of importance in the pathogenesis of multiple sclerosis (Lock et 
al., 2002, Matusevicius et al., 1999, Zhang et al., 2003). In papers III-V we 
investigated different aspects of IL-17A that might be of relevance in the pathogenesis 
of LCH. Possibly, in LCH, IL-17A and other cytokines in the circulation contribute to 
inflammation of the meninges and disruption of the blood brain barrier, allowing the 
influx of inflammatory substances and inflammatory cells into the CNS, as has been 
shown in multiple sclerosis (Kebir et al., 2007). This could trigger and sustain an 
inflammatory process leading to neuronal damage and eventually neurodegeneration. 
Our findings support a survival-promoting effect of IL-17A on DCs as will be 
explained further on. However, IL-17A in synergy with TNF-α has been shown to 
induce apoptosis in oligodendrocytes (Paintlia et al., 2011). The discrepancy could 
perhaps be explained by the well-known fact that IL-17A has different roles in different 
cell types, and might be of relevance to the neurodegeneration seen in LCH. One may 
also speculate that antibodies directed against IL-17A, or against an IL-17A-like 
substance, might cross-react with neuronal factors, mimicking a paraneoplastic process.  
 
 
4.2 LCH IN CHILDREN CONCEIVED BY IVF 
 
To understand the etiology of LCH, epidemiological studies may be of value. The aim 
of paper II was to confirm the findings of Källén et al. indicating that LCH was 
overrepresented in Swedish children born following IVF 1982-2005 (Källén et al., 
2010, Källén et al., 2005). We wanted to verify the diagnoses, and examine whether 
any specific form of LCH was more common in the children conceived by IVF than in 
the general population.  
 
Upon reviewing the medical records for the eight children identified in the registers 
(until 2008 in our case) seven cases were confirmed to have LCH. One patient turned 
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out to have been wrongly registered in the Patient Register⁄Hospital Discharge Register 
as LCH while the actual diagnosis was retinoblastoma (C69.2). Of the seven remaining 
cases, six had a definite diagnosis of LCH and were included in the National Cancer 
Register. One child had a presumptive diagnosis of LCH with a clinical picture fitting 
well into LCH but with repeated biopsies that were not fully conclusive, possibly 
because they were taken late in the course of LCH.  
 
Compared to children in the Stockholm County study the OR to develop LCH for all 
the 26 692 children conceived by IVF was 3.2 95% confidence interval (CI) 1.4-7.3. 
Interestingly, all children were born prior to 2002. For the first cohort of 16 280 
children studied by Källén et al., born 1982-2001, the OR was 5.2 95% CI 2.3-11.9. 
There was obviously no increased risk to develop LCH in the subsequent cohort of 
children born 2002-2005. Intracytoplasmic sperm injection (ICSI), used mainly in male 
infertility and much more common in the second cohort, does thus not appear to have 
affected the rate of LCH in the offspring.  
 
Table VI compares children affected by LCH, conceived respectively not conceived by 
IVF. Due to the risk of personal identification the data of this group of children cannot 
be presented individually. 
 
The reference group was chosen since it included children of similar ethnic and 
environmental background, and it was carried out on children born during 
approximately the same period of time. Compared to other studies, a higher incidence 
of LCH among the children (0-15 years of age) in our reference group was previously 
reported (Stalemark et al., 2008). Apart from this, characteristics were in line with other 
studies (Carstensen and Ornvold, 1993, Salotti et al., 2009). The information on 
neurodegenerative ﬁndings in this population stems from a separate study by our group 
on CNS involvement in LCH (Laurencikas et al., 2011). Since the groups are not 
matched and one (children born following IVF) is based on year of birth and the other 
(controls) on year of diagnosis (1992-2001) one should be cautious in interpreting the 
results. However, our study shows that the overrepresentation of LCH in children 
conceived by IVF was not due to misdiagnosis or overrepresentation of mild forms of 
the disease. Perhaps of relevance, the children with LCH conceived by IVF were 
younger at diagnosis than the children in the Stockholm County study, early onset 
being a known risk factor for severe forms of LCH (Gadner et al., 2008).   
 
Bearing in mind that an abundance of variables was studied in the original publication 
by Källén et al., it could be argued that the correlation between IVF and LCH for 
children born 1982-2001 is only a random finding related to statistical mass 
significance. One could also argue that since IVF has gradually become more common, 
the rate of LCH should increase in the follow-up cohort of children born 2002-2005 if 
there was a true connection between LCH and IVF, which was not the case. In this 
context, one could also consider the lack of difference in fertility between mothers of 
children with LCH and controls reported by Hamre et al. (Hamre et al., 1997). Neither 
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has it been reported in previous studies focusing on cancer risk in children conceived 
by IVF that LCH occurs more frequently in children born following IVF. However, it is 
not clear whether LCH has been included in these studies (Bruinsma et al., 2000, Klip 
et al., 2001). Yet, there might also be important information underlying the discrepancy 
observed between the cohorts in our study.  
 
It is difficult to separate potential effects of the IVF procedure from effects imposed by 
drugs used in the IVF treatment and from underlying maternal (or paternal) 
characteristics. Due to ethical considerations we were not able to gather information on 
the reasons for IVF in each specific case or information on which therapies that had 
been used, nor did we have any information on underlying diseases in the mothers or 
on inherited conditions. In the children’s medical records one mother was reported to 
have hypothyroidism, which may be of interest considering the previously reported 
connection between LCH and thyroid disease. With regard to infections, it is interesting 
to note that around the year 2000 synthetic gonadotropins began to substitute the use of 
gonadotropins extracted from the urine of pregnant women on a large scale (Huirne et 
al., 2004). One may speculate that an unknown substance might have been enriched in 
this extraction process, transmitted to the women and passed on to the fetus. 
 
There is also the possibility that the IVF procedure or IVF treatment might impose 
genetic or epigenetic changes in the embryo. IVF treatment and assisted reproductive 
technologies (ART) in general have indeed been associated with epigenetic 
modifications that may affect fetal growth or development (Khosla et al., 2001). 
Genomic imprinting is an epigenetic mechanism causing only one allele of a gene to be 
silenced by DNA methylation or other epigenetic modifications. This is a prerequisite 
for many genes to function physiologically but it sometimes also results in pathological 
processes, i.e. imprinting disorders. For many years there has been a concern that IVF 
and ICSI might lead to an increase in imprinting disorders. Some imprinting disorders, 
including Beckwith-Wiedemann syndrome, have been reported to occur more 
frequently in children following IVF (Cox et al., 2002, DeBaun et al., 2003, Odom and 
Segars, 2010, Sutcliffe et al., 2006). Retinoblastoma is a neoplastic disease that, in 
several case reports and small studies, has been reported to be overrepresented in 
children conceived by IVF (Anteby et al., 2001, Lee et al., 2004, Marees et al., 2009). 
As hypermethylation, leading to inactivation, of the tumor suppressor gene RB1 has 
been shown to play a role in retinoblastoma development, aberrant imprinting could 
also be a possible mechanism of IVF-associated retinoblastoma (Manipalviratn et al., 
2009). However, several population-based studies have not been able to demonstrate a 
correlation between IVF and retinoblastoma (Bradbury and Jick, 2004, Foix-L'Helias et 
al., 2012, Lidegaard et al., 2005) and it was recently shown that hypermethylation of 
the RB1 promoter is not responsible for tumor development in children with 
retinoblastoma and conceived by IVF (Dommering et al., 2012). In the Swedish 
material there were two cases of malignant eye neoplasms reported against one 
expected (Källén et al., 2010). 
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Epigenetic changes inherited, or occurring in the embryo, may be relevant in the 
pathogenesis of LCH, considering the reported cases of familial disease and the known 
association between malignancies on the one hand and the absence of mutations (apart 
from BRAF V600E) on the other (Arico and Danesino, 2001, Arico et al., 1999, Egeler 
et al., 1998, Egeler et al., 1993b). Relating to the findings of IL-17A in LCH presented 
later in this discussion, it may be interesting to note that increased endometrial 
secretion of several cytokines, including IL-17A, has been documented after the use of 
ART when comparing stimulated to normal ovulatory cycles, which might affect the 
embryo (Boomsma et al., 2010). 
 
As described in the introduction no association with LCH and birth complications or 
low birth weight has been seen (Carstensen and Ornvold, 1993). Consistent with this, in 
spite of the well-known association between IVF and preterm delivery and children 
being small for gestational age (SGA) (Jackson et al., 2004), there were no reports in 
our material of neonatal complications, or low birth weight, with the exception of one 
child being born preterm.  
 
The findings of paper II support a, possibly temporary, overrepresentation of LCH in 
children born following IVF which was not due to over-diagnosis of mild forms of the 
disease. However, we suggest that the possible association between LCH and IVF 
should be investigated in independent studies in other countries. Should the correlation 
between IVF and LCH be confirmed, further studies should be undertaken to 
investigate whether the cause is related to the IVF procedure, ART drugs used in the 
IVF treatment, or underlying characteristics of the mothers explaining the subfertility.  
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Table VI. Comparison between children affected by LCH, conceived respectively  
                not conceived by IVF 
 
 Children with  
LCH  
conceived by IVF  
(n=7) 
Children with 
LCH not 
conceived by IVF* 
(n=27) 
P value
#
 
Median age at diagnosis  2.0 years  4.3 years  0.15 
Sex: 
   Male  
   Female 
 
3 (43%)  
4 (57%)  
 
15 (56%)  
12 (44%)  
 
0.68 
Extension at diagnosis: 
   Single system 
   Multisystem 
 
4 (57%)   
3 (43%)  
 
19 (70%)  
  8 (30%)  
 
0.66 
Maximal extent of disease
§
: 
   Single system 
   Multisystem 
 
1 (14%)  
6 (86%)  
 
14 (52%)  
13 (48%)  
 
0.10 
 
Risk organ involvement at 
maximal extent of disease
§
: 
   Yes 
   No 
 
 
1 (14%)  
6 (86%)  
 
 
  5 (19%) 
22 (81%) 
 
 
1.00 
 
Endocrine sequelae**: 
   Yes 
   No 
 
2 (33%)  
4 (67%) 
   
  5 (19%) 
22 (81%) 
 
0.58 
Neurodegenerative MRI 
findings**
¤
 
   Yes 
   No    
 
2 (33%) 
4 (67%) 
   
  6 (22%)
 
21 (78%) 
 
0.62 
Treatment: 
   Systemic 
   Local or wait-and-see 
 
5 (71%) 
2 (29%) 
 
12 (44%) 
15 (56%) 
 
0.40 
 
*Children <15 years in Stockholm County treated for LCH 1992-2001 with children born after 
IVF (two) excluded (Stalemark et al., 2008);
 #
P values calculated by Fisher’s exact test, except 
for age at diagnosis which was calculated by Mann–Whitney test; §Maximal extent of disease 
includes all organs that have been involved during the disease course (Bernstrand et al., 2005); 
**Missing long-term data in one patient; 
¤
For neurodegenerative MRI findings in children with 
LCH, see (Laurencikas et al., 2011). 
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4.3 A POSSIBLE ROLE FOR IL-17A IN LCH 
 
4.3.1  Initial findings of IL-17A in LCH (paper III) 
 
As stated by Peters et al., LCH is in many ways a disease that is difficult to study 
(Peters et al., 2011). Apart from being a rare condition there are no validated in vitro or 
animal models. Research has to rely to a high extent on analyses of frozen or paraffin 
embedded tissue samples. Interpretation of data is also difficult since there is a lack of 
standardized control tissues (tissue samples or LCs from normal skin or dermatopathic 
lymphadenopathy containing “normal” LCs have been used in many studies, more 
seldom normal bone tissue has been used as controls). Working on Langerin/CD207 or 
CD1a sorted cells from fresh LCH lesions has its limitations because this process takes 
several hours which may affect the function of the cells. By sorting the cells by either 
Langerin/CD207 or CD1a it is also possible that all LCH DCs are not captured. As an 
alternative approach, we set out to study mo-DCs from LCH patients. This could allow 
experiments to be carried out on a larger scale. Support for this approach can be found 
in the growing body of evidence of a myeloid origin of the LCH DCs (DC progenitors 
or even monocytes), as described in the background (Allen et al., 2010b, Hutter et al., 
2012, Merad et al., 2008). At the time this was however an original approach. 
 
RANKL is important for osteoclast formation and stimulation of osteolysis and the 
RANK-RANKL axis has been shown to be active in LCH (da Costa et al., 2005, Ishii 
et al., 2006). It is known that IL-17A up-regulates RANKL in osteoblasts (Kotake et 
al., 1999) and the similarities between LCH and many other chronic inflammatory 
disorders where IL-17A is known to be involved in the pathogenesis, including bone 
destruction and granuloma formation, provided the rationale to study the role of IL-17A 
in LCH more closely.  
 
In paper III, IL-17A was measured in serum from LCH patients. We found that IL-
17A levels were increased in serum from patients with active LCH compared to 
controls, although, importantly, no correlation to disease activity or disease extension 
(MS LCH or SS LCH) could be made to IL-17A levels in serum. By 
immunofluorescence and confocal microscopy we then also demonstrated IL-17A in 
bone and skin lesions from LCH patients. Triple staining showed that IL-17A was 
associated with only a few T cells but instead overwhelmingly with CD1a
+
, and 
Langerin/CD207
+ 
cells, as well as MGCs, indicating that IL-17A in LCH serum and 
lesions might originate from DCs rather than T cells.  
 
This was further supported by analysis of cell populations from peripheral blood. In 
contrast to T cells that expressed and secreted IL-17A at levels similar to controls 
following proper stimulation, a proportion of mo-DCs from LCH patients 
spontaneously stained positive for intracellular IL-17A by flow cytometry, and secreted 
IL-17A into the supernatant as measured by ELISA. Indications that cells other than T 
cells are the major source of IL-17A in LCH were also obtained by the lack of IL-22 in 
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serum from these patients. IL-22 is normally secreted in parallel to IL-17A from Th17 
cells (Harrington et al., 2005, Park et al., 2005). We did not see any IL-17A production 
in monocytes from the six patients whose monocytes were analyzed in this study. To 
our knowledge this is the only disorder where IL-17A production has been described in 
DCs. However, in recent years, IL-17A production has been described in a number of 
cells belonging to the innate immune system (Cua and Tato, 2010, Sutton et al., 2012). 
Moreover, in two other granulomatous diseases of unknown origin, Crohn’s disease 
and sarcoidosis, IL-17A production has been described in myeloid cells defined as 
macrophages, in addition to T cells (Facco et al., 2011, Fujino et al., 2003). Whether 
IL-17A production from DCs in LCH (or perhaps myeloid cells in related 
granulomatous diseases in general) reflects a physiological process, or is pathogenic, 
has still not been answered, as will be elaborated upon below. 
 
Interestingly, we also found that mo-DCs from LCH patients responded to autocrine or 
paracrine IL-17A production. They spontaneously started to undergo cell fusion after 6-
8 days in culture (reaching a plateau phase after 10-12 days) to form long-lived MGCs 
and this process was dependent on IL-17A since antibodies against IL-17A turned out 
to block it in contrast to antibodies against IFN-γ. However, IFN-γ potentiated cell 
fusion.  
 
The MGCs in LCH lesions are still of unknown origin. These MGCs express CD68 and 
sometimes also CD1a (da Costa et al., 2005). To a varying degree, depending on the 
site of the lesion, they also express osteoclast markers, e.g. vitronectin receptor (VPN), 
cathepsin K, TRAP and MMP-9, and have been suggested by da Costa et al. to be 
derived from the fusion of immature DCs upon RANKL and M-CSF stimulation (da 
Costa et al., 2005). Fusion upon stimulation by IL-17A might be an alternative or 
additional origin of MGCs in LCH lesions. This is supported by our findings that IFN-
γ, which is present in LCH lesions, stimulated cell fusion along this pathway in contrast 
to in the M-CSF and RANKL pathway where cell fusion was inhibited by IFN-γ 
(Takayanagi et al., 2000). As it was shown that IFN-γ inhibited M-CSF and RANKL 
cell fusion by inhibiting TRAF6, important also in the classically described IL-17A 
signaling pathway, IL-17A signaling inducing cell fusion and cell survival of DCs may 
be mediated through the alternative, TRAF6 independent, pathway.    
 
Although serum levels of IL-17A did not correlate with disease activity, the grade of 
IL-17A-dependent fusion did. Using a biological assay measuring the fusion activity of 
healthy mo-DCs exposed to LCH serum and specific for IL-17A, we found a 
correlation between disease severity and fusion activity. The biological assay is 
important because with ELISA we may capture, perhaps not only free IL-17A, but also 
IL-17A bound to other molecules, or post-translationally modified IL-17A, not 
knowing whether it is active or not. To our knowledge no soluble receptor, 
antagonizing IL-17A signaling, has been described in vivo, although soluble forms of 
the IL-17RC have been identified in protein studies (Haudenschild et al., 2002). 
Alternatively, the degree of IL-17A receptor expression, and thus the sensitivity 
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towards IL-17A, may vary between patients, as has later been demonstrated by 
Murakami et al. (Murakami et al., 2012).  
 
Notably, we detected the presence of immune complexes directed against IL-17A in the 
serum of LCH patients, indicating either excessive production of the molecule or an 
immunogenic variant of canonical IL-17A. Since there is a viral homologue to IL-17A, 
expressed by the Herpesvirus Saimiri, known to infect some primate species (Callithrix 
jacchus and Saguinus oedipus) where it might induce T cell lymphoma, we also 
analyzed tissue and serum samples for the presence of Herpesvirus Saimiri and other 
viruses of the herpes group. However, in line with results from previous studies, these 
analyses did not imply any virus of the herpes group in the pathogenesis of LCH. The 
role of a possible, yet unidentified virus in the pathogenesis of LCH can of course still 
not be excluded. 
 
4.3.2 Effects of IL-17A on immature monocyte-derived DCs from 
healthy donors 
 
Spurred by the findings in LCH we continued to study how IL-17A modified immature 
mo-DCs from healthy donors. Independently of the LCH context this might also be 
relevant to other diseases where IL-17A may have a central role. We confirmed that IL-
17A induces fusion of immature mo-DCs from healthy donors into MGCs, a process 
augmented by, but not dependent on IFN-γ (or TNF-α). This finding has since then 
been confirmed by others and is thought to contribute to aberrant osteoclast formation 
in multiple myeloma (Tucci et al., 2013). It is well known that IL-17A works in 
synergy with other inflammatory cytokines and the functions of IL-17A are often 
studied in combination with other cytokines such as TNF-α (Onishi and Gaffen, 2010). 
In contrast to the combination of M-CSF and RANKL, IL-17A did not induce fusion in 
monocytes. This could, however, be achieved by the addition of GM-CSF which is 
present in LCH lesions (Egeler et al., 1999). Similarly to in the M-CSF and RANKL 
pathway of cell fusion, LPS-matured DCs did not fuse in the presence of IL-17A.   
 
In papers III and IV, we further elaborated on how IL-17A affected mo-DCs in 
various ways. Paper III focuses on the pro-inflammatory characteristics of these cells 
while paper IV, focuses on how IL-17A affects the viability of mo-DCs and 
potentially sustains DC function in a tumoral microenvironment. At the base of our 
observations was a transcriptomic analysis comparing IL-17A-treated mo-DCs to 
unstimulated mo-DCs. We then tried to confirm these initial observations by additional 
methods for key events.   
 
Interestingly, phenotype analysis of IL-17A-treated DCs showed that they shared many 
characteristics with LCH DCs. They acquired a semi-mature, mixed macrophage-DC 
phenotype expressing CD14, CD68, CD1a, MHC-II and CCR6 and they were 
CD40
high
. Like the MGCs in LCH lesions, MGCs induced by IL-17A expressed high 
levels of tissue destructive enzymes such as TRAP, MMP-9 and MMP-12.  
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IL-17A-treated mo-DCs also showed some similarities with M2 macrophages known to 
promote tumor growth in several ways as outlined in the background (e.g. by secretion 
of tissue degrading enzymes, promotion of angiogenesis and inhibition of adaptive anti-
tumor responses through induction and recruitment of Tregs and by keeping DCs in an 
immature state) (Mantovani et al., 2013, Sica et al., 2008). IL-17A-treated mo-DCs 
expressed high levels of mRNA for M2-related molecules such as CCL22, CD206, 
CD163 and an IL-1 receptor antagonist, IL-1RA. However, they did not express 
cytokines known to be associated with M2 macrophages such as IL-4, IL-10 or IL-13 
and thus resembled “pre-M2 macrophages-DCs” rather than traditional M2 type 
macrophages. Nor did they secrete M1 cytokines such as IFN-γ, IL-1β or IL-12. 
 
The role of IL-17A in cancer is controversial with pro-tumor versus anti-tumor effects 
described, as presented in the background. IL-17A and prostaglandin E2 (PGE2) have 
previously been shown to contribute to M2 differentiation of macrophages recruited to 
the tumoral microenvironment in lung cancer. However, in that study the driving force 
for M2 differentiation was attributed to PGE2 rather than to IL-17A (Liu et al., 2012).  
 
Since DCs are central in priming and activating T cells they may either stimulate anti-
tumor responses or conversely induce tumor cell tolerance by several mechanisms. 
When DCs fight against cancer cells, they prime T cells, promoting the differentiation 
of tumor specific CTLs. On the other hand, when DCs are skewed towards contributing 
to tumor development, not only are they incapable of priming T cells, but they also 
induce Tregs and stimulate angiogenesis. In vivo, the net effect of several cytokines is 
likely to determine the function and phenotype of DCs in the microenvironment of a 
tumorous or inflammatory (infectious) lesion. Interestingly, LCH lesions are 
characterized by a pro-inflammatory, still ineffective immune response. A high number 
of regulatory T cells have been demonstrated in the lesions, suggested to contribute to 
the failure of the host to eliminate LCH DCs (Senechal et al., 2007). IL-17A-treated 
DCs expressed both RANKL and CCL22. It has been shown in breast tumors that 
CCL22 attracts regulatory T cells (Gobert et al., 2009) and this function has also been 
demonstrated for RANKL in the skin (Loser et al., 2006).  IL-17A secreted from LCH 
DCs (or other cells in the lesion) might thus be one explanation for Tregs in LCH 
lesions. Together with IL-10, IL-4 and other immunosuppressive cytokines 
demonstrated in the lesions (Egeler et al., 1999, Geissmann et al., 2001), IL-17A may 
contribute to an impaired clearance of the LCH DCs due to tolerance induced by T 
regs.  
 
4.3.3 IL-17A increases viability of mo-DCs from healthy donors 
 
It was noted already in paper III that IL-17A prolongs survival of healthy mo-DCs 
enabling them to undergo fusion after 6-8 days. In paper IV, we further verified this 
increased viability and investigated the mechanisms behind it. Compared to 
lymphocytes, not so much information has been published on what sustains survival in 
human immature dendritic cells that are normally short lived (up to 48 h for mo-DCs 
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cultured in medium alone in vitro). We used information collected in the transcriptome 
analysis to identify pro-apoptotic and pro-survival genes that were expressed differently 
in these groups and that might be of importance for IL-17A-induced survival of mo-
DCs. Of the pro-survival BCL2 family members, unstimulated cells expressed only 
MCL1, insufficient to maintain survival for longer periods of time. In contrast, 
exposure to IL-17A led to significant up-regulation of another pro-survival gene, 
BCL2A1. MCL1 was still highly expressed but to a lower degree. These findings were 
verified at protein level with FACS and Western blot. While IFN-γ did potentiate IL-
17A induced DC fusion, it did not affect survival or expression of BCL2A1 either at 
mRNA or protein level. 
 
Myeloid cell leukemia sequence 1 (MCL1) was first discovered as a pro-survival 
member of the BCL2 family in a human myeloblastic leukemia cell line (Kozopas et 
al., 1993). B-cell lymphoma 2 related protein A1 (BCL2A1), is mainly expressed in B 
cells but has been described as being overexpressed in several hematological as well as 
non-hematological malignancies including B cell chronic lymphocytic leukemia (B 
CLL) and AML, where expression of BCL2A1 correlates with chemoresistance and 
poor prognosis (Feuerhake et al., 2005, Monti et al., 2005, Morales et al., 2005, 
Simpson et al., 2006, Olsson et al., 2007). However, transgenic mice do not develop 
lymphomas indicating that BCL2A1 alone is not sufficient to promote tumorigenesis 
(Chuang et al., 2002). 
 
Both BCL2A1 and MCL1 have been shown to be of importance for increased survival 
of myeloid cells such as macrophages and neutrophils in response to various 
inflammatory molecules (Ottina et al., 2012, Marsden and Strasser, 2003). In DCs, up-
regulation of BCL2A1 has been shown to occur in response to LPS or BCG (Ishii et al., 
2005).  
 
In our studies, silencing of BCL2A1 through introduction of siRNA was not possible 
since this resulted in DC maturation. Neither were we able to find any suitable inhibitor 
of BCL2A1. Thus, we have not been able to definitively prove that the pro-survival 
effect seen with IL-17A is dependent on BCL2A1. Intracellular expression of BCL2A1 
and IL-17A showed a clear correlation, as did BCL2A1 expression to survival. Still, it 
is possible that other mechanisms might contribute to the IL-17A-mediated survival. 
The pro-apoptotic genes, BCL2L11 and BID were expressed at low levels in 
unstimulated cells in our transcriptome analysis and their amounts decreased with about 
fifty percent after treatment with IL-17A. Additionally, there might be other genes 
affecting cell survival that we have not studied.  
 
The p65/RelA protein is a member of the NF-κВ transcription factor family known to 
regulate BCL2A1, and expressed in immature DCs. IL-17A-dependent induction of 
BCL2A1 was shown to be mediated through the NF-κВ pathway by investigating the 
cellular location of the p65/RelA protein in untreated DCs and DCs treated with IL-
17A. Further, addition of the NF-κВ inhibitor Bay-11-7085 blocked BCL2A1 mRNA 
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induction by IL-17A. It has previously been shown that the balance between NF-κВ 
and JNK/AP-1 activity controls apoptosis in DCs (Kriehuber et al., 2005) where JNK-
AP1 is under negative feedback control of NF-κВ. Thus, this pathway may also 
contribute to the increased survival of IL-17A treated DCs.  
 
In paper IV, we further investigated the effects of chemotherapeutic drugs and 
corticosteroids on the survival of IL-17A and IFN-γ-treated mo-DCs. This might be of 
interest in many disorders where IL-17A has been implied in the pathogenesis, 
including both cancers and chronic inflammatory disorders. Given that pathological 
DCs are the key target for chemotherapy in LCH and that our previous results indicate 
a role for IL-17A in LCH, it might be of specific interest in LCH. The agents tested 
targeted corticosteroid receptors, calcineurin, DNA synthesis, topoisomerase II and 
microtubules.  
 
A high expression of BCL2A1 has previously been associated with chemoresistance to 
fludarabine and etoposide in progressive lymphocytic leukemia cells or a cell line from 
fibrosarcoma in vitro (Morales et al., 2005, Wang et al., 1999a) and different sensitivity 
towards doxorubicin and etoposide has also been reported in freshly generated DC 
(Chao et al., 1999). In line with these results, the cells in our model were, to different 
degrees, resistant to a variety of the agents tested including glucocorticoids, 
fludarabine, etoposide, 6-mercaptopurine, methotrexate and the calcineurin inhibitors 
cyclosporine A and tacrolimus. Nevertheless, drugs that exerted a killing effect within 
the tested concentrations were VBL, vincristine, doxorubicin, cisplatin, ARA-C and 2-
CdA. The threshold for killing mediated by doxorubicin, cisplatin and 2-CdA 
corresponded to high doses, exceeding therapeutic doses. Ara-C was also efficient in 
high doses while VBL and vincristine killed at more moderate doses.  
 
Our in vitro system was of course reductionist regarding what happens in the body 
where bioavailability differs and enzymatic modifications of drugs take place. This 
could perhaps explain why we observed variable effects for drugs with similar 
mechanisms of actions. Still, it might provide a hint on how IL-17A-stimulated DCs 
respond to different drugs. It is interesting to note that VBL, which is the basis of the 
first line treatment in LCH, was also revealed to be efficient in our model. Moreover, 
high-dose ARA-C together with 2-CdA has been reported to have favorable results in 
the treatment of severe LCH in the LCH Salvage 2005 protocol (Bernard et al., 2005), 
and these drugs will also be used in the salvage regimen of LCH-IV. Furthermore, in 
LCH-IV, a combination of low-dose ARA-C and vincristine will be evaluated as a 
second-line treatment for non-risk LCH.  
 
To study whether VBL or ARA-C mediated degradation of BCL2A1 or MCL1, we 
performed western blots and found that these drugs mediated a decrease in MCL1 
levels but did not affect BCL2A1 expression. Interestingly, it has recently been shown 
that vincristine, acting through mechanisms similar to VBL, mediates degradation of 
MCL1 (Wertz et al., 2011). Our study extends these results to also include VBL. 
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Additionally, immunofluorescence experiments demonstrated that VBL also disrupted 
the microtubule network in IL-17A treated DCs fused into giant cells.  
 
Our results show that neither BCL2A1 nor MCL1 alone are sufficient to keep DCs 
alive. We conclude that both MCL1 and BCL2A1 are necessary to sustain long term 
survival of IL-17A-treated DCs.  
 
4.3.4 Increased survival of monocyte derived DCs from LCH patients is 
linked to up-regulation of BCL2A1  
 
Since the proliferation rate of LCH DCs is normally considered to be low (Brabencova 
et al., 1998, Senechal et al., 2007) it has been proposed that recruitment of pathogenic 
DCs or increased survival of LCH DCs may be responsible for the accumulation of 
LCH DCs in the lesions. Based on the findings of papers III and IV, in paper V, we 
investigated whether BCL2A1 expression might also contribute to increase viability of 
LCH DCs. We studied whether BCL2A1 was expressed in LCH lesions and whether it 
could be detected in mo-DCs from patients with LCH. 
 
We confirmed that mo-DCs were resistant to spontaneous apoptosis compared to DCs 
from healthy donors by studying survival of these cells at day seven with flow 
cytometry analysis and DiOC6/PI. Using immunofluorescence and confocal 
microscopy we found that BCL2A1 protein was present in mononuclear CD1a
+
 cells as 
well as MGCs in LCH lesions from bone. Further, in contrast to DCs from healthy 
donors, BCL2A1 expression nicely paralleled IL-17A expression in mo-DCs from 
LCH patients as assessed by both transcriptome analysis and FACS intracellular 
staining at mRNA and at protein levels respectively. Two different antibodies against 
IL-17A were tested and gave the same results. BCL2A1 levels correlated to the degree 
of survival. This indicates that BCL2A1 up-regulation is due to IL-17A stimulation also 
in LCH. Yet, as BCL2A1 is known to be up-regulated in DCs by LPS and BCG (Ishii et 
al., 2005) , signals other than IL-17A may induce BCL2A1 expression in LCH lesions, 
in vivo.  
 
As for healthy DCs it was not possible to block BCL2A1 directly. However, blocking 
IL-17A impaired both BCL2A1 expression and DC survival. Interestingly, VBL and 
anti-IL-17A antibodies acted synergistically to kill mo-DCs from LCH patients, 
allowing for lower doses of VBL to be used and overcoming the resistance to VBL that 
was noted in the DCs from one patient.  
 
BCL2 has previously been reported to be expressed in LCH lesions (Savell et al., 1998, 
Schouten et al., 2002). We did not see any up-regulation of BCL2 in mo-DCs from 
LCH patients but we did on the other hand not examine the LCH lesions for this protein 
and it could be induced by other cytokines in the lesions in vivo. Our findings of 
BCL2A1 in LCH lesions might be supported by the increased expression of BCL2A1 
also in the LCH derived CD207
+
 cells compared to normal LCs in the transcriptome 
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analysis performed by Allen et al. (Allen et al., 2010b). Many of the pro-survival and 
pro-apoptotic molecules previously detected in LCH lesions were not otherwise found 
to be expressed or up-regulated in this transcriptome analysis. Instead, the authors 
noted a high expression of the pivotal inflammatory cytokine osteopontin (expressed by 
the gene SPP1) compared to Langerin/CD207
+ 
cells from the skin. As suggested by 
Allen et al., osteopontin might be another cytokine of interest to study further since it 
has also been associated with granuloma formation, cell survival, T cell activation and 
induction of Tregs (Wang and Denhardt, 2008).  
 
4.3.5 Is there really any IL-17A in LCH? 
 
Since paper III was published there has been a lively debate as to whether IL-17A 
does or does not play a role in LCH. McClain’s group investigated the presence of IL-
17A mRNA and IL-17A protein in Langerin/CD207
+
 cells, CD1a
+
 cells and T cells 
derived directly from LCH lesions without being able to demonstrate the presence of 
IL-17A (Allen and McClain, 2009, Peters et al., 2011). They concluded that IL-17A 
was not present in LCH lesions and suggested that unspecific binding of antibodies 
might explain our findings of IL-17A. However, their studies leave many questions that 
remain to be answered and do not exclude a role for IL-17A in LCH. 
 
Firstly, as described in the background, a central problem in LCH research all along has 
been the difficulties to reproduce data. Differences in patient samples, cell types, the 
handling of material, techniques or interpretation of results may explain the 
discrepancies in results. As has been pointed out, several proteins previously reported 
to be present in LCH lesions were not found to be expressed in the transcriptome 
analysis performed by McClain’s group (Allen et al., 2010b). Their findings are 
strengthened by the fact that they did not detect any IL-17A mRNA in CD1a or 
Langerin/CD207
+
cells from LCH lesions in contrast to in T cells from tonsils using 
PCR on a separate set of samples (Peters et al., 2011). However, IL-17A mRNA might 
still be present in these cells but in low concentrations and thus not detected, or 
degraded upon sample processing including cell sorting. An alternative approach to 
minimize degradation of mRNA due to sample handling could be to perform in situ 
hybridization, to detect IL-17A mRNA in LCH lesions.  
 
Peters et al. used western blot to test the specificity of the antibodies against IL-17A 
used in our study. With this method they failed to demonstrate IL-17A in either LCH 
lysates or tonsil lysates (serving as their physiological positive control) with the 
PeproTech antibodies used by us for ELISA (PeproTech 500-P07G). On the other 
hand, the R&D Systems antibodies (R&D Systems 41802) that we used for 
intracellular staining (FACS and immunohistochemistry) strongly bound to a protein 
corresponding to the same size as IL-17A in both LCH lysates and tonsil lysates. 
Nevertheless, Peters et al. argued that this was a nonspecific protein since they could 
not identify any IL-17A peptides by masspectromery analysis in this band. However, 
this may result from material limitation because they did not identify this band at all, 
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again nor in the tonsil lysates. In conclusion, they challenged the specificity of a 
commercial antibody used in several papers without really proving that it is unspecific. 
By contrast we used two different antibodies to identify IL-17A by 
immunofluorescence inside the LCH lesions, the monoclonal antibody mentioned 
above (R&D Systems 41802) and a polyclonal goat antibody (R&D Systems AF-317-
NA).  
 
Studies from different groups have rendered different results with the same or different 
ELISA kits and multiplex methods regarding IL-17A in serum from LCH patients 
compared to healthy donors (Makras et al., 2012, Peters et al., 2011, Murakami et al., 
2012).  
 
Differences in subgroups (age, gender etc.) of patients and controls could account for 
these differences. It should be noted that some of our patients received chemotherapy at 
the time of sampling as reported in the paper. This might have influenced IL-17A levels 
and measurements should ideally be performed in newly diagnosed patients. However, 
history has also shown that it is difficult to study cytokines, which are normally short-
lived molecules, in serum, especially if the receptors are widely expressed, as is the 
case with IL-17RA. Illustrating this point, during the 1990’s, conflicting results 
regarding the serum levels of TNF-α were reported in patients with rheumatoid 
arthritis, although time has shown that TNF-α is indeed of major importance in this 
disease where many patients benefit from TNF-α inhibitors (Corvetta et al., 1990, 
Saxne et al., 1988). 
 
Different ELISA kits bind to different epitopes of cytokines which may result in 
different specificity. Since IL-17F share some homology with IL-17A one may wonder 
if there is any cross reactivity with this cytokines in spite of what is promised by the 
manufacturers. However, we have measured IL-17F in LCH serum with antibodies 
specific for IL-17F without finding any IL-17F (unpublished data) speaking against this 
explanation to be accountable for the discrepancies noted. Another possibility is that 
physiologically or pathologically modified molecules are recognized to different 
degrees by different antibodies.  
 
Secondly, and to the best of our knowledge not yet approached by any other team, is 
the capacity of mo-DCs from LCH patients to fuse and form long-lived MGCs in 
contrast to mo-DCs from healthy donors. In our system this process was specifically 
blocked by neutralizing antibodies against IL-17A. This demonstrates a role of this 
cytokine, or an IL-17A-like molecule with similar biological activity, perhaps 
corresponding to a genetically modified form of IL-17A or a molecule of exogenous 
origin, to be involved in the fusion mechanism. The IL-17A fusion capacity correlated 
to the disease severity. Interestingly, Murakami et al. recently reported that the 
expression of IL-17RA is higher in LCH DCs from patients with MS LCH than in 
patients with SS LCH, indicating that the level of receptor expression may also account 
for the amplitude of the response to IL-17A. Murakami et al. further suggest an 
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endocrine mode of action of IL-17A as they did not detect IL-17A protein in LCH DCs 
by mass spectrometry. However, only one sample was explored after laser capture 
microdissection of CD1a
+ 
cells of the lesion.  
 
The similarities to IL-17A related chronic inflammatory disorders, in terms of 
granuloma formation (IBD), bone resorption (RA) and neurodegeneration (multiple 
sclerosis) and the effects of IL-17A on mo-DCs from healthy donors make it plausible 
that IL-17A is somehow involved in the pathogenesis of LCH. Still, there is the risk of 
an “Emperor’s New Clothes” phenomenon, i.e. that we see what we want to see, and all 
new findings should legitimately be questioned. Several other cytokines also have the 
potential to explain many of the pathological characteristics of LCH lesions, including 
RANKL (osteoclastogenesis, Treg accumulation), TNF-α (induction of pro-
inflammatory molecules e.g. RANKL), GM-CSF (prolonged DC survival) or 
osteopontin (cell survival, granuloma formation) to mention just a few. Thus, it will be 
of great interest to follow further independent studies regarding the role of IL-17A in 
LCH.  
 
Provided that a role of IL-17A and BCL2A1 in LCH is confirmed, targeting BCL2A1 
or IL-17A activity in LCH might be worth considering. Among the new generation of 
anti-cancer drugs, small molecule inhibitors (SMI), that are under development, 
Obatoclax and Sabutoclax have been shown to target MCL1 or, MCL1 and BCL2A1, 
respectively (Nguyen et al., 2007, Wei et al., 2009). Sorafenib, developed as a BRAF 
inhibitor, has been shown to reduce MCL1 translation, leading to increased apoptosis in 
leukemia cells, and might be of special interest in LCH, considering the role that BRAF 
has been assigned in recent research (Rahmani et al., 2007).  
  
Monoclonal antibodies directed against cytokines such as TNF-α, IL-1β and IL-6 have 
been in clinical use in the treatment of autoimmune and chronic inflammatory disorders 
for many years now. As the detrimental effects of cancer-associated inflammation are 
becoming clearer, there are also several ongoing studies targeting cytokines and their 
receptors (such as CSF-1R, the receptor for M-CSF and IL-34) in various cancers 
(Biswas et al., 2013). 
 
Several clinical trials regarding inhibition of IL-17A are ongoing for various chronic 
inflammatory disorders, evaluating various IL-17A specific antibodies such as 
secukinumab and ixekizumab. There are also trials currently underway using an 
antibody, brodalumab, against the IL-17A receptor IL-17RA. Besides psoriasis (phase 
II completed, III ongoing), promising results have been reported for rheumatoid 
arthritis (phase II completed, III ongoing) and multiple sclerosis (phase II ongoing) 
(Deiss et al., 2013, Kellner, 2013, Miossec and Kolls, 2012). However, clinical trials of 
secukinumab and brodalumab failed to ameliorate symptoms in patients with Crohn’s 
disease, even leading to worsened symptoms in some patients (Miossec and Kolls, 
2012). This, again, stresses that it is not clear whether IL-17A is the cause or a 
consequence of the disease in granulomatous disorders of unknown origin. Thus any 
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future trial aiming at inhibiting IL-17A in LCH should be carefully and cautiously 
considered.    
  
The etiology of LCH remains to be revealed. The involvement of IL-17A in LCH is 
only one track among many others to study. Still, during recent years many steps to 
better understand the pathogenesis of the disease have been made and models 
embracing inflammatory aspects as well as neoplastic aspects of its origin are arising. 
As indicated by the results of Murakami and colleagues, LCH might perhaps be 
understood as a premalignant inflammatory disorder where cells with an underlying 
mutation, or perhaps a genetic variation in for example IL-17RA expression, overreact 
to infectious or other environmental stimuli. This might lead to inflammation and up-
regulation of survival pathways of LCH DCs, in turn favoring pro-survival mutations, 
and allowing for the accumulation of LCH granulomas (Murakami et al., 2012). As 
stipulated early on by our team, the potential role of myeloid DC progenitors rather 
than LCs as precursors for LCH DCs is now becoming increasingly recognized. 
 
Although no infectious agent has been associated with LCH, a specific disease causing 
pathogen, perhaps initiating the disease process by a “hit and run” mechanism, has, on 
the other hand, still not been excluded. 
 
 
 
 
Figure 4. A possible model for IL-17A mediated functions in LCH. 
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5 CONCLUSIONS  
 
 The study reported in paper I in this thesis is the first systematic study of CSF 
in children with neurodegenerative LCH. The results indicate that patients with 
neurodegenerative LCH have increased levels of at least one CSF biomarker 
and that NF-L, TAU and GFAp analyzed together may be useful to detect 
ongoing neurodegeneration in LCH. NF-L might be of special interest as a 
marker of progressive neurodegeneration. However, further studies are needed 
to evaluate the relationship between these biomarkers and the extension and 
progression of neurodegeneration, radiologically as well as clinically. 
 
 The findings of paper II support a, possibly temporary, overrepresentation of 
LCH in children conceived by IVF which was not due to over-diagnosis of mild 
forms of the disease. This finding is intriguing but remains to be confirmed in 
independent studies in other countries. Should a correlation between IVF and 
LCH be proven, further studies would be valuable to investigate whether the 
cause is related to the IVF procedure, ART drugs used in the IVF treatment or 
underlying characteristics of the mothers explaining the subfertility.  
 
 In papers III and IV we demonstrate that IL-17A modifies monocyte-derived 
immature DCs to cells with a mixed macrophage-DC phenotype. These cells 
are resistant to apoptosis which is associated with up-regulation of the pro-
survival protein BCL2A1. They are also prone to undergo cell fusion to form 
MGCs. IL-17A-treated DCs express a variety of pro-inflammatory molecules 
and share some characteristics with tumor promoting M2 macrophages seen in 
the microenvironment of various tumors. They also resemble LCH DCs.  
 
 The significance of IL-17A in the pathogenesis of LCH remains to be 
confirmed. Yet, our findings in papers III and V indicate a role for this 
cytokine in LCH where IL-17A might contribute to the pro-inflammatory tissue 
degrading environment characteristic of LCH lesions, and an inefficient 
immune response resulting in the failure of the body to clear the LCH lesions. 
Moreover, IL-17A may contribute to an increased viability of LCH DCs 
allowing for the formation of MGCs and favoring pro-survival mutations.  
 
 The findings in paper III indicate that dendritic cells are the major source of 
IL-17A in LCH. Whether this is an intrinsic characteristic of LCH or a common 
phenomenon that will also be reported in other inflammatory disorders remains 
to be seen. However, that myeloid DC progenitors or precursors may be 
affected and relevant in the pathogenesis of LCH is increasingly recognized by 
the LCH research community.   
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6 GENERAL REMARKS AND FUTURE 
PERSPECTIVES 
 
The overall aim of this thesis was to contribute to a better understanding of LCH. While 
the underlying cause of LCH still remains elusive, hopefully the papers included here 
will contribute in different ways to the growing body of knowledge of LCH, and inspire 
future research. 
 
Since neurodegeneration in LCH is one of the most severe consequences of the disease, 
further studies in this area are highly important. Studying inflammatory markers and 
other molecules in the CSF might help to better understand the neurodegenerative 
process and to develop appropriate treatments. In line with this, our group plans to 
expand our CSF studies in the coming years. Apart from the importance of 
international collaboration on this issue, patients might also gain from increased 
collaboration with neurologists. A major clinical challenge will be how to identify 
children with signs of CNS inflammation and progressive neurodegeneration early on 
who could benefit from prompt treatment, before the process presumably has entered a 
phase where it is difficult to stop and clearly has caused significant harm. Motivating 
examinations and treatment in children who are still neurologically intact may be 
difficult, as is the question of when to stop treatment. Such decisions could be 
supported by the monitoring of reliable biomarkers in the CSF (or serum).  
 
The study of cytokines in LCH naturally came to circle a great deal around IL-17A, 
following the initial findings of paper III and this story is, as reflected in the 
discussion, still ongoing. Independent studies will verify whether IL-17A is of 
importance in the pathogenesis of LCH. These should optimally include studies of both 
the IL-17A protein and its receptor IL-17RA. It would be interesting to study 
expression levels of IL-17A, RORγt and IL-17RA in cells that might be the source of 
LCH DCs. Furthermore it might be interesting to sequence IL-17A and IL-17RA in 
CD1a
+ 
sorted LCH DCs or mo-DCs from LCH patients to look for mutations in this 
pathway. By comparing any findings in LCH to those of other granulomatous diseases 
we could perhaps learn more about this group of diseases as a whole. 
 
In a broader perspective, the speed of technical progress facilitating the search for 
somatic or germ line mutations in LCH, is indeed inspiring. Apart from screening LCH 
DCs, or suspected precursors, for oncogenic mutations, directed analyzes of receptors, 
cytokines and chemokines that might mediate an aberrant recruitment, skewed 
maturation, or skewed T cell activation of DCs would be very interesting to perform. 
Why not focus directly on CD1a or CD207 for example?  
 
Alternatively, improved possibilities to identify new pathogens may perhaps lead 
further along the pathway of solving the LCH enigma.  
  
89 
 
7 SVENSK SAMMANFATTNING  
 
Langerhans cell histiocytos (LCH) är en ovanlig sjukdom vars orsak är okänd. LCH kan drabba 
alla åldrar men är vanligast hos barn. Små barn är i högre grad drabbade av allvarliga former av 
sjukdomen. Vid LCH bildas det granulomatösa inflammationshärdar i olika organ. Dessa 
innehåller alltid dendritiska celler positiva för markören CD1a. Flerkärniga jätteceller av okänd 
härkomst är också vanligt förekommande. Sjukdomsförloppet vid LCH är extremt varierande. 
Vissa får bara en enstaka, självläkande inflammationshärd i skelettet eller huden, medan andra 
får återkommande inflammationer i flera ben eller andra organ, och ytterligare andra drabbas av 
utbredda sjukdomshärdar förenliga med ett dramatiskt, livshotande sjukdomsförlopp. Nyligen 
identifierades i vävnadsprover av LCH en mutation i genen BRAF, som kodar för ett protein 
viktigt för cellsignalering via den s.k. RAS-RAF-MAPK- kaskaden, av betydelse för cellens 
överlevnad och proliferation. Trots detta vet man ännu inte om LCH är en tumörsjukdom eller 
om mutationer som BRAF uppkommer sekundärt, till följd av att cellerna (över)stimulerats av 
inflammatoriska signaler.  
 
Spridda former av sjukdomen behandlas vanligen med kortison och cytostatika. Överlevnaden 
vid LCH är god, förutom vid utbredda former av sjukdomen där bättre behandlingsmetoder 
behövs. Dessvärre utvecklas ofta olika former av följdtillstånd efter sjukdomen. En allvarlig 
sådan komplikation är en långsamt tilltagande neurodegeneration som utvecklas hos omkring 
10-25% av barnen. Man har kopplat utvecklingen av neurodegeneration till, sannolikt 
sjukdomsmedierad, inflammation i centrala nervsystemet men man vet inte vad som orsakar 
denna eller hur den kan stoppas. När förändringar syns vid magnetkameraundersökningar (MR) 
har betydande nervskador redan skett.  Det finns således ett behov av att hitta markörer som kan 
identifiera neurodegeneration tidigare i förloppet. Sådana skulle även kunna användas till att 
snabbare utvärdera behandlingsförsök än vad som är möjligt med MR. 
 
I avhandlingens första artikel studerade vi tre välkända biomarkörer för neurodegeneration i 
ryggmärgs-vätska från barn med röntgenologiskt verifierad neurodegenerativ LCH; NF-L, Tau 
and GFAp. Samtliga dessa barn hade förhöjda värden av åtminstone en av dessa markörer. 
Analyserade tillsammans kan de således vara av värde för att upptäcka neurodegeneration vid 
LCH. NF-L kan eventuellt vara av särskilt värde för att avspegla progressiv neurodegeneration 
men fortsatta studier krävs för att klargöra detta.  
 
Tidigare registerstudier har indikerat en överrepresentation av LCH hos barn födda efter in vitro 
fertilisering (IVF) i Sverige 1982-2005. Detta sporrade oss till att undersöka dessa fall närmare i 
avhandlingens andra artikel. Genom att konfirmera diagnoserna och karakterisera 
sjukdomsbilden hos barnen som identifierats i registerstudien verifierade vi en, möjligen 
tidsbunden, överrepresentation av LCH hos barn födda efter IVF vilken inte berodde på 
överdiagnostik av milda sjukdomsformer. Orsaken till detta, vilket möjligen skulle kunna 
återspegla orsaken till LCH, är dock inte känd och ett eventuellt samband mellan IVF och LCH 
behöver konfirmeras i separata studier.  
 
I avhandlingens tre sista artiklar studerade vi betydelsen av den inflammationsfrämjande 
molekylen IL-17A vid LCH. Vi fann att IL-17A på många sätt påverkade dendritiska celler 
framställda från monocyter. De IL-17A-behandlade cellerna antog en speciell fenotyp, en 
blandning av dendritiska celler och makrofager, med förstärkt överlevnadspotential vilket var 
associerat med uppreglering av ett överlevnadsstimulerande protein, BCL2A1. Dessa celler 
tenderade att fusionera och bilda flerkärniga jätteceller, de uttyckte en uppsjö av 
proinflammatoriska ämnen och liknade på många sätt de patologiska celler som ses vid LCH. 
Vid studier av vävnadsprover av LCH fann vi rikligt med IL-17A, och monocytframställda 
dendritiska celler från LCH patienter utsöndrade spontant IL-17A till skillnad från friska 
kontroller. Dessa celler hade en förlängd överlevnad jämfört med friska kontroller, uttryckte 
BCL2A1 och bildade spontant jätteceller, en process som gick att bryta med antikroppar mot 
IL-17A.  
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Betydelsen och förekomsten av IL-17A vid LCH är omdebatterad. Sammantaget talar våra fynd 
dock för en betydelse av IL-17A i patogenesen till LCH där IL-17A kan bidra till LCH-
härdarnas inflammatoriska karaktär, en förlängd överlevnad av patologiska celler och bildandet 
av jätteceller. Huruvida en uppreglering av IL-17A vid LCH skulle vara fysiologisk, som del i 
ett försvar mot ett främmande antigen, eller bero på en mutation, alternativt viralt stimulerad 
produktion, är ännu heller ej klarlagt.  
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